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ABSTRACT
Protein degradation plays an important role in te control and regulation of
many biological functions, ranging from cell cycle progression to presentation of
viral antigens for scrutiny by cells of the immune system. At the heart of many
of these catabolic events is the multi-catalytic proteinase complex known as the
proteasome. This large barrel-shaped protein complex executes a remarkable set
of functions ranging from the complete destruction of abnormal and misfolded
proteins to the exquisitely specific proteolytic activation of crucial signaling
molecules. Inhibitors of this proteolytic complex have thus been extremely
useful for perturbing its function and deciphering its role in these widely diverse
biologica; processes.
The first part of this work describes the synthesis of a class of peptides in
which the C-terminal carboxylic acid is replaced with a vinyl sulfone moiety.
Although initially described as inhibitors of cysteine proteases, peptide vinyl
sulfones containing the core sequence LeuLeuLeu are capable of covalent,
irreversible inhibition of proteasomal proteolysis by modification of the
catalytic, threonine hydroxyl nucleophile. Peptide vinyl sulfones composed of
different amino acid sequences were also synthesized and evaluated for activity
against the proteasome. These structure-function studies provide further insight
into the proteolytic mechanism and substrate specificity of the proteasome.
The second portion of this thesis describes the in vivo application of the
peptide vinyl sulfones and in their use in uncovering the role of the proteasome
in the Human cytomegalovirus (HCMV)-mediated destruction of MHC class I
heavy chains The genome of the Human cytomegalovirus contains two genes,
US2 and US11 which are responsible for the rapid degradation of MHC class I
molecules. Treatment of HCMV infected cells with peptide vinyl sulfone
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inhibitors of the proteasome lead to the accumulation of a heavy chain break-
down intermediate which was devoid of N-linked glycan and was found in the
cytosol. Not only does the proteasome play a role in destruction of this ER
resident protein but also, the process by vhich the viral gene products US2 and
US11 catalyze proteolvytic destruction of MHC class I molecules involves the
reverse translocation of a polypeptide from the ER to the cytosol. Further, this
process of retrograde translocation in the ER may be a much more general
phenomenon used by normal cells to purge the ER of misfolded proteins.
The final portion of this work describes the characterization of a population
of lymphoblastoid cells which are adapted to growth in the presence of the
peptide vinyl sulfone inhibitors. Normally, prolonged exposure of cells to
proteasome inhibitors results in death, presumably due to loss of proteasome
function. However, we have found that prolonged exposure of cells to low
concentrations of the proteasome inhibitor NIP-L3VS results in the outgrowth of
cells which are able to grow in concentrations of inhibitor which are toxic to
previously un-exposed cells. These cells are not the result of a genetic mutation
nor are they the result of a multi-drug resistance phenomenon. Biochemical
characterization of these cells indicates that these cells are able to survive in the
absence of normal proteasome function. Examination of other non-proteasomal
proteolytic activities in these cells revealed that adaptation may be the result of
up-regulation of additional proteases which are able to compensate for
proteasome functions required for cell survival. Thus the use of the peptide
vinyl sulfone proteasome inhibitors in living cells has allowed for the study of
other proteolytic functions which may otherwise have been overlooked.
Thesis supervisor: Professor Hidde L. Ploegh
Title: Professor of Biology
4
For Pake: You will always be an inspiration to me
5
ACKNOWLEDGEMENTS
First and foremost I would like to thank my research advisor Hidde
Ploegh. I have greatly enjoyed working with him over the past three years. I
thank him for always taking me seriously and most importantly for respecting
my opinions and ideas. I have found that I have learned much more than I ever
thought possible in the short time since I have known him. His unbounded
enthusiasm transforms the lab into an exciting work environment and I hope that
I may someday use the skills he has taught me to run a lab as successfully as he
does.
I would also liko to thank Jun Liu for supporting me in the beginning
stages of my quest for the PhD. He has always been an extremely positive
influence for me here at the Center for Cancer Research. There are many things
that I learned from him during the my year in his lab that will always be a part of
the way I do science. I also thank Larry Stem for taking the time to read this
massive document and for agreeing to be my joint-advisor.
I now have the difficult task of thanking all the people who have
contributed to my thesis work at MIT. Much of the work presented in this thesis
was done in collaboration with other members of the Ploegh lab and with the
help of my friends in the chemistry department. I would like to first thank
Rickard Glas. He is responsible for the discovery of adapted cells (chapter 5)
and has done a tremendous amount of work uncovering the exciting story which
may explain how these cells survive. I thank him for his patience, selflessness,
and willingness to learn biochemical techniques (even if I was teaching him
while doing a million experiments simultaneously).
I want to also thank John McMaster. Little did I know what I was getting
into when I hired him as a UROP (at first I thought he got confused and thought
he was applying for the U are Really Old Program (just kidding John!)). I must
say that I will never regret my decision to hire him. He has done a tremendous
amount of work since his first day "in the hood" (chemistry hood that is). Again,
much of the data reported here would not have been possible without him. I
hope that he has Icamrned as much from me as I have from him. I also thank him
for his patience (since that is not my strong point) and for teaching me how to
play golf. I am really going to miss him when he starts he own graduate career
shortly.
I would also like to thank Emmanuel Wiertz. He contributed the bulk of
the work described in chapter 4. His ever-present smile really gave me a lift on
those days when it seems like nothing works. I also thank Maria Gaczynska
who has helped me throughout my thesis work with her vast expertise about the
proteasome. I thank Sunny Shin for all that she has done since joining the lab. I
especially thank her for all the help she gave me doing those "last minute"
experiments that I needed to make a particular point in this thesis. Much of the
work in chapter 3 could not have been finished without her.
6
I would also like to thank Domenico Tortorella (Dom). He contributed a
large part of the work described in chapter 4. I thank him for making the lab
such a fun place to work and for always looking out for me (when I get hit in the
shin with a softball). I think of him more as a brother than a co-worker.
I thank the other members of the Ploegh lab Dina, Patrick, Evelyn, Dan,
Johannes, Armin, Jose, Begonia, Fleur and of course, Rocco. I thank Evelyn for
all her help making my poster on this work for the Peptide Symposium. I thank
Rocco for playing the 6 -degrees of Kevin Bacon (I can link Barney Rubble to
Kevin Bacon in 5!). I also thank Mamadi and Paula for helping me from day 1 in
the lab when I had no place to sit and I hardly knew what a gel was.
I would also like to thank all my fiends in the Chemistry department;
Dave, Evan, Ben, Bill, Jeff, Martha, Becky, and Chris. They all helped to
make my graduate experience a fun one and many times helped me when I just
didn't know what to try next. I thank Evan for letting me move into his lab on
occasion and for sharing his incredible wealth of knowledge with me. I thank
Sonya for helping me that first day with my mice (I forgive you for killing that
one...there was nothing you could do...he had a bad heart) and for being a great
friend ever since. I thank Ben for all his help during my first year in Jun's lab and
for all the feedback (like rippin' guitar solo, indie rock feedback) he has given me
on a number of occasions as well as for always playing the Devil's advocate
when I show him my data ("I think you're labelilg GST!").
I would also like to thank the members ef my family who have made all
this possible. I thank my Dad for his help and support and for being one of the
few people in the family that I can really ansi er the question "so what are
working on?". I thank Tom Bardos (st cousin twice removed. for those of you
who are interested in genealogy) for all his support throughout my scientific
career and my entire life. He has been a strong motivating force in my life and
for that I thank him. I would also like to thank my uncle Gerry (WUG) for
everything he has done for me. I will never forget the year I spent living in "the
bachelor pad" during my first year at MIT. He made what could have been a
difficult first year of graduate school seem like a piece of cake.
I would also like to thank my mom. It is hard to follow such a huge list of
people with someone as important as my mom. I will never be able to say thanks
enough by writing it here at the beginning of my thesis. I feel extremely lucky to
have had her love and support throughout this, yet another milestone in my life.
It is many of her personal traits, that I see in myself, that have made the
daunting tasking of achieving a PhD possible for me.
Finally, I want to thank my future wife (fiancee, there I said it) Becky. She
has always been around to cheer me up when I feel like nothing will ever work.
She has given me the same advice I gave her when she was writing her thesis
"don't worry, it will get done". She is a truly remarkable person and I feel very
lucky to have her standing behind me ever step of the way.
7
TABLE OF CONTENTS
TITLE PAGE ......................... ...... .. . ........1
COMMITTEE PAGE ... ............ ...................... 2
ABSTRACT ...........................................
ACKNOWLEDGEMENTS ...... ........... ... ........................... 6
TABLE OF CONTENTS..... ................... ..................... .... 8
LIST OF FIGURES .................. 1..............................14
LIST OF ABBREVIATIONS .............................................. 19
I. BACKGROUND.... . ................................................ 21
A. Introduction .................. ... .... .........22
B. Structure and Mechanism of the Proteasome . ............. 22
C. Inhibitors of he Proteasome ................................... 34
D. Antigen Presentation ............... ...... ........... 40
E. The Proteasome's Role in Antigen Presentation ................... 43
II. COVALENT MODIFICATION OF THE ACTIVE SITE THREONINE
OF PROTEASOMAL I3-SUBUNITS AND THE ESCHERICHIA COLI
HOMOLOG HslV BY A NEW CLASS OF INHIBITORS .................. 47
A. Introduction ................................................. 48
B. Materials and Methods ... ...... ....................... 51
1. Cells and Cell Culture ...................................... 51
2. Antibodies ... ............................................51
3. Biochemical Materials and Methods ......................... 51
4. Kinetics of Inhibition of Proteasomal Peptidase Activity ........ 52
5. Synthesis of Peptide Vinyl Sulfones .... ...................... 52
a. Synthesis of Boc-leucinyl-leucinyl-methyl ester ........... 52
b. Synthesis of Boc-leucinyl-leucine ....................... 53
c. Synthesis of Boc-leucine-dimethyl hydroxyl
am ide ............................................ 53
d. Synthesis of Boc-leucinal ............................ 54
e. Synthesis of Boc-leucine-vinyl sulfone ................... 54
f. Synthesis of leucine-vinyl sulfone tosic acid salt ........... 55
8
g. Synthesis of Boc-Leucinyl-leucinyl-leucine-
vinyl sulfone ....... 5................................ 5
h. Synthesis of carboxylbenzyl-leucinyl-leucinyl-
leucine-vinyl sulfone (Z-L3VS) ....................... 56
I. Synthesis of leucinyl-leucinyl-leucine-vinyl
sulfone tosic acid salt . ........ ................. 56
j. Synthesis of biotin-leucinyl-leucinyl-leucine-
vinyl sulfone (Biotin-L3VS) .................. ..... 57
k. Synthesis of 5-iodo-4-hydroxv-3-nitropheny-acetyl-
leucinyl-leucinyl-leucine-vinyl sulfone
(NIP-L3VS) .............................. 57
1. Synthesis of 4-hydroxyl-3-nitrophenyacetyl-
leucinyl-leucinyl-leucine-vinyl sulfone ................ 58
m. Synthesis of radio labeled 4-hydroxyl-3-
nitrophenyacetyl-leucinyl-leucinyl-leucine-
vinyl sulfone ( 25I-NIP-L3VS) .............. 58
6. Pulse-Chase Analysis ................... .............. 59
7. Gel Electrophoresis ........................ ................ 59
C. Results ................................ .............. 60
1. Synthesis of peptide vinyl sulfones .................... 60
2. Peptide vinyl sulfones irreversibly inhibit proteasome
activity in vitro . ......................................... 60
3. 125I-NIP-L3-VS covalently modifies multiple p subunits
in purified proteasome preparations and in total cell
extracts .............................................. 65
4. The peptide vinyl sulfones are reactive against the
archaebacterial proteasome from Ttzermoplasma .............. 65
5. The bacterial protease complex HslV/HslU from E. coli
is a target for the peptide vinyl sulfones .................... 65
6. 125I-NIP-L 3-VS covalently modifies subunits of the
proteasome in living cells in a time- and dose-dependent
manner ................................. 70
7. All three classes of proteasome inhibitors compete for
binding with 125I-NIP-L 3-VS .............................. 77
8. Peptide vinyl sulfones inactivate the proteasome in vivo ........ 82
D. Discussion ................................................... 86
IH. STRUCTURE-FUNCTION STUDIES OF TRI- AND TETRA-
PEPTIDE VINYL SULFONES ........................................ 88
A. Introduction ................................................. 89
B. Materials and Methods ................... ..................... 92
1. Inhibitor Synthesis ........................................ 92
9
2. Synthesis of Tetra-Peptide Vinyl Sulfones Containing the L3
Core Sequence ................... ....................... 92
a. Synthesis of Boc-tyrosine-!eucinyl-leucinyl-leucine
vinyl sulfone (YL3-VS) ............................ 92
b. Synthesis of tyrosine-leucinyl-leucinyl-leucine vinyl
sulfone trifluoroacetic acid salt (YL3-VS) ............... 93
c. Synthesis of (D)-tyrosine-leucinyl-leucinyl-leucine vinyl
sulfone ((D)YL3-VS) . ..... ................... 93
d. Synthesis of Boc-glycine-leucinyl-leucinyl-leucine vinyl
sulfone (Boc-GL3-VS) ............. ............... 93
e. Synthesis of glycine-leucinyl-leucinyl-leucine vinyl
sulfone (GL3-VS) . ................................... 94
f. Synthesis of p-Benzoyl-phenylalanine-leucinyl-leucinyl
-leucine vinyl sulfone (BpaL3-VS) ...................... 94
3. Synthesis of AAF Containing Peptide Vinyl Sulfones .......... 94
a. Synthesis of Boc-phenylalanine-vinyl sulfone(Boc-Phe-VS) ... .................................... 95
b. Synthesis of phenylalanine-vinyl sulfone tosic acid
salt (Phe-VS) .................................... 95
c. Synthesis of Boc-alanine-alanine methyl ester
(Boc-AA-OMe) . ... .................................. 95
d. Synthesis of Boc-Alanine-alanine (Boc-AA-OH) . ........ 96
e. Synthesis of Boc-alanine-alanine-phenylalanine vinyl
sulfone (Boc-AAF-VS) ................................ 96
f. Synthesis of alanine-alanine-phenylalanine vinyl
sulfone tosic acid salt (AAF-VS) ........................ 97
g. Synthesis of Boc-tyrosine-alanine-alanine-
phenylalanine vinyl sulfone (YAAF-VS) .. .............. 97
h. Synthesis of tyrosine-alanine-alanine-phenylalanine
vinyl sulfone (YAAF-VS) ............................. 98
4. Synthesis of LLG Containing Vinyl Sulfones ............. 98
a. Synthesis of Boc-3-amino-1,2-propane diol ............. 98
b. Synthesis of Boc-glycinal (Boc-Gly-H) .. ...... 101
c. Synthesis of Boc-glycine vinyl sulfone, cis and trans
isomers (Boc-G-cVS and Boc-G-tVS) .................. 101
d. Synthesis of glycine-vinyl sulfone tosic acid salt cis
and trans isomers (G-cVS, G-tVS) . ................... 102
e. Synthesis of Boc-Leucinyl-leucinyl-glycine vinyl
sulfone cis and trans isomers (Boc-LLG-cVS,
Boc-LLG-tVS) ...................... 102
f. Synthesis of leucinyl-leucinyl-glycne vinyl sulfone
tosic acid salt cis and trans isomers (LLG-cVS,LLG-tVS) ...... . ............... 103
10
g. Synthesis of 4-hydroxy-3-nitrophenyl acetyl-leucinyl-
leucinyl-glycine vinyl sulfone cis and trans isomers
(NP-LLG-cVS, NP-LLG-tVS) ........ ............... 103
5. Synthesis of Phenolic Vinyl Sulfones ............. ...........104
a. Synthesis of 3-Hydroxy-thiophenyl-methyl-
diethylphosponate ((EtO)2P(O)CH2S-Ph-OH) .......... 104
b. Synthesis of 3-Hydroxv-thiophenyl-methyl-
diethylphosponate sulfone
((EtO)2P(O)CH2S(O)2-Ph-OH) ............ ............ 104
c. Synthesis of Leucinyl-leucinyl-leucine-vinyl sulfone
phenol tosic acid salt (L3-VS-PhOH) ................... 107
d. Synthesis of 4-hydroxy-5-iodo-3-Nitrophenyl acetyl-
leucinyl-leucinvyl-leucine vinyl sulfone phenol
(NIP-L3-VS-PhOH) .............................. 107
e. Synthesis of Boc-leucinyl-leucinyl-eucinyl-leucine
vinyl sulfone phenol (Boc-L4-VS-PhOH) ............... 108
f. Synthesis of leucinyl-leucinyl-leucinyl-leucine vinyl
sulfone phenol tosic acid salt (.4-VS) .................. 108
6. Cells and Cell Cultire ................... 1................ 08
7. Antibodies .............................................. 109
8. Fluorogenic Substrate Hydrolysis Assay .................. 109
9. Partial Purification of Proteasomes from EL-4 Cells by
Differential Centrifugation ........... .................... 109
10. Labeling of Proteasomes with Peptide Vinyl Sulfones ........ 110
11. Competition Experiments .............................. 110
12. Gel Electrophoresis ...................................... 111
13. Immunoprecipitation .................................... 111
C. Results .. ...... .. . ...................................... .. 112
1. Synthesis of peptide vinyl sulfones ........................ 112
2. P4 amino acid influences inhibition of fluorogenic
substrate hydrolysis ..................................... 121
3. Labeling of proteasomes with tetra-peptide vinyl sulfones .... 130
4. GL3-VS competes for binding of the 21 kDa proteasomal
-subunit ........................................... 137
5. Modifications at the C-terminus of the peptide vinyl
sulfones .................................. 137
6. Inhibitor binding to f-subunits is sequence specific ........... 149
D. Discussion .............................................. 154
WV. THE HUMAN CYTOMEGALOVIRUS US2 AND US11 GENE
PRODUCTS DISLOCATE MHC CLASS I HEAVY CHAINS
FROM THE ENDOPLASMIC RETICULUM TO THE CYTOSOL
FOR DEGRADATION BY THE PROTEASOME ....................... 158
11
A. Introduction ................................................ 159
B. Materials and Methods .......................................161
1. Cells and Cell Culture .................................... 161
2. Antibodies .. ............................................ 161
3. Inhibitors . ................ ....................... 161
4. Pulse Chase Analysis ..................................... 162
5. Gel electrophoresis ........................ ... . 162
6. Subcellular Fractionation . ................................ 162
7. Re-immunoprecipitation of class I heavy chains or US2
from immuno complexes containing proteasomes, US2,
or Sec61 ....... . . ...................................... 163
C. Results ..... 164
1. Class I heavy chains are destroyed in US11+ and US2+ cells...164
2. A class I heavy chain break-down intermediate appears in
US11+ and US2+ cells upon treatment with proteasome
inhibitors ......... .................................... 167
3. N-linked glycans are removed from class I molecules in
US11 and US2 cells by a peptide N-glycanase activity . ... 172
4. The de-glycosylated class I heavy chain is found in
the cytosol .... ......................................... 176
5. The de-glycosylated class 1 heavy chain directly associates
with the proteasome .................................... 180
6. US2 and the class I heavy chain intermediate associate with
Sec61p ................... 186
D. Discussion .. .. 190
V. A NEW PROTEOLYrIC SYSTEM IN MAMMALIAN CELLS THAT
CAN COMPENSATE FOR THE LOSS OF PROTEASOME FUNCTION... 195
A. Introduction ................................................ 196
B. Materials and methods .................. ..................... 198
1. Cells and Cell Culture .................................... 198
2. Inhibitors ............................................... 198
3. Synthesis of alanine-alanine-phenylalanine chloromethyl
ketone (AAF-cmk) .............. ............. 198
a. Synthesis of Boc-Ala-Phe-OMe ........................ 198
b. Synthesis of Boc-Ala-Phe-OH ......................... 199
c. Synthesis of Boc-Ala-Phe-diazomethyl ketone
(Boc-AF-CHN2) ................................... 199
d. Synthesis of Ala-Phe-Chloromethyl Ketone
(AF-cmk) .......................................... 200
e. Synthesis of Boc-Ala-Ala-Phe-Chloromethyl Ketone(Boc-AAF-cmk) ....... .................... 200
12
f. Synthesis of Ala-Ala-Phe Chloromethyl Ketone(AAF-cmk) ......................................... 201
4. Antibodies ... 2... .............. .........................2 01
5. Cell Growth Analysis .................................... 202
6. Limiting Dilution to Determine Frequency of Adaptation ..... 202
7. Assembly of Proteasomes . ... ............................. 202
8. Affinity Labeling of Intact Cells with 125I-NIIP-L3-VS ......... 203
9. Preparation of Lysates from Control EL4, NLVS Treated
or Adapted Cells ....................................... 203
10. Fluorogenic Peptide Substrate Assay ....................... 203
11. FACS Analysis of Cell Cycle .............................. 204
12. Class I Assembly ........................................ 205
13. Gel Filtration of 5h Pellets ................................ 206
C. Results ..... .. ...... ...... .....................................2 06
1. EL-4 cells can adapt to prolonged exposure of NLVS ......... 206
2. Adaptation is not the result of a mutation ................... 206
3. The proteasome is synthesized and assembled normally
in adapted cells ................... 2......................206
4. Toxicity of NLVS correlates with modification of
proteasomal -subunits ................... .............. 209
5. Labeling of proteasomal frsubunits by '12I-NIP-L3-VS
is blocked in adapted cells ............................... 215
6. Proteasomal hydrolysis of fluorogenic substrates is
impaired in adapted cells ........................ 215
7. Adapted cells are able to generate peptides for binding
to MHC class I molecules ................................ 227
8. Poly-ubiquinated proteins accumulate in cells treated with
NLVS but not in adapted cells ............................ 232
9. Adapted cells overcome the G2 cell cycle arrest induced
by proteasomal inhibition ............................. 235
10. A non-proteasomal activity is up-regulated in adapted cells.. ..235
11. AAF-MCA hydrolytic activity fractionates as a high molecular
weight complex distinct from the proteasome ...... ... 240
12. AAF-MCA hydrolysis activity is required for adapted
cell survival ............................................ 240
D. Discussion ...... .......... .... ..............................48
VI. FUTURE DIRECTIONS ............................................ 250
REFERENCES ....................................................... 253
13
LIST OF FIGURES
CHAPTER 1
Figure 1.1:
Figure 1.2:
Figure 1.3:
Figure 1.4:
Figure 1.5:
Figure 1.6:
Figure 1.7:
Structure of the eukaryotic and prokaryotic 20S and 26S
proteasome .............................................. 24
Conjugation of ubiquitin to a target protein for destruction
by the 26S proteasome ....................................... 26
Peptide bond hydrolysis by the proteasome by two possible
mechanisms ........ ........ .......................30
Possible mechanism for autocatalytic processing of a proteasomal
p-subunit .................................................. 32
Structures of several classes of inhibitors of proteasomal
proteolysis ................................................. 35
Mechanism of inactivation of the N-terminal threonine
residue of catalytic p-subunits by proteasomal inhibitors ......... 37
Presentation of antigenic peptides via MHC class I and class
II molecules ................................................ 41
CHAPTER 2
Figure 2.1: (A) Structure of inhibitors of the proteasome. (B) mechanism of
inhibition of the proteasome by the peptide vinyl sulfones ....... 61
Figure 2.2. The peptide vinyl sulfones inhibit the proteasome in vitro ......... 63
Figure 2.3:
Figure 2.4:
Figure 2.5:
The peptide vinyl sulfone, 1251-NIP-L3VS labels multiple 3 subunits
of the proteasome in total cell extracts and in purified proteasomepreparations . ........... ................................. 66
The peptide vinyl sulfones covalently modify the HslV gene product
from the E.coli protease complex HslV/HslU ................... 71
The peptide vinyl sulfones covalently modify multiple , subunits
of the proteasome in living cells, including the y-IFN inducible
subunits LMP-2 and LMP-7 ................................... 73
14
Figure 2.6: The peptide vinyl sulfones, the peptide aldehyde, and lactacystin
compete for binding to all proteasome subunits modified by
125I-NIP-L3VS ............. 7.................................78
Figure 2.7: The peptide vinyl sulfones block proteasome function in vivo ...... 84
CHAPTER 3
Figure 3.1: Synthesis of glycine-based vinyl sulfones by oxidation of
3-amino-1,2-propanediol derivatives ........................... 99
Figure 3.2: Synthesis of the phenolic peptide vinyl sulfone ................. 105
Figure 3.3: Structures of the methyl and phenolic N-terminally modified
vinyl sulfones ............................................. 113
Figure 3.4: The P-notation used to identify amino acid positions relative
to the site of hydrolysis ..................................... 115
Figure 3.5: Structures of the free-amino tri-peptide vinyl sulfones ........... 117
Figure 3.6: Structures of the free-amino tetra-peptide vinyl sulfones ......... 119
Figure 3.7: Structures of the cis and trans isomers of NP-LLG-VS ........... 122
Figure 3.8: The free-amino tri peptide L3-VS is a poor inhibitor of trypsin-like,
chymotrypsin-like and PGPH activities of the proteasome when
compared to NIP-L3VS and Z-L3-VS .......................... 124
Figure 3.9: Addition of an aromatic, aliphatic, or bulky P4 amino acid to the
free amino tri-peptide L3-VS results in potent inhibition of the
trypsin-like, chymotrypsin-like and PGPH activities of the
proteasome ........................................... 126
Figure 3.10: A D-amino acid at the P4 position results in a modest reduction of
inhibitory potency of substrate hydrolysis by the proteasome... .128
Figure 3.11: Glycine in the P4 position increases potency of the free-amino
tri-peptide L3-VS against the PGPH activity but not the trypsin-like
or chymotrypsin-like activities of the proteasome .......... 131
15
Figure 3.12: Addition of tyrosine to the free-amino tri-peptide AAF-VS increases
potency against the chymotrypsin-like and trypsin-like activities of
the proteasome .......................................... 133
Figure 3.13: The tetra-peptide vinyl suifones label proteasomal f,-subunits with
different relative intensities ... .......................... 135
Figure 3.14:
Figure 3.15:
The tetra-peptide vinyl sulfone GL3-VS binds predominantly the
22 kDa proteasomal f-subunit ................ .............. 138
The phenolic vinyl sulfones inhibit the trypsin-like, chymotrypsin-
like, and PGPH activities of the proteasome with similar potency
as the methyl vinyl sulfones ........................... 141
Figure 3.16: The phenolic vinyl sulfones modify 22 kDa proteasomal [5-subunit
more effectively than the methyl vinyl sulfones ................ 143
Figure 3.17: A cis double bond abolishes the inhibitory potency of the peptide
vinyl sulfones .................................. 145
Figure 3.18: The trans but not the cis isomer of NP-LLG-VS covalently modifies
proteasomal [B-subunits ..................................... 147
Figure 3.19: Inhibition of proteasome by several N-terminally modified
tri-peptide vinyl sulfones containing different amino acid
sequences ........................................ ... 150
Figure 3.20: Inhibitor binding to proteasomal 5-subunits is sequence
specific .................................................. 152
CHAPTER 4
Figure 4.1:
Figure 4.2:
The half-life of class I heavy chains in US11+ cells is less than
1 m inute.................................................. 165
LLnL, but not BFA, induces a class I breakdown intermediate
in US11+ cells..............................................168
Figure 463: US11 and US2 mediated class I breakdown does not require
N-linked glycans and is inhibited by inhibitors of the
proteasome ...................................... 170
16
Figure 4.4: N-linked glycans are removed from class I molecules in
US11+ cells by an N-glycanase type activity ...... ............ 173
Figure 4.5: In US11+ cells treated with LLnL and US2+ cells treated with
Z-L3-H, most class I heavy chains are present in the cytosol ..... 177
Figure 4.6: US2 molecules form a complexes with properly folded class I
heavy chains, is deglycosylated and destroyed by the
proteasome ........................... 181
Figure 4.7: The deglycosylated class I heavy chain breakdown intermediate
can be found as a complex with the proteasome in US2+ and
US11+ cells .. ..... ......................................... 183
Figure 4.8: Class I molecules destined for degradation associate
with Sec6lp . ... . . .. ....................................... 187
Figure 4.9: Model for Sec61-dependent dislocation . ....................... 191
CHAFER 5
Figure 5.1: EL-4 cells adapt and grow in the presence of otherwise toxic
levels of NLVS ........................................... 207
Figure 5.2: Synthesis and assembly of proteasome subunits is normal in
adapted cells . ...... .. .. . .. . ............................... 210
Figure 5.3: Acute toxicity of the peptide vinyl sulfones is sequence
specific ................................................... 212
Figure 5.4. Labeling of proteasomal 5-subunits is blocked in adapted cells ... 216
Figure 5.5: Labeling of proteasomal 5-subunits is blocked in adapted
cell lysates .. ... . . ..... .. ...................................218
Figure 5.6: Hydrolysis of fluorogenic substrates is reduced in cells treated
with proteasomal inhibitors as well as in adapted cells .......... 221
Figure 5.7. Proteasomal activity is rapidly restored upon removal of NLVS
from adapted cells .............. ................... 223
17
Figure 5.8:
Figure 5.9:
Figure 5.10:
Figure 5.11:
Labeling of proteasomal 5-subunits with 125I-NIP-L3-VS is blocked
in adapted cytosol as well as in highly enriched proteasome
pellets ............................... ................ 225
Partially purified proteasomes isolated from adapted cells have
severely diminished fluorogenic substrate hydrolysis activity .... 228
Assembly of MHC class I molecules is impaired in cells treated
with NLVS but not in adapted cells ........... ............ 230
Polyubiquinated proteins accumulate in NLVS treated but not
in adapted EL-4 cells ..................................... 233
Figure 5.12: The G2 cell cycle arrest caused by NLVS treatment of EL-4 cells
is overcome in adapted cells ................................. 236
Figure 5.13:
Figure 5.14:
Multiple independent cell lines which are adapted to growth
in the presence of NLVS have an increase in AAF-MCA
hydrolysis activity ......................................... 238
The increased AAF-MCA hydrolysis activity found in adapted
cells is a high molecular weight protein or protein complex
distinct from the proteasome ............................... .. 241
Figure 5.15: The AAF-MCA hydrolysis activity is inhibited by treatment with
the tri-peptide chloromethyl ketone AAF-cmk ................. 243
Figure 5.16: AAF-MCA hydrolysis activity is required for adapted
cell growth .................................. 4............246
18
LIST OF ABBREVIATIONS
Antibody
Adenine tri-phosphate
Brefeldin A
t-butoxy-carbonyl
p-benzoyl-phenylalanine
p2-microglobulin
-nitroanilide
Benzyloxycarbonyl
Dichloromethane
Carbohydrate
Di-cyclohexyl-carbodiimide
Diisopropylethyl amine
Dulbecco's modified Eagle's medium
Dimethyl formamide
Dimethyl sulfoxide
Dithiothreitol
Di-ethyl ether
Ethyl acetate
Fluorescence activated cell sorter
Heavy chain
Human cytomegalovirus
Human histocompatibility leukocyte antigen
N-hydroxybenzotriazole
Herpies simplex virus
50% inhibiting concentration
Isoelectric focusing
Kilodalton
Acetyl-leucinyl-leucinyl-norleucinal
Low molecular weight protein
4-methyl-cumaryl-7-amide
Murine cytomegalovirus
Major histocompatibility complex
Non-equilibrium pH gradient gel electrophoresis
4-hydroxy-3-iodo-nitropheylacetic acid
4-hydroxy-3-iodo-nitrophylacet yl-leucinyl-leucine
vinyl sulfone
4-hydroxy-nitropheylacetic acid
Nonidet P-40
Phosphate buffered saline
Peptidyl glutamyl peptide hydrolylzing activity
Peptide N-glycanase
19
Ab
ATP
BFA
Boc
Bpa
32m
BNA
Cbz
CH2C12
CHO
DCC
DIEA
DMEM
DMF
DMSO
DTT
Et20
EtOAC
FACS
HC
HCMV
HLA
HOBt
HSV
IC50
IEF
kD
LLnL
LMP
MCA
MCMV
Mi 
NEPhGE
NIP
NLVS
NP
NP-40
PBS
PGPH
PNGase
PPO
PyBOP
SDS-PAGE
TAP
TFA
THF
TsOH
z
2,5-diphenyloxazole
Benzotriazole-1-yl-oxy-pyrrolidino-phosphonium
hexafluorophosphate
Sodium dodecylsulfate-polyacrylamide gel electrophoresis
Transporter associated with antigen presentation
Trifluoroacetic acid
Tetrahydrofuran
Tosic acid
Benzyloxycarbonyl (also Cbz)
20
I. BACKGROUND
Matthew Bogyo, Maria Gaczynska, and Hidde L. Ploegh. Proteasome
Inhibitors and Antigen Presentation. Peptide Science. In press.
21
A. Introduction
The proteasome is a multi-subunit complex responsible for the degradation
of many if not all cytosolic proteins (Coux et al., 1996). It plays a crucial role in a
variety of biological processes including degradation of key regulatory proteins
such as the cyclins and the activation of transcription factors by removal of
inhibitory factors (Palombella et al., 1994; Sheaff and Roberts, 1996; Ghislain et
al., 1993; Hateboer et al.. 1996; Glotzer et al., 1991). The proteasome is also
required for the generation of antigens for presentation to cytotoxic T-cells via
the major histocompatibility complex (MHC) class I pathway (Goldberg and
Rock, 1992; Goldberg et al., 1995). Its role in these diverse biological processes
has been uncovered largely through the use of inhibitors and genetic mutants
which allow for the controlled blocking of proteolytic function.
B. Structure and Mechanism of the Proteasome
The proteasome is a large, barrel-like structure made up of four stacked
rings of 7 subunits each (Coux et al., 1996; L6we et al., 1995; Lupas et al., 1995).
These rings form a tunnel with openings at either end and an inner core where
controlled proteolysis takes place. There are two types of subunits termed a and
1, with the a-subunits playing mainly a structural role while the 1-subunits are
endowed with catalytic activity. The simplest type of proteasomes are found in
bacteria such as Rhodococcus (Lupas et al., 1994)and in the archaebacterium
Thermoplasma acidophilum. (Lupas et al., 1995). In these organisms the
proteasome is made up of only a single type of a subunit and a single type of P
subunit. The eukaryotic proteasome, although structurally similar to the
eubacterial enzyme, is much more complex, consisting of 14 unique but related
a and 14 unique but related , subunits (Coux et al., 1996; Lupas et al., 1995;
Dahlmann et al., 1989; Heinemeier et al., 1994). The eukaryotic proteasome exists
as a 20S complex made up of two rings of catalytic 1-subunits (7 subunits per
ring) and two rings of a-subunits (also seven subunits per ring), or as a larger 26S
complex in which regulatory subunits (termed the 19S complex) are added to the
core 20S complex. These regulatory subunits include ATPase, isopeptidases
(discussed below) and several proteins thought to be responsible for the
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unfolding of a protein substrate prior to insertion into the proteolytic core of the
20S proteasome. The structure of the 20 and 26S proteasomes is shown in figure
1.1.
The 26S complex, unlike the 20S complex, binds ATP and is responsible for
the degradation of proteins which have been targeted for degradation by
conjugation with a 72 amino acid polypeptide known as ubiquitin (Hershko and
Ciechanover, 1992). Ubiquitin is attached to a target protein by an isopeptide
bond formed between the e-amino group of lysine on the target and the C-
terminal glycine reside of ubiquitin. This conjugation is performed by a series of
enzymes called El, E2 and E3 (Hershko and Ciechanover, 1992). The mechanism
by which ubiquitin is conjugated to a protein for degradation is shown in figure
1.2. Ubiquitin conjugating enzymes act in series by transferring a ubiquitin chain
from one enzyme to the next by an activated thio-ester linkage to a cysteine
residue. The final step is a transfer of the activated ubiquitin chain from the E2
enzyme to the target protein. The mono-ubiquitinated protein is then acted on
again and the same ubiquitin conjugating enzymes attach an additional ubiquitin
to the previous one at either of two possible lysine residues. Ubiquitin
conjugation continues and results in a high molecular weight poly-ubiquitin
protein complex. This heterogeneous population of ubiquitin tagged molecules
is then the target for rapid degradation by the 26S proteasome (Coux et al., 1996).
Once a ubiquitin-protein conjugate begins to be destroyed by the 26S
proteasome, ubiquitin is recycled by removal of the large, branched poly
ubiquitin chain (Wilkinson et al., 1995). The resulting polymer is subsequently
cleaved to individual monomer units by enzymes called isopeptidases which
perform the cleavage of the ubiquitin-isopeptide bond. In some cases an
isopeptidase may remove a polyubiquitin chain from a protein, thus saving the
potential substrate from destruction by the proteasome (Lam et al., 1997). There
are several known isopeptidases in this family of enzymes but still little is known
about the mechanism by which these enzymes act (Hadari et al., 1992; Falquet et
al., 1995; Lam et al., 1997; Wilkinson et al., 1995). Possible inhibitors of these
peptidases could be of great importance in deciphering the role of ubiquitin
conjugation in protein degradation.
One of the qualities which distinguishes the proteasome from many other
proteolytic enzymes is its multiple peptidase activities. Initial studies of the
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Figure 1.1. Structure of the eukaryotic and prokaryotic 20S and 26S
proteasome. (A) cartoon representation and (B) sketch based on the
electron micrograph.
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proteasome using fluorogenic substrates consisting of a variety of sequences
indicated that the proteolytic activity of the proteasome could be categorized into
three main activities: cleavage after hydrophobic side chains (chymotrypsin-
like), cleavage after acid side chains (post glutamyl peptidase), and cleavage
after basic side chains (trypsin-like)(Orlowski, 1990; Wilk and Orlowski, 1983;
Rivett, 1989). These activities were found to be the result of distinct active sites
and could be modulated by mutation of -subunits or by changing the
composition of individual subunits (Goldberg et al., 1995; Hilt and Wolf, 1995). In
addition to the three major proteolytic activities of the proteasome, two other
activities have been discovered as the result of their resistance to inhibition by
the serine protease inhibitor 3,4-dichloroisocoumarin (Cardozo et al., 1992).
These two proteolytic activities result in cleavage after branched-chain amino
acids (BrAAP activity) and cleavage after small neutral amino acids (SNAAP
activity)(Cardozo et al., 1992).
Initial studies of the proteasome were unable to classify it into a category
with other known proteases mainly due to lack of homology and unusual
reactivity with protease inhibitors (Zwickl et al., 1991; Zwickl et al., 1992). It was
initially thought to utilize a cysteine or serine as the catalytic nucleophile, but
exhaustive mutational analysis found neither of these residues to be required for
catalytic activity (Seemuiller et al., 1995). Recently mutation analysis of the 
subunits of the Thermoplasma proteasome showed the N-terminal threonine
residue to be required for hydrolysis (Seemuller et al., 1995). This, combined
with the X-ray crystal structure of the 20S proteasome from Thermoplasma with
an inhibitor bound in the active site, provided strong evidence that the sidechain
hydroxyl of Thrl was the catalytic nucleophile (Lowe et al., 1995; Seemuller et al.,
1995). The proposed mechanism of peptide hydrolysis by a 1-subunit of the
proteasome is shown in figure 1.3. Activation of the sidechain hydroxyl of
threonine is thought be catalyzed by either the free amino terminus or the amine
of a nearby lysine. This lysine residue, in conjunction with a glutamic acid
residue, may act as a charge relay system analogous to that found in most serine
proteases. Thus the proteasome is an example of a N-terminal hydrolase, of
which there are only a few known other examples (Tikkanen et al., 1996;
Duggleby et al., 1995; Smith et al., 1994).
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Like many proteolytic enzymes, activation of the N-terminal nucleophile
found on the catalytically active subunits of the proteasome is a process
involving a proteolytic processing step. The proteasorne synthesizes all of its
catalytic 13-subunits as inactive precursor proteins which must first be activated
by removal of an N-terminal pro-sequence. This prosequence is remarkably
diverse from subunit to subunit and there is also little homology within the pro-
sequences of -subunits from different species (Seemiller et al., 1996).
Mutational analysis has shown that the catalytic Thrl as well as a conserved
glycine residue on the N-terminal side of Thrl (termed Gly-1) are both required
for efficient processing of the 5-subunits (Schmidtke et al., 1996; Chen and
Hochstrasser, 1996). It has been reported by multiple laboratories working with
yeast and mammalian systems that removal of the prosequence is not required
for assembly of subunits into the large 20S and 26S complexes, and therefore it is
believed that the pro-sequences prevent catalytic activation of 5-subunits before
they become part of the larger proteolytic complex (Chen and Hochstrasser, 1996;
Schmidtke et al., 1996). The mechanism of pro-sequence hydrolysis, however,
still remains unclear. Several reports have proposed an intermolecular
mechanism in which another p-subunit is required for processing (Chen and
Hochstrasser, 1996; Seemiller et al., 1996), while a purely autocatalytic,
intramolecular process remains possible. The proposed mechanism for
autocatalytic processing of a 3-subunit is shown in figure 1.4. The details of the
processing events are difficult to address and the process may in fact be a
combination of the two proposed mechanisms.
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Figure 1.3. Peptide bond hydrolysis by the proteasome by two possible
mechanisms. The side chain hydroxyl of threonine is activated by either
the N-terminal amino group (mechanism A) or by a lysine amino group
(mechanism B).
30
Mechanism A
o)
R(SO
CH3 ./ H
Enz H,, ,7Ht 'H
H2
cH3 .
2N -
H2
H2N- R + + ENZ- OH
OR
Mechanism B /
H 
Glu17
RAOH
Figure 1.4. Possible mechanism for autocatalytic processing of a
proteasomal p-subunit.
32
HLyS3 N- - H 
H2 1
H
Ly +'° H
NH3
Ser 29
Gly.!
Ly .° °H H/
H
RHOH
Thrl
-YJ33
1
Ser29,
R
H2 N'
O
,H
I o
H2N
C. Inhibitors of the proteasome
Crucial to understanding proteasome function is the ability to modulate its
activity in vivo. This goal has been accomplished with the advent of several
classes of proteasome inhibitors which are able to penetrate living cells and block
proteasome function without affecting normal biological processes such as ATP
metabolism and protein synthesis (Iqbal et al., 1995; Fenteany et al., 1995;
Harding et al., 1995; Rock et al., 1994). The structures of several classes of
proteasome inhibitors are shown in figure 1.5. The first class of compounds to
be studied as inhibitors of the proteasome were the C-terminal peptide
aldehydes (Rock et al., 1994; Jensen et al., 1995; Iqbal et al., 1995; Wilk and
Figueiredo-Pereira, 1993). The C-terminal aldehyde group is capable of forming
a covalent hemi-acetal with a threonine hydroxyl and may also form a stable
oxizolidine ring by simultaneous reaction with the N-terminal amine and the
sidechain hydroxyl. The mechanism of inhibition of the proteasome by the
peptide aldehydes as well as several other classes of inhibitors is shown in figure
1.6. These types of covalent adducts, although energetically favored, are
reversible and therefore peptide aldehyde inhibitors may be removed, resulting
in the return of proteolytic function (Rock et al., 1994).
Initial studies using peptide aldehydes were carried out with compounds
previously described to inhibit other proteolytic enzymes. The tri-peptide
aldehyde acetyl-leu-leu-norleucinal (Calpain I inhibitor) was found to reversibly
inhibit the chymotrypsin like activity of the proteasome while the tri-peptide
aldehyde leupeptin was found to be a weak inhibitor of the trypsin-like activity
(Cardozo et al., 1992; Wilk and Figueiredo-Pereira, 1993). Because of the
therapeutic possibilities of proteasome inhibitors and driven by the need for tools
to dissect proteasome function, other more potent inhibitors of the proteasonle
including the tri-peptide aldehyde, cbz-leu-leu-leucinal (or Z-L3-H)have been
reported (Read et al., 1995; Wiertz et al., 1996a; Wiertz et al., 1996b; Jensen et al.,
1995; Rock et al., 1994). This tri-peptide aldehyde has been subsequently used to
block proteasome function in living cells and was shown to be a reversible
inhibitor of the post glutamyl and trypsin-like as well as the chymotrypsin-like
activities of the proteasome. Although these types of inhibitors have found
widespread use, caution must be taken when interpreting effects of the peptide
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Figure 1.5. Structures of several classes of inhibitors of proteasomal
proteolysis.
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aldehydes due to their known inhibitory effect on other proteases such as the
lysosomal cathepsins and calpains (Coux et al., 1996; Bogyo et al., 1997). In
addition, the highly reactive aldehyde functional group allows for possible side
effects as the result of Schiff's base formation with circulating free amines.
More recently peptides modified at the C-terminus by a vinyl sulfone
moiety have proven to be another class of compounds capable of inhibiting
proteasome function (Bogyo et al., 1997). This type of C-terminally modified
peptides are Michael acceptors and were therefore initially designed to be
reactive towards soft nucleophiles such as thiols in the active site of a lysosomal
cysteine proteases (Br6mme et al., 1996; Palmer, 1995; Rosenthal et al., 1996).
However, this class of inhibitors, when equipped with the proper tri-peptide
sequence, is capable of covalent modification of the N-terminal threonine of the
proteasome. In addition, since the vinyl sulfones act as "suicide substrates" for
the active site nucleophile, attachment of a radioisotope to these peptides results
in an active site label which can covalently tag the proteasome in living cells
(Bogyo et al., 1997). These compounds have also been found to be less reactive
than peptide aldehydes towards lysosomal proteases and have no adverse effects
on normal metabolic functions such as protein synthesis (Bogyo et al., 1997).
An inhibitor of the proteasome which is structurally quite different from
the peptide based inhibitors is the natural antibiotic lactacystin (Figures 1.6 and
1.7). This compound was initially identified by virtue of its ability to promote
neurite outgrowth in cultured neurons (Omura et al., 1991). A radiolabeled form
of lactacystin was used to identify the target of the drug as a single catalytic 
subunit (named X) of the eukaryotic proteasome (Fenteany et al., 1995).
Subsequently, several laboratories have shown that lactacystin in fact modifies all
active p-subtu:its (Bogyo et al., 1997; Craiu et al., in press). Lactacystin is distinct
from the peptide aldehydes and peptide vinyl sulfones in its specificity for the
proteasome, having little or no effect on lysosomal proteolysis (Fenteany et al.,
1994; Coux et al., 1996). Lactacystin is a covalent inhibitor of the chymotrypsin-
like and the trypsin-like activities of the proteasome and a weak reversible
inhibitor of the postglutamyl peptidase activity (Fenteany et al., 1995). Kinetic
and biochemical studies of proteasomal inhibition by lactacystin and related
derivatives have uncovered the unusual mechanism by which these compounds
covalently modify the N-terminal threonine of the proteasome. Upon prolonged
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incubation in aqueous media, a hydroxyl group reacts with the thioester
functional group resulting in the formation of a -lactone (figures 1.6 and 1.7)
(Dick et al., 1996). It is this highly reactive 1-lactone that is thought to be the
species which is responsible for the covalent modification of the N-terminal
threonine of proteasomal -subunits.
Still other classes of compounds have been described which are capable of
either reversible or irreversible inhibition of the proteasome. These reagents
include several di- and tri-peptide aldehydes with sequences different from that
of Z-L3-H (Iqbal et al., 1995), peptide boron esters (Iqbal et al., 1996; McCormack
et al., Submitted), peptide c-ketocarbonyls (Iqbal et al., 1996), and tripeptide ca,B-
epoxyketones (Spaltenstein et al., 1996). These compounds all have potential use
in studying proteasome function but have not yet been exploited to their full
potential.
D. Antigen Presentation
The topic of antigen presentation has been the subject of many review
articles (Heemels and Ploegh, 1995; Wolf and Ploegh, 1995; Germain and
Margulies, 1993) and therefore the details of these pathways will not be
discussed at length in this introduction. Figure 1.7 shows a general scheme for
presentation of peptides via the two main routes. Presentation of peptides via
MHC class II molecules begins with the endocytosis of foreign material. Once
inside the endocytic pathway, proteins are broken down into peptide fragments
by lysosomal proteases known as cathepsins (Germain and Margulies, 1993).
These proteases have optimal activity at the acidic pH of the lysosomal
compartment. Consequently, neutralization of the endosome leads to a block in
antigen presentation via this pathway (Ziegler and Unanue, 1982; Bnaroch et al.,
1995). At the same time, MHC class II molecules are transported from the
endoplasmic reticulum through the golgi apparatus and are targeted to vesicles
containing the foreign peptides. These peptides may then bind in the groove of a
class II molecule and move on as a complex to the cell surface for display to CD-4
positive helper T-cells. Engagement of the proper class II-peptide complex with
the T-cell receptor of a CD4+ T-cell can lead to an inflammatory response and to
the production of antibodies.
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Figure 1.7. Presentation of antigenic peptides via MHC class I and class II
molecules.
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Largely distinct from this pathway is presentation of peptides by MHC
class I molecules. In this pathway, class I heavy chains are synthesized and
assembled with the light chains, 2-microglobulin (132m) in the endoplasmic
reticulum. A peptide of 7-9 residues in length is the third and final component of
this complex and is required for proper assembly and release of the class I
complex from the ER. Peptides presented by class I molecules are in most cases
derived from cytosolic proteins by proteolysis, as described below. Thus, the
host cell must have a mechanism which allows for the transport of these peptides
across the ER membrane. This translocation process is carried out by a dedicated
transporter called TAP (for Transporter associated with Antigen Presentation).
TAP is a heterodimeric complex consisting of two transmembrane proteins
(TAP1 and TAP2) which utilize energy from ATP to translocate peptides from
the cytosol to the lumen of the ER. Once peptides bind to Class I molecules in
the ER, the complex is allowed to leave the ER and is transported thought the
secretory pathway. Eventually this peptide MHC complex is displayed to
cytotoxic T-cells at the cell surface. Upon engagement of a T-cell receptor with
an MHC class I molecule containing an appropriate peptide, the T-cell becomes
activated and may proceed to kill the infected cell.
In order for a cell to advertise the presence of an intruding organism to
cytotoxic T-cells, it must first be able to generate peptide fragments from proteins
synthesized by the presenting cell. Crucial to presentation of antigens by this
pathway is the generation of peptides suitable for transport by TAP and also
capable of binding to class I molecules. The proteasome is a key player in the
generation of these antigenic peptides and its role in this pathway will be the
focus of further discussion throughout this thesis.
E. The Proteasome's Role in Antigen Presentation
Cells of the immune system must be able to recognize when a cell is
infected with a foreign pathogen and subsequently deal with the intruder by
destruction of the infected cell. This communication between the T-cell and a
virus infected cell is mediated by molecules of the major histocompatibility
complex, or MHC. MHC proteins carry bits of foreign proteins, in the form of 8-
10 residue peptides, to the cell surface to interact with antigen speaific receptors
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on the surface of circulating T-lymphocytes. These peptides must be generated
from intact proteins by the action of proteolytic enzymes such as the proteasome.
Although the existence of a soluble ATP dependent proteolytic complex
known as the proteasome was known since the late 70's (Etlinger and Goldberg,
1977), its role in the processing of class I antigens for presentation to cytotoxic T-
lymphocytes has only recently been uncovered. Initial studies of genes encoded
in the MHC region identified several low molecular weight proteins given the
name the LMPs (Monaco and McDevitt, 1986). Since the expression of two of the
LMP subunits was inducible by -interferon (Monaco and McDevitt, 1986),
known to stimulate immune responses, it was proposed that these genes played
a role in antigen presentation. Although the LMP subunits were similar in size to
proteasomal subunits and formed complexes of high molecular weigh similar to
the proteasome, it was not until many years after their discovery that the two
were found to be identical (Kelly et al., 1991; Brown et al., 1991; Glynne et al.,
1991).
With this initial discovery, many laboratories began examining the details
of the proteasome's involvement in antigen presentation. Initial studies focused
on the two LMP subunits, LMP-2 and LMP-7, the genes for which were found
adjacent to the TAP transporter genes in the MHC class II region and whose
expression could be modulated with y-interferon (Kelly et al., 1991; Brown et al.,
1991; Glynne et al., 1991). These two subunits were found to be homologous to
the catalytically active P-type subunits of the proteasome (Kopp et al., 1993;
Heinemeier et al., 1994). The effect of these subunits on antigen presentation
was studied using a mutant human cell line in which the MHC region containing
the LMP-2 and LMP-7 genes as well as the TAP-1 and TAP-2 genes had been
deleted (Momburg et al., 1992; Arnold et al., 1992). By replacing the TAP genes
by transfection, it was possible to examine the effects of loss of LMP-2 and LMP-
7 alone. Interestingly, several laboratories showed that the presentation of a
variety of epitopes was unaffected by the absence of these subunits, indicating
that LMP-2 and LMP-7 were not essential for the generation of epitopes (Yewdell
et al., 1994).
Initially, these findings seemed to dispute claims of the proteasome's
involvement in antigen presentation. However, these experiments provided no
information about more subtle effects of LMP-2 and LMP-7 on proteasome
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function. Several laboratories then examined the catalytic activities of the
proteasome either containing or lacking the rinterferon inducible subunits LMP-
2 and LMP-7 (Gaczynska et al., 1993; Driscoll et al., 1993). Activity of the
proteasome against several different fluorogenic peptide substrates designed to
act as substrates for the chymotrypsin-like, the trypsin-like and the post
glutamyl peptidase activities was compared for cells which had or had not been
exposed to r-interferon. The results form these experiments showed that the
activity of the proteasome changes quite dramatically upon inclusion of LMP2
and LMP7, favoring cleavage after hydrophobic and basic residues and strongly
reducing cleavage after acidic residues. Furthermore, the activity of
proteasomes isolated from mutant cells lacking the LMP-2 and LMP-7 subunits
showed the exact opposite effects of r-interferon treatment, favoring cleavage
after acidic residues and reducing the propensity for cleavage after hydrophobic
and basic residues (Gaczynska et al., 1994; Gaczynska et al., 1996). These
findings fit surprisingly well with the sequences of peptides known to bind with
high affinity to MHC class I molecules. Several studies also showed the
importance of hydrophobic or basic residues at the C-terminus of peptides for
efficient transport by TAP (Heemels et al., 1993). These data restored the belief
that the proteasome played an important role in antigen presentation.
More recently the requirement of the proteasome for generation of
antigenic peptides was examined using inhibitors capable of blocking
proteasome function (Harding et al., 1995; Rock et al., 1994). Studies performed
by several laboratories provided strong evidence that proteasome function was
crucial to presentation of epitopes to cytotoxic T-lymphocytes. Several peptide
aldehydes comprised of different amino acid sequences were used to block
proteasomal proteolysis. These inhibitors were able to cause a block in the rate of
break-down of both long and short lived proteins, as well as the degradation of
abnormal proteins, all of which were believed to be the result of proteasomal
inhibition. Further, when cells were pre-treated with the peptide aldehyde
inhibitors and subsequently assembly of class I molecules was examined by
metabolic labeling and pulse chase analysis, it was found that inhibition of the
proteasome led to a block in the formation of stable MHC class I heterodimers
(heavy chain and 2m). Since studies with cells lacking the TAP transporter
showed a similar assembly defect due to a lack of peptides in the ER (Salter and
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Cresswell, 1986), this result was presumed to be caused by a loss of peptides
capable of binding to and stabilizing class I dimers. These data strongly
suggested that proteasomal proteolysis was required for generation of peptides
which bind to class I molecules in the ER.
Finally, proteasome inhibitors were found to have a dramatic effect on the
ability of cells to present epitopes to cytotoxic T-lymphocytes (Rock et al., 1994).
When an antigenic protein was introduced into cells followed by pre-incubation
with a peptide aldehyde known to inhibit proteasome function, there was a
complete block in lysis by epitope-specific T-lymphocytes. However, when a
mini-gene encoding only the epitope required for transport, binding and
presentation was introduced into the same cells, lysis by CTLs was resistant to
treatment with proteasome inhibitors. Further, when a peptide aldehyde known
to inhibit lysosomal and soluble proteases other than the proteasome was used,
there was no effect on antigen presentation.
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II. COVALENT MODIFICATION OF THE ACTIVE SITE
THREONINE OF PROTEASOMAL P-SUBUNITS AND
THE ESCHERICHIA COLI HOMOLOG HslV BY A NEW
CLASS OF INHIBITORS
Matthew Bogyo, John S. McMaster, Maria Gaczynska, Domenico
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A. Introduction
Proteasomes are multi-catalytic proteolytic complexes found in almost all
living cells and are responsible for the degradation of the majority of cytosolic
proteins in mammalian cells (Coux et al., 1996). The 20S proteasome is a 70G kDa
barrel-shaped structure composed of four stacked rings with seven-fold
symmetry (L6we et al., 1995). These rings are composed of two types of
subunits; a subunits make up the outer two rings of the complex and the catalytic
1 subunits the inner two rings. Proteasomes of the archaebacterium,
Thermoplasma acidophilum, and certain eubacteria are comprised of 14
identical a and 14 identical 3 subunits. In contrast, the a rings of the eukaryotic
proteasomes contain 7 different but homologus a subunits and the f3 rings contain
7 distinct but related subunits (20S proteasome) (Dahlmann et al., 1989). The
20S proteasome functions as the catalytic core of the larger, ATP-dependent, 26S
complex which is responsible for the degradation of ubiquitin conjugated
proteins ((Hershko and Ciechanover, 1992)). Further complexity arises from the
possible replacement of the catalytic subunits X,Y, and Z with the IFN-y
-inducible, MHC-encoded subunits LMP-2, LMP-7, and MECL-1 (Gaczynska et
al., 1993).
Initial attempts to classify the proteasome's catalytic mechanism into a
category with known proteases were unsuccessful mainly due to lack of
homology with known peptidases (Zwickl et al., 1992). Mutational studies and
the x-ray crystal structure of the Thermoplasma proteasome in a complex with a
tri-peptide aldehyde inhibitor provided evidence that the proteasome employs a
novel catalytic mechanism, involving an N-terminal threonine residue as the
catalytic nucleophile (L6we et al., 1995; Seemuiller et al., 1995). In this
mechanism, either the free-amino terminus or the -amino group from a
conserved, nearby lysine residue activates the side-chain hydroxyl group for
nucleophilic attack on the peptide bond (Seemuiller et al., 1995). This mechanism
thus does not involve a charge relay system utilized by most cysteine and serine
proteases.
The ubiquitin proteasome pathway plays a crucial role in the degradation
of highly abnormal and many short lived regulatory proteins and has been
shown to be involved in many diverse cellular functions including cell cycle
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progression, antigen presentation, and activation of transcription factors
(Ghislain et al., 1993; Harding et al., 1995; Palombella et al., 1994). Inhibitors of
the proteasome are thus of considerable interest as tools for studying the detailed
molecular mechanistic aspects and physiological consequences of proteasome
activity. Peptide aldehydes are potent, reversible inhibitors that inactivate the
proteasome's multiple active sites by forming a transient, covalent hemi-acetal
with the catalytic N-terminal threonine hydroxyl (Harding et al., 1995; Rock et
al., 1994). Peptide aldehydes are active against proteasomal proteolysis both in
vitro and in cells grown in tissue culture. However, this class of inhibitors can
also inhibit cellular thiol proteases (e.g. calpains or lysosomal cathepsins) which
can complicate the interpretation of certain studies (Coux et al., 1996; Rock et al.,
1994).
The natural product lactacystin is an irreversible, covalent inhibitor of the
chymotrypsin-like and trypsin-like activities and a weak, reversible inhibitor of
the peptidylglutamyl peptidase activity of the proteasome (Fenteany et al., 1995).
The ability of lactacystin to covalently inactivate its target led to its use as a
probe to examine the specificity of binding. A radiolabeled analog of lactacystin,
was reported to uniquely label a single proteasomal 3 subunit, MB-1 or X
(Fenteany et al., 1995). Its exquisite specificity has made it a very useful reagent
for studying proteasome function in mammalian cells, but its modest activity
against proteasomes from archaebacterium and certain eubacterial homologs has
limited its use in studies of these related proteolytic enzymes.
We report here a new class of inhibitors of the proteasome: peptide vinyl
sulfones. The vinyl sulfone acts as a Michael acceptor for soft nucleophiles such
as thiols, leading to the formation of a covalent bond (Palmer, 1995) (figure 2.1B).
However, these compounds are not susceptible to attack by free thiols which can
cause inactivation of other classes of protease inhibitors (Palmer, 1995). We show
that the tripeptide vinyl sulfone Z-L3-VS and related derivatives quite
unexpectedly inhibit the trypsin-like, the chymotrypsin-like and, unlike
lactacystin, the peptidylglutamyl peptidase activity of the proteasome in vitro by
covalent modification of the N-termninal threonine of the catalytically active [3
subunits. They are more easily synthesized than lactacystin and can be
conveniently tagged with either biotin for purposes of affinity chromatography
(Bogyo & Ploegh, unpublished observation), or a nitro-phenol moiety for
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subsequent radiolabeling. We show that a 125I -labeled vinyl sulfone of the tri-
peptide sequence Leu-Leu-Leu selectively modifies -subunits in purified
proteasome preparations as well as in whole cell homogenates and in living cells
of widely different origin.
Recently an ATP-dependent protease complex from E. coli comprised of
two heat shock proteins has been discovered (Rohrwild et al., 1996). The HslV
gene product is a peptidase which shows homology to 5-type subunits of the
proteasome, including the presence of a N-terminal threonine (Lupas et al., 1994;
Rohrwild et al., 1996). HslV is co-transcribed with the adjacent HslU gene which
encodes an ATPase with homology to other known E.coli ATPases such as ClpX
(50% identity) (Chuang et al., 1993). Together the HslV and HslU gene products
make up a complex with an ATP-dependent proteolytic activity similar to that of
the eukaryotic proteasome (Rohrwild et al., 1996). The peptide vinyl sulfones
were used as probes to examine the proteolytic mechanism of this peptidase
complex. We show that peptide vinyl sulfones covalently modify HslV only in
the presence of HslU and ATP, consistent with the reported nucleotide
dependence of the activity of this complex (Rohrwild et al., 1996). These
observations provide experimental support for the HslU/HslV complex's
proposed functional homology to the proteasome and indicate that ATP
influences the formation of the active site of this enzyme complex.
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B. Materials and Methods
1. Cells and Cell Culture
The human cell lines HOM-2, T2, and US11 transfectants prepared from
the astrocytoma cell line, U373-MG have been described (Wiertz et al., 1996a).
The US11 transfectants were cultured in Dulbecco's modified Eagle medium
supplemented with 10% fetal calf serum and puromycin (Sigma, St. Louis, MO)
at a final concentration of 0.375 gg/ml. All other cells were grown in RPMI
media supplemented with 10% fetal calf serum.
2. Antibodies
Proteasomes were precipitated using the mono-clonal antibody which
recognizes an a subunit as part of the mature 720 kDa proteasome complex
(Organon Teknika, Turnhout/Belgium) (Briane et al., 1992). MHC class I
molecules were precipitated using a rabbit anti-class I heavy chain serum
described elsewhere (Beersma et al., 1993).
3. Biochemical Methods and Materials
Peptide inhibitors (Z-L3H, Z-L3VS, and NIP-L3VS) were dissolved in
DMSO and diluted in cell culture media to the desired concentration, keeping
the final concentration of DMSO to be < 1%. Cells (1.5 x 106), purified
proteasomes (0.1 gg for rabbit, S. cerevisiae, and Thermoplasma acidophilum; 0.1 jig
HslV and 0.4 gg HslU) or lysates (100 jig total protein) were labeled with 125I-
NIP-L3VS, diluted to a final concentration of 1.8 x 104 Bq/ml in tissue culture
medium (cells) or reaction buffer (50 mM Tris pH 7.4, 2 mM DTT, 5 mM MgC12,
2mM ATP, purified proteasomes), at 37° C for two hours. For labeling in the
absence of ATP, apyrase (5 units/ml) was used instead of ATP. Labeling of cells
was quenched by washing 3X with PBS followed by addition of 1X SDS-Laemmli
sample buffer. Labeling of purified proteasomes and total lysates was quenched
by addition of 4X Laemmli sample buffer (to 1X). All samples were resolved by
51
SDS-PAGE, NEPHGE-PAGE or IEF-PAGE. Preparation of lysates and immuno-
precipitations were performed as described ((Beersma et al., 1993)).
4. Kinetics Analysis of inhibition of proteasomal peptidase activity
Purified mixtures of 20S and 26S proteasomes were isolated from U373-MG
cells by differential centrifugation and anion-exchange chromatography as
previously described (Gaczynska et al., 1993; Gaczynska et ai., 1994). 20S
proteasomes were separated from these mixtures by native PAGE (4%
polyacrylamide gel). Mixtures of 20S and 26S proteasomes or pure complexes
were used to determine kinetics of inhibition of the proteasomal peptidases.
Fluorogenic peptide substrates (100gM final conc.) were used as substrates for
the hydrophobic (Suc-LLVY-MCA), basic (Boc LRR-MCA) and acidic (Cbz-LLE-
NA) peptidase activities as described (Gaczynska et al., 1993; Gaczynska et al.,
1994)). The rates of association (Kassoc) of Z-L3VS were determined as previously
described (Fenteany et al., 1995).
5. Synthesis of the Peptide Vinyl Sulfones
The peptide vinyl sulfones were synthesized by standard solution
chemistry as described below. The synthetic route is shown in figure 2.1 along
with the mechanism of inhibition of the proteasome by this class of inhibitors.
a. Synthesis of Boc-leucinyl-leucinyl-methyl ester (I)
Boc-Leu-OH (12.4 g, 50 mmol) was dissolved in DMF. To the flask was
added dicyclohexylcarbodiimide (12.3 g, 60 mmol) and HOBT (8.1g, 60 mmol).
The reaction was then stirred for 30 min until a precipitate formed. Finally,
leucine methyl ester hydrochloride salt (6.0 g, 33 mmol) and diisopropylethyl
amine (6.3 ml, 36 mmol) were added and the reaction stirred overnight. The
reaction mixture was then filtered to remove solids and the DMF was removed
by rotary evaporation. The resulting crude oil was dissolved in dichloromethane
and washed with three volumes of 0.1 N HC1 and three volumes of saturated
sodium bicarbonate. The organic layer was dried over magnesium sulfate and
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then concentrated to dryness by rotary evaporation. The pure dipeptide ester
was obtained by recrystallization of the crude solid from ethyl acetate/hexane.
Yield (8.4 g, 23.5 mmol, 71%).
Boc-Leucinyl-leucine-methyl ester 1H-NMR (300 MHz, CDC13) d 6.45 (1H, d),
4.89 (1H, d), 4.62 (1H, m), 4.10 (1H, q), 3.75 (3H, s), 1.50-1.78 (6H, m), 145 (9H,
s), 0.88-099 (12H, m).
b. Synthesis of Boc-leucinyl-leucine (II)
Boc-Leucinyl-leucine methyl ester (I; 4.0 g, 11.2 mmol) was dissolved in 50
ml of methanol. To the flask was added 50 ml of an aqueous solution of 20%
potassium carbonate and the reaction stirred overnight. The reaction was
quenched by the addition of 3N HC1. The resulting aqueous solution was then
extracted with three volumes of methylene chloride. The organic phases were
combined, dried over MgSO4, and evaporated to dryness and used without
further purification. Yield (2.7 g, 7.8 mmol, 71%).
c. Synthesis of Boc-leucine-dimethyl hydroxyl amide (III)
Boc-leucine (2.0 g, 5.6 mmol) was dissolved in dichloromethane. PyBOP
(2.9 g, 5.6 mmol) and triethyl amine (782 gl, 5.6 mmol) were then added and the
reaction was allowed to stir for 10 minutes. Dimethylhydroxyl amine (0.61g, 6.2
mmol) was then added followed immediately by more triethylamine (860 gl, 6.2
mmol). The reaction was stirred for 1 hour and then quenched by addition of
three volumes of 0.1 N HC1. The remaining aqueous phase was extracted with
three volumes of methylene chloride. The organic layers were combined,
washed with one volume of saturated sodium bicarbonate and one volume of
saturated sodium chloride, dried over MgSO4 concentrated to an oil. The crude
oil was purified by flash column chromatography over silica gel using
hexane/ethyl acetate (3:1 V:V) as the mobile phase. Yield (2.2 g, 4.5 mmol, 80%).
53
Boc-Leucine-dimethyl hydroxyl amide 1H- NMR (300 MHz, CDC13) d 5.05 (1H,
d), 4.72 (1H, m) 3.80 (3H, s), 3.20 (3H, s), 1.70 (1H, ni), 1.45 (9H, s) 1.40 (2H,
m), 0.95 (3H, d), 0.90 (3H, d).
d. Synthesis of Boc-leucinal (IV)
Boc-leucine-dimethyl hydroxyl amide (III) (1.8 g, 4.5 mmol) was dissolved
in 10 ml of anhydrous diethyl ether under argon. Lithium aluminum hydride
(210 mg, 5.6 mmolj was added as a solid and the reaction stirred for 1 hour. The
reaction was quenched by the addition of potassium hydrogen sulfate (1.0 g, 7.9
mmol) in 30 ml of water. The reaction mix was stirred for 20 minutes and then
the organic layer was removed. The remaining aqueous phase was washed with
three volumes of diethyl ether. The organic layers were combined, washed with
three volumes each of 3N HCl, saturated sodium carbonate, and saturated
sodium chloride, dried over MgSO4 and then evaporated to dryness. Due to
problems of racemizaton upon column chromatography, Boc-leucinal was used
without further purification. Yield (1.3 g, 3.9 mmol, 87%).
Boc-Leucinal 1H-NMR (300 MHz, CDC13) d 9.60 (1H, s), 4.95 (1H, d), 4.25 (1H,
dd), 1.70 (1H, m), 1.45 (9H, s), 1.40 (2H, m), 0.95 (3H, d), 0.90 (3H, d).
e. Synthesis of Boc-leucine-vinyl sulfone (V)
Diethyl (methylthiomethyl) phosphonate was oxidized to the
corresponding phosphonate sulfone using peracetic acid in aqueous dioxane.
The product was isolated by crystallization from warm ethyl acetate. Diethyl
phosphonate sulfone (802 mg, 3.5 mmol) was dissolved in anhydrous THF.
Sodium hydride (128 mg, 3.2 mmol) was added and the reaction is stirred for 30
minutes. Finally, Boc-leucinal (IV; 500 mg, 2.3 mmol) was dissolved in
anhydrous THF and added slowly by canula to the reaction mix. The reaction
was then allowed to stir for 2 hours. The reaction was quenched with water and
the resulting aqueous phase washed three times with dichloromethane. The
organic phases were combined, dried over MgSO4 and evaporated to dryness.
the crude oil was purified by flash chromatography over silica gel using a
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hexane/ethyl acetate (3:1 v:.v) as the mobile phase. Yield (785 mg, 1.9 mmol,
82%).
Boc-leucine-vinyl sulfone 1H-NMR (300 MHz, CDC13) d 6.78-6.88 (1H, dd), 6.41-
6.52 (1H, dd), 4.60 (1H, d), 4.40 (1H, m), 2.92 (3H, s), 1.60-1.75 (1H, m), 1.45
(9H, s), 1.35-1.45 (2H, m), 0.95 (3H, d), 0.89 (3H, d).
f. Synthesis of leucine-vinyl sulfone tosic acid salt
p-Toluenesulfonic acid monohydrate (386 mg, 2.0 mmol) was dissolved in 5
ml isopropanol with gentle heating. Toluene (20 ml) was then added and the
solution rotary evaporated to dryness. The resulting oil was further dried in
vacuo for several hours. Boc-leucine-vinyl sulfone (V; 200 mg, 677 j1mol) was
dissolved in 10 ml diethyl ether and the added to the flask containing the
anhydrous p-toluenesulfonic acid. The reaction was stirred overnight and the
resulting amine salt precipitated. The precipitate was isolated by centrifugation
and the pellet was washed two times with diethyl ether. Yield (237 mg, 643
gmol, 95%).
Leucine-vinyl sulfone tosic acid salt 1H-NMR (300 MHz, CDC13) d 7.75 (2H, d),
7.15 (2H, d), 6.85-6.95 (1H, dd), 6.5-6.6 (1H, dd), 3.60 (1H, m), 2.95 (3H, s), 1.60-
1.78 (1H, m), 1.35-1.42 (2H, m), 0.95 (3H, d), 0.86 (3H, d).
g. Synthesis of Boc-Leucinyl-leucinyl-leucine-vinyi sulfone
Boc-leucinyl-leucine (II) (400 mg, 1.2 mmol) was dissolved in
dichloromethane. PyBOP (726 mg, 1.3 mmol) and triethylamine (180 l1, 1.3
mmol) were then added and the reaction was allowed to stir for 10 minutes.
Leucine-vinyl sulfone tosic acid salt (VI; 500 mg, 1.4 mmol) was then added
followed immediately by additional triethylamine (195 gl, 1.4 mmol). The
reaction was stirred for 1 hour and then quenched by addition of three volumes
of 0.1 N HCl. The remaining aqueous phase was extracted with three volumes of
methylene chloride. The organic layers were combined, washed with one
volume of saturated sodium bicarbonate and one volume of saturated sodium
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chloride, dried over MgSO4, and concentrated to an oil. The crude oil was
purified by flash column chromatography over silica gel using hexane/ethyl
acetate (2:1 V:V). A small amount of a slightly less polar compound was isolated
and found to have a nearly identical NMR as the desired product except for a
slight change in the splitting of the vinyl resonance adjacent to the alpha carbon
of leucine at P1. This minor product is likely to be the tripeptide containing a D-
leucine in the P1 position and was the result of a small amount of racemizaton
during the synthesis of leucine-vinyl sulfone. Yield (600mg, 1.15 mmol, 96%).
Boc-Leu3-VS 1H-NMR (300 MHz, CDCl3) d 7.95 (1H, d), 6.78-6.88 (1H, dd), 6.52-
6.62 (1H, dd), 6.48 (1H, d), 2.95 (1H, d), 4.71 (1H, m), 4.46 (1H, m), 4.0 (1H, m),
2.95 (3H, s), 1.50-1.80 (6H. m), 1.45 (9H, s), 1.40-1.50 (3H, m), 0.80-0.99 (18 H, m).
FAB Mass Spectrum: [M+H] Calculated for C25H47N 3 0 6 S: 518.7 Found: 518.3
h. Synthesis of carboxylbenzyl-leucinyl-leucinyl-leucine-vinyl sulfone (Z-
L3VS)
The synthesis of Z-L3VS was performed exactly as described for Boc-
leucinyl-leucinyl-leucine-vinyl sulfone except that carboxylbenzyl-leucine was
used instead of Boc-leucine in the first step of the synthesis.
Z-L3-VS 1H-NMR (300 MHz, CDC13) d 7.33-7.45 (5H, m), 7.80-7.90 (1H, dd) 7.85
(1H, d), 6.52-6.60 (1H, dd), 6.35 (1H, d), 5.20 (1H, d), 5.12 (2H, s), 4.71 (1H, m),
4.38 (1H, m), 4.08 (1H, m), 2.95 (3H, s), 1.45-1.85 (9H, m), 0.88-1.00 (18H, m).
FAB Mass Spectrum: [M+H] Calculated for - C28H45N306S: 552.7 Found: 552.5
i. Synthesis of leucinyl-leucinyl-leucine-vinyl sulfone tosic acid salt (VIII)
p-Toluenesulfonic acid monohydrate (299 mg, 1.7 mmol) was dissolved in
1.5 ml isopropanol with gentle heating. Toluene (8 ml) was then added and the
solution rotary evaporated to dryness. The resulting oil was further dried in
vacuo for several hours. Boc-leucinyl-leucinyl-leucine-vinyl sulfone (VII; 300 mg,
56
580 ugmol) was dissolved in 2 ml diethyl ether and then added to the flask
containing the anhydrous p-toluenesulfonic acid. The resulting amine salt
precipitated as the reaction proceeded and was isolated by centrifugation. The
pellet was washed two times with diethyl ether and dried under vacuum. Yield
(278 mg, 470 pgmol, 81%).
Leucinyl-leucinyl-leucinyl-vinyl sulfone tosic acid salt 1H-NMR (300 MHz,
CDC13 ) d 7.78 (2H, d), 7.75 (1H, d), 7.18 (2H, d), 7.87 (1H, d), 7.75-7.84 (1H, dd),
6.49 (1H, dd), 4.68 (1H, m), 4.34 (1H, m), 3.40 (1H, m), 2.95 (3H, s), 1.50-1.80
(6H, m), 1.40-1.50 (3H, m), 0.82-1.00 (18H, m).
FAB Mass Spectrum: [M+H] calculated for C2 0H39 N 30 4 S- 418.6 Found: 418.2
j. Synthesis of biotin-leucinyl-leucinyl-leucine-vinyl sulfone (Biotin-L 3VS)
Biotin-nitrophenyl ester (37 mg, 102 pmol) and leucinyl-leucinyl-leucine-
vinyl sulfone (VIII) (50 mg, 85 pmol) were weighed into a dry flask.
Dimethylformamide (1 ml) was then added followed by diisopropylethyl amine
(16 l, 85 pmol). The reaction was stirred overnight. A white precipitate formed
and the reaction mixture was diluted with ten volumes of diethyl ether. The
precipitate was collected by centrifugation and the pellet was washed two times
with diethyl ether. The pure solid was dried in vacuo. Yield (45 mg, 84 pgmol,
82%).
FAB Mass Spectrum: [M+H] Calculated for C30 H5 3N5 06 S2: 644.8 Found: 644.3
k. Synthesis of 5-iodo-4-hydroxy-3-nitrophenyacetyl-leucinyl-leucinyl-
leucine-vinyl sulfone (NIP-L3VS)
5-iodo-4-hydroxyl-3-nitrophenylacetic acid (37 mg, 115 gmol) was
dissolved in dichloromethane. PyBOP (70 mg, 127 punol) and triethyl amine (23
gl, 127 gmol) were then added and the reaction was allowed to stir for 10
minutes. Leucinyl-leucinyl-leucine-vinyl sulfone tosic acid salt (VIII; 75 mg, 127
gmol) was then added followed immediately by additional triethyl amine (21 gl,
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115 mol). The reaction was stirred for 1 hour and then quenched by addition of
three volumes of 0.1 N HCI. The remaining aqueous phase was extracted with
3xl volume of methylene chloride. The organic layers were combined, washed
with 2xl volume of 0.1 N HC1, one volume of saturated sodium chloride, dried
over MgSO4, and concentrated to dryness. The crude solid was purified by
crystallization from warm ethyl acetate. Yield (71.6 mg, 100 pmol, 87%).
NIP-L3-VS 1H-NMR (300 MHz, DMSO-d6) d 10.98 (1H, s), 8.38 (1H, d), 8.15 (1H,
d), 8.05 (1H, s), 8.00 (1H, d), 7.85 (1H, s), 6.65 (1H, dd), 6.55 (1H, dd), 4.55 (1H,
m), 4.25 (1H, m), 3.50 (2H, d), 2.95 (3H, s), 1.20-1.60 (9H, m), 0.70-0.90 (18H, m).
FAB Mass Spectrum: [M+H] Calculated for C28H43N4 08SI: 723.6 Found: 723.3
1. Synthesis of 4-hydroxyl-3-nrsophenyacetyl-leucinyl-leucinyl-leucine-vinyl
sulfone (VIV)
Compound VIV was synthesized using the same conditions described for
NIP-L3VS except 4-hydroxyl-3-nitrophenylacetic acid was used instead of 5-
iodo-4-hydroxyl-3-nitrophenylacetic acid.
4-hydroxyl-3-nitrophenylacetyl-leucinyl-leucine vinyl sulfone 1H-NMR
(300 MHz, DMSO-d 6) d 10.95 (1H, s), 8.30 (1H, d), 8.25 (1H, t), 8.05 (1H, d), 7.80
(1H, s), 7.45 (1H, d), 7.10 (1H, d), 6.65 (1H, dd), 6.55 (1H, dd), 4.55 (1H, m),
4.25 (1H, m), 3.50 (2H, d), 2.95 (3H, s), 1.20-1.60 (9H, m), 0.70-0.90 (18H, m).
m. Synthesis of radio labeled 4-hydroxyl-3-nitrophenyacetyl-leucinyl-
leucinyl-leucine-vinyl sulfone (1251-NIP-L3VS)
A glass test tube was coated with 100 gg of Iodo-gen® (Pierce, Rockford,
IL). The tube was placed on ice and compound VIV (25 gL of a 10 mM solution
in Ethanol/phosphate buffer pH 7.5 (v:v)) was added to the tube. Finally, 1 mCi
of Na'25I (10 gL) was added to the tube and incubation continued on ice for 15
minutes. The labeled inhibitor was purified by application to a sep-pak®
(Waters, Milford, MA) column containing a C18 stationary phase. After the
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sample was applied to the column, the column was washed with 30 ml of
phosphate buffer pH 7.5. 125I-NIP-L3VS was then eluted using 100% acetonitrile.
Fractions of 1 ml were collected and the fractions with peak radioactivity were
pooled. Aliquots of the acetonitrile stock were evaporated to dryness before use
in biological systems.
6. Pulse Chase Analysis
Cells were detached by trypsin treatment and incubated in methionine-free
Dulbecco's modified Eagle's medium with or without added inhibitors for 1 hr.
Two million cells (10 min. pulse; 250 gCi of label) were used per sample.
Incorporation was terminated by the addition of non-radioactive methionine to a
final concentration of 1 mM. Immediately after the chase, samples were placed
on ice and lysed in 1 ml of ice-cold NP-40 lysis mix. Preparations of lysates and
immuno-precipitations were performed as described (Beersma et al., 1993).
7. Gel Electrophoresis
SDS-PAGE, two dimensional IEF-PAGE, fluorography and
autoradiography were performed as described (Mozdzanowski et al., 1995;
Wiertz et al., 1996a). Two dimensional NEPHGE-PAGE was performed as
described (Monaco and McDevitt, 1982).
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C. Results
1. Synthesis of peptide vinyl sulfones
Tripeptide vinyl sulfones were synthesized containing the sequence Leu-
Leu-Leu (Z-L3VS, figure 2.1). Analogs of Z-L3VS in which the carboxylbenzyl
group was replaced with biotin (Biotin-L3VS), the hapten 4-hydroxyl--iodo-3-
nitrophenyl acetate (NIP-L3VS), and the corresponding radiolabeled hapten
(125I-NIP-L3VS) were also synthesized.
2. Peptide vinyl sulfones irreversibly inhibit proteasome activity in vitro
The ability of the peptide vinyl sulfones to inhibit proteasomal proteolysis
was determined in vitro using a partially purified mixture of 20S and 26S
proteasomes with fluorogenic peptides as substrates. Strongest inhibition was
observed for the chymotrypsin-like peptidase activity of the proteasome with
somewhat lesser inhibition of the trypsin-like and peptidylglutamyl peptidase
activities, as shown for Z-L3VS (Fig. 2.2). The peptide vinyl sulfones, including
the biotin and NIP derivatives (data not shown), were only slightly less potent
inhibitors than the peptide aldehyde Z-L3H (Fig. 2.2A) and were more active
towards all three peptidase activities than was lactacystin upon simultaneous
addition with substrates. When each of the three classes of inhibitors was pre-
incubated for one hour with proteasomes and then diluted ten-fold, the extent of
inhibition by the aldehyde was reduced as expected for a reversible inhibitor,
while the extent of inhibition by both lactacystin and Z-L3VS increased,
consistent with time dependent, irreversible inhibition (Fig. 2.2B). Furthermore,
Z-L3VS caused inhibition of the trypsin-like peptidase activity to a greater extent
than lactacystin (Fig. 2. 2B), indicating that Z-L3VS binds to a subunit or binding
site more effectively than lactacystin.
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Figure 2.1. (A) Structure of inhibitors of the proteasome. (B) mechanism of
inhibition of the proteasome by the peptide vinyl sulfones.
(A) PyBop, DIEA, CH 3 NHOCH 3 , CH2 CI2; (B) LAH, Et2 O; (C)
(EtO)2P(O)CH 2 S(O)2CH3 , NaH, THF; (D) TsOH, Et2O; (E) DCC, HOBt, DMF;
(F) 20% K2C0 3 /MeOH; (G) PyBOP, DIEA, CH2C12; (H) TsOH, Et20; (I)
Biotin-nitrophenyl ester, DMF, DIEA; (J) 4-hydroxy-3-iodo-5nitrophenylacetic
acid, PyBOP, DIEA, CH2C12; (K) 4-hydroxy-3-nitrophenylacetic acid, PyBOP,
DIEA, CH2 C2; (L) Nal 25 I, Iodogen®.
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Figure 2.2. The peptide vinyl sulfones inhibit the proteasome in vitro.
Purified preparations of 20S and 26S proteasomes were incubated with
increasing concentrations of the three inhibitors; Z-L3H, Z-L3VS and lactacystin,
either simultaneously with substrates (A) or samples were pre-incubated for 1
hour (37°C) and diluted ten-fold prior to addition of substrates (B). Hydrolysis of
substrates corresponding to the acidic (Cbz-LLE-pNA), basic (Boc-LRR-MCA),
and hydrophobic (Suc-LLVY-MCA) activities of the proteasome were measured
by fluorescence spectroscopy. Association constants (Kassoc) for the compound,
Z-L3VS, were determined for the three peptidase activities of purified 20S
proteasomes (C). V represents velocity of the reaction at the time t, and VO is the
velocity at time 0. Kassoc = ln(V/Vo)/[I] where [I] is the concentration of
inhibitor (5 gM for hydrophobic activity, 50 pgM for basic and acidic activity).
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3. 12SI-NIP-L3VS covalently modifies multiple p subunits in purified
proteasomes preparations and in total cell extracts
A radiolabeled version of the peptide vinyl sulfone NIP-L3VS was used to
examine the ability of this class of compounds to react with proteasomes of
diverse origin. 125I-labeled NIP-L3VS was incubated with purified 20S
proteasomes and with total cell homogenates from rabbit muscle and yeast (Fig.
2.3A, 2.3B). A single band of 23 kDa was labeled both in crude cell extracts and
in purified proteasomes. However, in both cases this band could be resolved
into at least two polypeptides of similar molecular weight but different
isoelectric points.
4. The peptide vinyl sulfones are reactive against the archaebacterial
proteasome from Thermoplasma
Recombinant mutant and wild type proteasome P subunits from the
archaebacterium, Thermoplasma, were used to directly examine whether the N-
terminal threonine is required for covalent modification by a peptide vinyl
sulfone. Labeling of total cell lysates from Thermoplasma was compared to three
preparations of recombinant proteasomes in which the catalytic N-terminal
threonine was replaced with either serine or alanine. Recent studies have shown
that 1-subunits in which the N-terminal threonine is replaced by serine retain full
activity against peptide substrates, while replacement with alanine leads to
complete loss of peptidase activity. 125I-NIP-L3VS labeled not only the subunits
in total extracts, but also in the mutant complex in which the N-terminal
threonine is replaced by serine (Fig. 2.3C). The N-terminal alanine mutant was
refractory to labeling indicating that covalent modification of , subunits requires
the catalytic N-terminal threonine of the proteasome. The slight difference in
apparent molecular weight between the subunits from total cell extracts and the
recombinant forms of subunits is due to the presence of a His tag.
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Figure 2.3. The peptide vinyl sulfone, 125I-NIP-L3VS labels multiple subunits of
the proteasome in total cell extracts and in purified proteasome preparations.
Total cell extracts (T) and purified preparations of proteasomes(P) were
incubated with 125I-NIP-L3-VS (1.8 x 104 Bq/ml) at 37°C for 2 hours, resolved on
a 12.5% polyacrylamide gel and visualized by silver staining, by
autoradiography or by two-dimensional IEF/SDS-PAGE for rabbit muscle (A),
S. Cerevisiae (B), or T. acidophilum (C). For Thermoplasma acidophilum
recombinant f3 subunits containing an N-terminal Thr, Ser, or Ala were
compared, as indicated.
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5. The bacterial protease complex HslV/HslU from E.coli is a target for the
peptide vinyl sulfones
The proteasome-like protease complex from E.coli is composed of two types
of heat shock protein subunits, HslV and HslU (Rohrwild et al., 1996). The -like
subunit HslV contains an N-terminal threonine but direct evidence for a catalytic
role for this residue is lacking (Lupas et al., 1994). To address the catalytic
mechanism of this complex, purified preparations of HslV/HslU were treated
with the 125I-labeled peptide vinyl sulfone. 125I-NIP-L3VS covalently modified
HslV, but only in the presence of HslU and ATP (Fig. 2.4), consistent with the
reported requirement for ATP of the HslV/HslU complex (Rohrwild et al., 1996).
Combined, our results show that the peptide vinyl sulfones are capable of
inhibiting proteases of the proteasome family found in a wide variety of species,
including the eubacterial species E. coli., by targeting the catalytic, active site
threonine residue.
6. 125I-NIP-L3VS covalently modifies p subunits of the proteasome in living
cells in a time and dose dependent manner
The ability of the tri-peptide vinyl sulfones to penetrate cells and
specifically modify proteasomal P subunits was established using several
different cell lines (Fig. 2.5A). Incubation of 125I-NIP-L3VS with the human
astrocytoma cell line U373-MG, the human B-cell line HOM-2 and the human T2
cell line (Salter and Cresswell, 1986) lacking the two interferon inducible 
subunits LMP-2 and LMP-7 showed labeling of a 23 kDa species similar to that
described for rabbit muscle preparations. The labeling increased linearly with
time and with concentration of 125I-NIP-L3VS (data not shown). The labeled
polypeptides could be immuno-precipitated using a monoclonal antibody raised
against an a subunit common to the 20S and 26S proteasome, but not with an
irrelevant antibody, thus establishing that the labeled polypeptides are part of
the proteasome complex.
The identity of the proteasome 3 subunits modified by the radiolabeled
vinyl sulfone was determined using the mutant human cell line, T2, in which
the MHC region coding for the two interferon inducible proteasome subunits,
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Figure 2.4. The peptide vinyl sulfones covalently modify the HslV gene product
from the E.coli protease complex HslV/HslU.
Purified preparations of HslV and HslU were incubated with 125I-NIP-L3VS (1.8 x
104 Bq/ml) independently or as a 1:4 mixture (HslV:HslU) in the presence of 2
mM ATP (+ATP) or 5 units/ml apyrase (-ATP).
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Figure 2.5. The peptide vinyl sulfones covalently modify multiple 3 subunits of
the proteasome in living cells, including the rIFN inducible subunits LMP-2 and
LMP-7.
(A) US11+, HOM-2, and T2 cells (1.5 x 106 cells) were incubated with 125I-Nip-
L3VS (1.8 x 104 Bq/ml) for 2 hours at 37°C, washed several times and lysed. Total
cell extracts were resolved on a 12.5% polyacrylamide gel and visualized by
autoradiography. Immuno-precipitations were performed on lysates from 125I-
NIP-L3VS labeled HOM-2 cells using monoclonal antibodies recognizing MHC
class I molecules (W6-32) or a proteasomal a subunit (a prot.)
(B) HOM-2 cells were incubated with 125I-NIP-L3VS, lysed and analyzed by
autoradiography (Direct Load) or proteasomes were immuno-precipitated (I.P.
Proteasome) as in A. Note the absence of a single labeled polypeptide (26 kDa) in
the proteasome immuno-precipitation. A total cell lysate from 125I-NIP-L3VS
labeled HOM-2 cells was also separated by two-dimensional NEPHGE-PAGE,
(11% polyacrylamide gel) and visualized by autoradiography.
(C) T1 and T2 cells (1.5 x 106 cells) were incubated with 125I-NIP-L 3VS (1.8 x 104
Bq/ml) for 2 hours at 37°C, lysed, resolved by two dimensional NEPHGE-PAGE
and analyzed by autoradiography. Note the presence of labeled LMP-2 and
LMP-7 in lysates from T1 cells only.
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LMP-2 and LMP-7 has been deleted (Salter and Cresswell, 1986). We could thus
determine which of the major species labeled with 125-I-NIP-L3VS were LMP-2
and LMP-7 by comparison with the wild type cell line T1 (Figure 2.5C). The
most intensely labeled, basic polypeptide corresponding to the subunit X was
present in similar quantities in both cell lines, as were the two minor species of
higher molecular weight. The more acidic polypeptide was absent in the labeling
of T2 cells. Based on the known pIs of the p subunits (Coux et al., 1996), the
latter spot was identified as LMP-2. Similarly, a polypeptide of a molecular
weight identical to X but with a slightly more acidic pI was present in the T1 cells
and absent from T2 cells, identifying it as the LMP-7 subunit of the proteasome.
These assignments were confirmed by comparison of mouse LMP-2 and LMP-7
obtained from different H2 haplotypes, where these subunits can be resolved
based on differences in their molecular weight and isoelectric point (Nandi et al.,
1996) (data not shown).
Upon longer exposure of autoradiographs from the labeled cell extracts,
three less intensely labeled polypeptides of 26, 28 and 29 kDa were visible (Fig.
2.5B). Two of these species were co-immunoprecipitated with the predominant
23 kDa band when using a proteasome-specific antibody. The third, minor
species is a non-pioteasomal protease modified to some extent by the peptide
vinyl sulfones (see below). Analysis by two-dimensional gel electrophoresis (Fig.
2.5B) shows that the predominantly labeled, 23 kDa band is composed of three
polypeptides of different isoelectric points, while the higher molecular weight
species each represent individual subunits.
7. All three classes of proteasome inhibitors compete for binding with 1251-
NIP-L3VS
To address the specificity of the radiolabeled inhibitor for the proteasome,
competition experiments were performed on intact mammalian cells (Fig. 2.6A).
The peptide aldehyde Z-L3H blocks covalent binding of the labeled inhibitor to
all p subunits at a concentration of 10 gM. The compounds NIP-L 3 VS, as well as
the structurally related compound, Z-L3VS, also competitively reduced subunit
modification by125I-NIP-L3VS, but were slightly less effective than the aldehyde
Z-L3H and lactacystin. The tripeptide vinyl sulfone in which the COOH-terminal
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Figure 2.6. The peptide vinyl sulfones, the peptide aldehyde, and lactacystin
compete for binding to all proteasome subunits modified by 125I-NIP-L3VS.
(A) HOM-2 cells were incubated simultaneously with 12 5 I-NIP-L3 VS (1.8 x 104
Bq/ml) and with increasing concentrations of NIP-L3VS, Z-L3VS, lactacystin, or
with 500 gM of the control peptides Z-L3-OH, Z-L3NH2, or (D)Z-L3VS for 2
hours at 37cC. Note that the 26 kDa polypeptide rhown in figure 5B remains
resistant to competition by lactacystin (see arrow).
(B) HOM-2 cells were labeled with 125I-NIP-L3VS as described or with the
cysteine protease inhibitor Cbz-125I-Tyr-Ala-CN2 for two hours at 37C. Lysates
were separated on a 12.5 % polyacrylamide gel and analyzed by
autoradiography.
(C) HOM-2 cells were incubated simultaneously with Cbz-125I -Try-Ala-CN2 and
increasing concentrations of Z-L3H, NIP-L3VS, and lactacystin as indicated for 2
hours at 37°C. Lysates were resolved on a 12.5% polyacrylamide gel and
analyzed by autoradiography.
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leucine is replaced with the D-isomer ((D)ZL3-VS) did not compete for binding
even at 500 jgM.
Of the species modified by the radiolabeled vinyl sulfone, only one rather
minor polypeptide (seen only in mammalian cells) was resistant to competition
by lactacystin (Fig. 2.6A; arrow). Because peptide aldehydes such as Z-L3H are
known to inhibit other classes of proteases (Coux et al., 1996; Rock et al., 1994),
while lactacystin does not, we presumed this minor polypeptide to be a non-
proteasomal protease .
To identify the lactacystin-resistant, 26 kDa species, cells were labeled with
the cysteine protease-selective probe, Cbz-12 5I-Tyr-Ala-N2 (Fig. 2.6B). This
modified di-peptide covalently modifies cysteine proteases of the cathepsin
family, predominantly cathepsins B and S (Riese et al., 1996). Co-migration of
the weakly labeled 26 kDa species with the polypeptide identified as the
lysosomal protease cathepsin S confirmed its identity. We further examined the
ability of all three classes of proteasome inhibitors to compete with the Cbz-125I-
Tyr-Ala-CN2 probe for binding to cathepsins B and S (Fig. 2.6C). The peptide
aldehyde, Z-L3H, was able to prevent labeling of both cathepsin S and B at
concentrations as low as 1pM, while lactacystin showed no inhibition of labeling
of either, at concentrations as high as 100 gM. NIP-L3VS showed only partial
inhibition of labeling of cathepsin S and no inhibition of labeling of cathepsin B
even at the two highest concentrations tested. This result strongly suggests that
Z-L3H could, in principle, block lysosomal proteases involved in antigen
presentation.
8. Peptide vinyl sulfones inactivate the proteasome in vivo
The in vivo effects of the peptide vinyl sulfones were compared to the
other two classes of proteasome inhibitors Z-L3-H and lactacystin. The peptide
vinyl sulfones were less toxic to cells than the peptide aldehyde Z-L3H as
assessed by their inhibitory affects on protein synthesis (data not shown).
Proteasomal inhibition was examined using an assay in which a viral protein
promotes destruction of MHC class I heavy chains in a proteasome-dependent
manner (Wiertz et al., 1996a; Wiertz et al., 1996b). The HCMV gene US11 causes
the dislocation of free class I heavy chains from the ER to the cytosol, at which
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point the single N-linked glycan is removed and the class I heavy chain is
degraded by the proteasome. Thus, in the presence of US1. 1 and an active
proteasome inhibitor, the transient appearance of a cytosoc, deglycosylated
breakdown intermediate results (Wiertz et al., 1996a; Wiertz et al., 1996b). Z-
L3VS caused the characteristic build-up of this heavy chain intermediate. The
peptide vinyl sulfone analog containing the hapten NIP at the N-terminus
showed activity at 2 pM, better than that of lactacystin, Z-L3H and the related
compound, Z-L3VS. The peptide vinyl sulfone in which the COOH-terminal
leucine was replaced with the D-isomer (DBocL3VS) was inactive in this assay.
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Figure 2.7. The peptide vinyl sulfones block proteasome function in vivo.
US11+ cells were pre-incubated in methionine-free medium without (minus) or
with the indicated concentrations of Z-L3H, Z-L3VS, NIP-L3VS or lactacystin for
1 hour. Cells were pulse labeled for 10 min., and chased for 20 min. Class I
molecules were immuno-precipitated with rabbit anti-heavy chain serum,
resolved on a 12.5% polyacrylamide gel and analyzed by fluorography. Note the
presence of a class I heavy chain band devoid of carbohydrates, which migrates
faster than the glycosylated species, and accumulates in the presence of an active
proteasome inhibitor.
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D. Discussion
Inhibitors of the proteasome have been instrumental in deciphering its role
in a diverse assortment of cellular processes (Harding et al., 1995; Jensen et al.,
1995; Palombella et al., 1994). We report here a class of inhibitors, the peptide
vinyl sulfones, which inactivate the proteasome by covalent modification of the
active site threonine of the catalytic p subunits of widely different origin. The
ability of the peptide vinyl sulfones to permeate cells and covalently modify
proteasome subunits also makes them useful active site probes for studying the
function of the proteasome in living cells.
Although originally characterized as mechanism-based inhibitors of
cysteine proteases, the peptide vinyl sulfones inhibit the chymotrypsin-like,
trypsin-like and petidylglutamyl peptidase activities of the proteasome both in
vitro and in vivo. The activity of the vinyl sulfones against a sidechain threonine
hydroxyl nucleophile is surprising considering that these types of Michael
acceptor structures were designed as mechanism-based inhibitors for soft
nucleophiles such, as cysteine (Palmer, 1995). The peptide vinyl sulfones
therefore provide new information about the reactivity of a threonine residue as
an active site nucleophile. The ability of the vinyl sulfone to covalently modify
a sidechain hydroxyl of serine when placed at the N-terminus of a proteasomal f-
subunit but not when part of the active site of a serine protease suggests basic
differences in the way the proteasome and serine proteases utilize a hydroxyl
group as a catalytic nucleophile.
The reactivity of the peptide vinyl sulfones against the ATP-dependent
eubacterial proteasome homologue, HslU/HslV, provides solid evidence that
this multi-component protease complex utilizes a catalytic mechanism similar to
that of the proteasome. Moreover, modification required the presence of the
peptidase subunit (HslV), the regulatory ATP-ase (HslU) and ATP, all of which
are necessary for the cleavage of a peptide substrate. These findings suggest that
the vinyl sulfones inactivate their target via a mechanism resembling that
involved in peptide hydrolysis.
Competition experiments using the radiolabeled peptide vinyl sulfone was
used to assess the activity and specificity of three different classes of
proteasome inhibitors. The inability of the tri-peptide vinyl sulfone containing a
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D-leucine in the P1 position to inhibit labeling of any of the 3 subunits labeled by
125I-NIP-L3VS indicated the proteasome's stereochemical selectivity at the site of
hydrolysis. The labeling of a rather minor 26 kDa polypeptide, identified as
cathepsin S, was completely blocked by Z-L3H but was unaffected by lactacystin
at all concentrations tested. This finding, combined with the competition data
obtained for Z-L3H, NIP-L3VS, and lactacystin using the 125I-Tyr-Ala probe, fits
not only the known specificity of lactacystin for the proteasome, but also
suggests that the peptide aldehyde, Z-L3H, should be a potent competitive
inhibitor of lysosomal proteases. Related peptide aldehydes are known to
inhibit lysosomal and Ca+-dependent cysteine proteases, and such possible
effects must be considered in studies using these agents on intact cells (Coux et
al., 1996; Rock et al., 1994).
The finding that lactacystin competes for labeling of all five subunits by
125I-NIP-L3VS, is inconsistent with the initial identification of a single [3 subunit,
X (also known as MB-1), as the target of the drug (Fenteany et al., 1995). While
the predominant species modified by lactacystin is X, modification of other
subunits which require higher concentrations of drug may have escaped
detection due to the relatively low concentration of labeled compound used as
confirmed in subsequent work (Craiu et al., in press). We conclude that 25I-NIP-
L3VS labels at least 5 distinct P subunits, all of which are also targets for
lactacystin. Thus, the peptide vinyl sulfones are useful diagnostic tools which
provide detailed information about proteasomal inhibition by other classes of
compounds. Their ease of synthesis and ability to covalently inactivate
proteasomal 3 subunits in intact cells makes peptide vinyl sulfones powerful
new tools for the study of proteasome function.
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III. STRUCTURE-FUNCTION STUDIES OF TRI- AND TETRA-
PEPTIDE VINYL SULFONES
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A. Introduction
The proteasome is a large, multi-subunit complex which is involved in
many of the catabolic events taking place in the cell. The proteasome employs a
rather unique catalytic mechanism and is a member of the small family of
proteolytic enzymes known as N-terminal Hydrolyses. This class of enzyme
utilizes an N-terminal amino acid as the catalytic residue, which in the case of
the proteasome is threonine. The proteasome's N-terminal threonine hydroxyl
sidechain is activated by a single water molecule involving a charge relay system
with other important internal amino acids such as lysine (Seemiller et al., 1995;
Lupas et al., 1995). As a threonine protease, it does not fall into a standard
category with other proteolytic enzymes in terms of its reactivity towards
different classes of inhibitors. Its reactivity with serine as well as cysteine
protease inhibitors complicated its initial characterization (Coux et al., 1996).
Quite surprising is the number of types of C-terminally modified peptides which
are reactive with the proteasome's N-terminal catalytic residue (Cardozo et al.,
1992; Harding et al., 1595; Iqbal et al., 1996; Spaltenstein et al., 1996; Rock et al.,
1994; Bogyo et al., 1997).
Central to understanding the mechanism of action of this enzyme complex
is the ability to modulate its activity experimentally with small molecule
inhibitors. The natural product lactacystin irreversibly inhibits the proteasome
by covalent modification of the catalytic threonine hydroxyl (Dick et al., 1996;
Fenteany et al., 1995). To this day, the proteasome remains the only known
proteolytic enzyme inhibited by lactacystin. Lactacystin is also the only example
of a non-peptide-based inhibitor with potent activity against the proteasome. Its
lack of structural similarity to the C-terminal peptide aldehyde proteasome
inhibitors (see chapter 1 figure 1.5 for structure) suggests that it may bind to the
proteasome active sites differently. The peptide aldehydes are likely to more
closely mimic a physiological protein substrate.
In fact, this suggestion has been verified with the advent of the crystal
structure of the Thermoplasma 20S proteasome (Lowe et al., 1995) and more
recently, the yeast 20S proteasome (Groll et al., 1997). Crystals obtained of
proteasomes in a complex with either the peptide aldehyde Cbz-Leucinyl-
leucinyl-norlc _cinal (LLnL or Calpain I inhibitor), or with lactacystin indicate
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that the two inhibitors do not interact with the proteasome equivalently. While
LLnL was found bound to all three catalytically active -subunits (PUP1 or Z,
PRE2 or X, and PRE3 or Y), lactacystin predominantly targeted the X (PRE2) 
subunit (Groll et al., 1997).
Because of the proteasome's role in the production of antigenic peptides
and in the activation of signaling molecules required for inflammation, work is in
progress to develop potent inhibitors of the proteasome as potential drugs for
use as anti-inflammatory agents and for treatment of auto-immune diseases. The
usefulness of such inhibitors depends on criteria such as bioavailability and cell
permeability, criteria which favor small, hydrophobic, non-peptide like
compounds. However these compounds, while possibly useful as therapeutic
agents, may fail to accurately mimic a protein substrate and therefore fail to
provide information about issues such as catalytic mechanism and substrate
specificity.
The unveiling of the yeast 20S proteasome crystal structure uncovered the
possibility of other active sites within the large multli-subunit complex that do
not employ the catalytic N-terminal threonine residues (Groll et al., 1997).
Multiple magnesium binding sites were discovered which create a very acidic
environment within the center of the proteasome's internal cavity. Thus, bound
water molecules may serve as catalytic nucleophiles similar to the mechanism of
hydrolysis by a generic aspartic acid protease. Short inhibitors and fluorogenic
substrates may not access such a secondary binding pocket and therefore may
not accurately mimic substrate binding. Possible additional proteasome-
substrate interactions may therefore only be addressed using longer peptides.
We describe here the synthesis and characterization of a series of peptide
vinyl sulfones composed of different amino acid sequences, lengths, and C and
N-terminal modification. These inhibitors are all equipped with a C-terminal
vinyl sulfone, shown previously to covalently modify the catalytic N-terminal
threonine residue of the proteasome (Bogyo et al., 1997). Tri-peptide vinyl
sulfones containing a free amino-terminus fail to inhibit proteasomal proteolysis,
but the addition of a fourth, hydrophobic, aliphatic, or aromatic amino acid (at
position P4) results in a dramatic increase in inhibitor potency. Interestingly,
when these peptide inhibitors are equipped with a 25I radiolabel, it is possible to
directly assess binding to proteasomal subunits by 1- and 2-dimensional
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electrophoretic methods. The increase in inhibitory potency by addition of a P4
amino acid is accompanied by a change in the pattern of polypeptides labeled by
the inhibitor. This change in labeling profile is likely to shed some light on
previously undescribed substrate binding interactions, and may allow for a
correlation of potency of inhibition of fluorogenic substrate hydrolysis with the
subunit/subunits covalently modified.
Still little is known about how the proteasome is able to control the
proteolytic processing of the large number of possible protein substrates into the
proper peptide fragments. Many favor an interpretation in which a protein
substrate enters the proteasomal cavity and where the sites of hydrolysis are
designated by physical location of the polypeptide within the cavity. To address
this question we examined a series of tri-peptide vinyl sulfones that differ in
amino acid sequence and N- and C-terminal modifications for their ability to
inhibit the hydrolysis of a series of fluorogenic substrates. 125I-labeled
derivatives were then used to explore subunit binding. Marked differences in
the labeling patterns were observed for the different inhibitors, indicating that
individual proteasome subunits may in fact discriminate between substrates
based on their sequence. This result may begin to explain how substrates are
differentially processed by the proteasome.
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B. Materials and Methods
1. Inhibitor Synthesis
NIP-L 3-VS, 12 5I-NIP-L 3-VS, L3 -VS and Z-L3 -VS were synthesized as
described in chapter 2. The synthesis of all other inhibitors are described below.
All inhibitors were dissolved in DMSO and used in biological assays at the
concentrations specified. Stock solutions were prepared such that the
concentration of DMSO never exceeded 1%.
2. Synthesis of Tetra-Peptide Vinyl Sulfones Containing the L3 Core Sequence
The tri-peptide free amine L3-VS described in chapter 2 was used as a
building block for the synthesis of the tetra-peptide vinyl sulfones containing the
sequences: YL3-VS, (D)YL3-VS, BpaL3-VS, and GL3-VS. The synthesis of these
tetra-peptides was carried out by the coupling of the desired Boc-amino acid to
L3-VS using the same protocol for all four derivatives. The Boc- protecting group
was then removed from the tetra-peptides by treatment with TFA. All tetra-
peptides were characterized as the free amine salts only and are described below.
a. Synthesis of Boc-tyrosine-leucinyl-leucinyl-leucine vinyl sulfone (YL3-VS)
Boc-tyrosine (5.2 mg, 18.6 pnol) and PyBOP (10.2 mg, 18.6 gmol) were
dissolved in 1 ml of dichloromethane. Diisopropylethyl amine (3.3 Al, 18.6
gmol) was then added. the reaction was stirred for 5 minutes and L3-VS tosic
acid salt (10 mg, 16.9 gmol) was added, followed by diisopropylethyl amine (3.0
pl, 16.9 pnol). The reaction was stirred for 30 min at room temperature and the
solvent was removed by rotary evaporation. The resulting crude reaction
mixture was purified by flash column chromatography using ethyl
acetate:hexane (2:1) as the mobile phase. Yield (10.4 mg, 15.3 gmol, 90%).
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b. Synthesis of tyrosine-leucinyl-leucinyl-leucine vinyl sulfone trifloroacetic
acid salt (YL3 -VS)
Boc-YL3-VS (9 mg, 13.2 gmol) was dissolved in 1 ml of dichloromethane.
Trifloroacetic acid (lml) was then added and the reaction stirred at room
temperature for 1 hour. The reaction was quenched by the addition of 5 ml of
toluene followed by removal of the solvent by rotary evaporation. A second
portion of toluene was then added to the crude solid and again evaporated to
dryness. The pure tetra-peptide was obtained by trituration of the solid residue
in diethyl ether. Yield (9 mg, 13 gmol, 99%).
YL3-VS 1H-NMR (500 MHz, CD30D) 8 7.05 (2H, d), 6.80 (1H, dd), 6.70 (2H, d),
6.64 (1H, t), 4.7 (1H, m), 4.45 (1H, m), 4.20 (1H, dd), 3.25 (1H, m), 2.95 (3H, s),
2.95 (2H, ddd), 1.50-1.78 (9H, M), 0.95 (18H, m).
FAB Mass Spectrum: [M+H] Calculated for C29 H48N4 06 S: 581.7 Found: 581.4
c. Synthesis of (D)-tyrosine-leucinyl-leucinyl-leucine vihiyl sulfone ((D)YL3-
VS)
The tetra-peptide containing the D-isomer of tyrosine at the P4 position
((D)YL3-VS) was synthesized as described above for the L-isomer. Yield (70%).
FAB Mass Spectrum: [M+H] Calculated for C2 9 H48N4 06 S: 581.7 Found: 581.4
d. Synthesis of Boc-glycine-leucinyl-leucinyl-leucine vinyl sulfone (Boc-GL3-
VS)
GL3-VS was synthesized as described above for YL3-VS except Boc-glycine
was used instead of Boc-tyrosine. Boc-GL3-VS was purified by flash column
chromatography using ethyl acetate:hexane (2:1) as the mobile phase. Yield
(71%).
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Boc-GL3-VS 1H-NMR (300 MHz, Acetone-d 6) 7.85 (1H, d), 7.56 (1H, d), 7.23
(1H, d), 6.79 (1H, dd), 6.70 (1H, d), 6.62 (1H, d), 4.70 (1H, m), 4.37 (1H, t), 4.24
(1H, q), 3.75 (2H, dd), 2.96 (3H, s), 1.55- 1.82 (9H, m), 1.42 (9H, s), 0.88 (12H,
Irl).
e. Synthesis of glycine-leucinyl-leucinyl-leucine vinyl sulfone (GL3-VS)
GL3-VS was synthesized from Boc-GL3-VS by removal of the Boc protecting
group using trifluoroacetic acid as described above for YL3-VS. Yield (74%).
FAB Mass Spectrum: [M+H] Calculated for C22H42N4 05S: 475.6 Found: 475.3
f. Synthesis of p-Benzoyl-phenylalanine-leucinyl-leucinyl-leucine vinyl
sulfone (BpaL3-VS)
BpaL3-VS was synthesized as described for YL3-VS except Boc-p-benzoyl-
phenylalanine was used instead of Boc-tyrosine. The Boc-BpaL3-VS intermediate
was purified by flash chromatography using ethyl acetate:hexane (3:2) as the
mobile phase. Yield (Boc-Bpa-L 3-VS 92%, BpaL3-VS, 96%).
BpaL3-VS 1H-NMR (500 MHz, CD3 0D) 8 7.78 (4H, dd), 7.65 (1H, t), 7.55 (2H, t),
7.45 (2H, d), 6.79 (1H, dd), 6.59 (1H, d), 4.65 (1H, m), 4.45 (1H, dt), 4.18 (1H, t),
3.18 (1H, m), 2.98 (3H, s), 1.30-1.75 (9H, m), 0.95 (18H, m).
FAB Mass Spectrum: [M+H] Calculated for C36 H5 2 N4 06 S: 669.8 found: 669.5
3. Synthesis of AAF Containing Peptide Vinyl Sulfones
Peptide vinyl sulfones consisting of the core sequence AAF were
synthesized essentially as described for the synthesis of L3-containing vinyl
sulfones described in chapter 2. The free amino AAF-VS compound was used as
a building block for the synthesis of the tetra-peptide vinyl sulfone YAAF-VS.
The synthetic procedures are described below.
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a. Synthesis of Boc-phenylalanine-vinyl sulfone (Boc-Phe-VS)
Boc-phenylalanine-vinyl sulfone was synthesized exactly as described for
the synthesis of Boc-leucine vinyl sulfone (compound V) in chapter 2 except Boc-
phenylalanine was used in place of Boc-leucine. Similar yields were obtained at
each step. The NMR data and typical yie ds obtained for each intermediate are
listed below.
Boc-Phe-dimethyl hydroxyl amide: Yield (97%), H-NMR (300 MHz, CDC13) 6
7.18-7.38 (5H, m), 5.19 (1H, d), 4.98 (1H, m), 3.69 (3H, s), 3.20 (3H, s), 3.0 (2H,
ddd), 1.40 (3H, s).
Boc-Phenylalanal: Yield (73%), 1H-NMR (300 MHz, CDC13) 6 9.65 (1H, s), 7.18-
7.38 (5H, m), 5.05 (1H. d), 4.44 (1H, m), 3.15 (2H, d), 1.45 (9H, s).
Boc-Phe-VS: Yield (73%) H-NMR (300 MHz, CDC13) 67.35 (3H, q), 7.19 (2H, d),
6.90 (1H, dd), 6 39 (1H, dd), 4.67 (1H, m), 4.58 (1H, d), 2.95 (2H, d), 2.93 (3H, s),
1.43 (9H, s).
b. Synthesis of phenylalanine-vinyl sulfone tosic acid salt (Phe-VS)
Phenylalanine-vinyl sulfone was synthesized from Boc-Phe-VS by removal
of the Boc protecting group as described for Boc-Leucine-vinyl sulfone in chapter
2.
Phe-VS tosic acid salt 1H-NMR (300 MHz, CD 3OD) 8 7.74 (2H, d), 7.35 (3H, q),
7.25 (4H, d), 6.74 (2H, m), 4.29 (1H, q), 2.99-3.23 (2H, ddd), 2.89 (3H, s), 2.39
(3H, s).
c. Synthesis of Boc-alanine-alanine methyl ester (Boc-AA-OMe)
To a flask was added Boc-alanine (2.0 g, 10.5 mmol),
dicyclohexylcarbodiimide (DCC; 2.4g, 11.6 mmol), and HOBt (1.57g, 11.6
mmol) in 25 ml dimethyl formamide (DMF). The reaction was stirred for 30 min
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at room temperature. A white precipitate formed upon standing. Alanine-
methyl ester hydrochloride salt (2.2g, 15.8 mmol) was then added followed by
diisopropylethyl amine (DIEA; 2.8 ml, 15.8 mmol). The reaction was stirred
overnight at room temperature. Next, the crude reaction mixture was filtered to
remove precipitated solids and then evaporated to a minimal volume by rotary
evaporation. The resulting crude solution was diluted with 250 ml ethyl acetate
and then extracted with three 75 ml portions of 0.1 N HCL and three 75 ml
portions of saturated sodium bicarbonate. The remaining organic phase was
dried over MgSO4 and dried to a solid by rotary evaporation. The pure di-
peptide methyl ester was isolated by re-crystallization from ethyl
acetate/hexane. Yield (2.1g, 7.6 mmol, 72%).
Boc-AA-OMe 1H-NMR (300 MIz, CDC13) 6 6.64 (1H, d), 5.01 (1H, d), 4.54 (1H,
p), 4.15 (1H, q) 3.73 (3H, s), 1.42 (9H, s), 1.40 (3H, d). 1.38 (3H, d).
d. Synthesis of Boc-Alanine-alanine (Boc-AA-OH)
The methyl ester of Boc-AA was converted to the corresponding acid by
hydrolysis using sodium carbonate and methanol as described for the synthesis
of Boc-LL-OH (compound II) in chapter 2. This compound was used in
subsequent steps without further purification.
e. Synthesis of Boc-alanine-alanine-phenylalanine vinyl sulfone (Boc-AAF-
VS)
Boc-AAF-VS was synthesized by reaction of Boc-AA-O! with
phenylalanine-vinyl sulfone tosic acid salt usinb the protocol described for the
synthesis of Boc-L3-VS described in chapter 2. The product was purified by flash
column chromatography using ethyl acetate/hexane (4:1 v:v) as the mobile
phase. Yield (57%).
Boc-AAF-VS 1H-NMR (300 MHz, CDCI3) 6 7.25-7.38 (4H, m), 7.20 (2H, d), 7.12
(1H, d), 6.88 (1H, dd), 6.60 (1H, d), 6.56 (1H, d), 4.98 (1H, m), 4.37 (1H, t), 4.05
(1H, q), 2.95 (2H, dd), 2.90 (3H, s), 1.48 (9H, s), 1.36 (3H, d), 1.34 (3H, d).
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f. Synthesis of alanine-alanine-phenylalanine vinyl sulfone tosic acid salt
(AAF-VS)
The Boc protecting group was removed from Boc-AAF-VS using the
protocol described for removal of Boc from Boc-L3-VS described in chapter 2.
Yield (95%).
AAF-VS 1H-NMR (300 MHz, CD3 0D) 7.74 (2H, d), 7.20-7.38 (7H, m), 6.85
(1H, dd), 6.56 (1H, d), 4.82 (1H, q), 4.32 (1H, q), 3.95 (1H, q), 2.99 (2H, dd),
2.90 (3H, s), 2.39 (3H, s), 1.50 (3H, d), 1.32 (3H, d).
FAB Mass Spectrum: [M+H] Calculated for C17 H25N30 4S: 368.4 Found: 368.3
g. Synthesis of Boc-tyrosine-alanine-alanine-phenylalanine vinyl sulfone
(YAAF-VS)
To a flask was added Boc-tyrosine (38 mg, 134 jimol) and PyBOP (74 mg,
134 pmol) in 1 ml of dichloromethane. Diisopropylethylamine (23 pl, 134 gnol)
was then added and the reaction stirred at room temperature for 5 minutes.
AAF-VS (66 mg, 122 munol) was added to the reaction followed by
diisopropylethylamine (22 gl, 122 gmol). The reaction was stirred for an
additional 30 minutes. The crude reaction mixture was evaporated to dryness
and applied directly to a silica gel column for purification. The pure Boc-YAAF-
VS was isolated using 1% methanol in ethyl acetate as the mobile phase. Yield
(65 mg, 100 gmol, 82%).
Boc-YAAF-VS 1H-NMR (300 MHz, DMSO-d 6) 8 9.32 (1H, s), 8.24 (2H, d), 8.15
(1H, d), 7.31-7.52 (5H, m), 7.22 (2H, d), 7.05 (1H, d), 6.90 (1H, dd), 6.81 (2H, d),
6.75 (1H, d), 4.95 (1H, p), 4.42 (1H, dt), 4.23 (1H, t), 3.00 (3H, s), 2.85-2.95 (2H,
m), 2.20 (2H, d), 1.40 (3H, s), 1.50 (3H, d), 1.32 (3H, d).
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h. Synthesis of tyrosine-alanine-alanine-phenylalanine vinyl sulfone (YAAF-
VS)
Boc-YAAF-VS (48 mg, 74 nmol) was dissolved in 2ml of dichloromethane.
Trifluoroacetic acid (2.0 ml) was then added slowly to the stirring solution. The
reaction was stirred for 1 hour at room temperature and then quenched by the
addition of 10 ml of toluene. The resulting reaction mixture was evaporated to
dryness by rotary evaporation and the residue re-dissolved in 10 ml toluene.
Again the solution was dried to a clear oil. The pure salt of YAAF-VS was
isolated by trituration of the crude oil with diethyl ether. Yield (48 mg, 73 hgmol,
98%).
FAB Mass Spectrum: [M+H] Calculated for C26H34N4 06 S: 531.6 Found: 531.2
4. Synthesis of LLG-Containing Vinyl Sulfones
Vinyl sulfones containing glycine at position P1 were synthesized as
described for the synthesis of the tri-leucine vinyl sulfones except for the method
of preparation of the Boc-glycinal intermediate. Boc-glycinal was prepared by
the oxidation of Boc-3-amino-1,2-propane diol (figure 3.1). The resulting
aldehyde was converted to the corresponding vinyl sulfone as described for the
synthesis of Boc-leucine vinyl sulfone.
a. Synthesis of Boc-3-amino-1,2-propane diol
3-amino-1,2-propane diol (5.0g, 55 mmol) was dissolved in 20 ml of 1,4-
dioxane and 10 ml of 3M NaOH. Di-tert-butoxy cabonyl ((Boc)20; 12 g, 55
mmol) was then added and the reaction stirred for 4.5 hours until the evolution
of gas ceases. The solvent was then removed by rotary evaporation and the
resulting crude white solid dissolved in ethyl acetate. The ethyl acetate solution
was then washed with three 50 ml portions of 5% potassium hydrogen sulfate
(KHSO4). The aqueous layers were then combined and back extracted with ethyl
acetate. All organic layers were then combined, dried over MgSO4, and
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Figure 3.1. Synthesis of glycine-based vinyl sulfones by oxidation of 3-amino-
1,2-propanediol derivatives.
(A) (Boc)20, 3N NaOH; (B) NaIO4, pH 7.0 (C) (EtO)2P(O)CH2S(O)-PhOH, NaH,
THF.
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concentrated to an oil by rotary evaporation. The crude oil was used in
subsequent steps without further purification.
b. Synthesis of Boc-glycinal (Boc-Gly-H)
Boc-3-amino-1,2-propane diol (3.8g, - 20 mmol) was dissolved as a crude
oil in 30 ml of ethanol. Sodium periodate (NaIO4; 12.8g, 60 mmol) was added as
a solution in 90 ml of 0.01M phosphate buffer (pH 7). The reaction was then
stirred for 1.5 hours. The reaction mix was washed with three 50 ml portions of
chloroform with the addition of 50 ml of saturate sodium chloride (to separate
organic and aqueous phases). The organic phases were then combined, dried
over MgSO4, and evaporated to dryness. The crude Boc-glycinal was used in
subsequent steps without further purification.
c. Synthesis of Boc-glycine vinyl sulfone, cis and trans isomers (Boc-G-cVS
and Boc-G-tVS)
The cis and trans isomers of Boc-glycine vinyl sulfone were synthesized
from the crude 'Voc-glycinal as described for the synthesis of Boc-leucine vinyl
sulfone from Boc-leucinal (chapter 2). This reaction resulted in two compounds
which were separable by flash chromatography using hexane: ethyl acetate (2:1)
as the mobile phase. Mass spectrum obtained for the two tri-peptides isolated
were identical (NP-LLG-tVS and NP-LLGcVS; see below) indicating that they
were likely to be isomers. Since enantiomers are not likely to be resolved by
column chromatography, we concluded that the lack of a sidechain on glycine
allowed for the formation of both the cis and trans isomers of the newly formed
double bond. NMR analysis (shown below) confirmed this hypothesis. The two
compounds had nearly identical spectra with the largest difference observed for
the vinyl resonances. The alpha carbon was also found to be slightly different for
the two isomers. These data were consistent with cis/trans geometric isomers.
Finally the cis and trans isomers were assigned using Z-factor calculations
(Pascual et al., 1966) to predict the chemical shift of the vinyl protons for the ciL
and trans isomers. The greatest difference in shifts between the two vinyl
resonances was found for the cis isomer and was reflected in the NMR obtained
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for the slightly less polar compound isolated. Yield (2:1 trans:cis, 43 % overall
yield).
Boc-glycine vinyl sulfone cis isomer 1 H-NMR (300 MHz, CDC13) 6 6.45 (1H, dd),
6.32 (1H, d), 4.98 (1H, m), 4.28 (2H, t), 3.04 (3H, s), 1.45 (9H, s).
Boc-glycine vinyl sulfone trans isomer 1H-NMR (300 MHz, CDC13) 6 6.94 (1H,
dt), 6.52 (1H, dt), 4.78 (1H, m), 4.00 (2H, t), 2.96 (3H, s), 1.45 (9H, s).
d. Synthesis of glycine-vinyl sulfone tosic acid salt cis and trans isomers (G-
cVS, G-tVS)
The Boc protecting group was removed from the glycine vinyl sulfones as
described for the removal of Boc from Boc-leucine vinyl sulfone described in
chapter 2. Yield (97%)
Glycine vinyl sulfone cis isomer H-NMR (300 MHz, CD30D) 6 7.72 (2H, d),
7.24 (2H, d), 6.78 (1H, dt), 6.43 (1H, dt), 4.21 (2H, d), 3.08 (3H, s), 2.38 (3H, s).
G!ycine vinyl sulfone trans isomer 1H-NMR (300 MHz, CD30D) 6 7.72 (2H, d),
7.24 (2H, d), 6.95 (1H, d), 6.87(1H, dt), 3.84 (2H, d), 3.02 (3H, s), 2.38 (3H, s).
e. Synthesis of Boc-Leucinyl-leucinyl-glycine vinyl sulfone cis and trans
isomers (Boc-LLG-cVS, Boc-LLG-tVS)
Boc-LLG-VS cis and trans isomers were synthesized from the tosic acid
salts of cis and trans glycine vinyl sulfone as described for the synthesis of Boc-
L3-VS (chapter 2). The compounds were purified by flash column
chromatography using ethyl acetate as the mobile phase. Yield (95% cis, 97%
trans).
Boc-LLG-cVS H-NMR (300 MHz, CDCI3) 6 7.52 (1H, m), 6.88 (1H, dq), 6.63
(1H, t), 6.54 (1H, d), 5.09 (1H, dd), 4.44 (1H, m), 3.94-4.09 (2H, m), 2.93 (3H, s),
1.40-1.82 (6H, m), 1.42 (9H, d), 0.95 (12H, m).
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Boc-LLGtVS H-NMR (300 MHz, CDC13 ) 8 7.52 (1H, m), 6.56 (1H, d), 6.30 (2H,
m), 5.05 (1H, dd), 4.47 (1H, m), 4.34 (1H, t), 4.03 (1H, m), 3.06 (3H, s), 1.40-1.82
(6H, m), 1.42 (9H, d), 0.95 (12H, m).
f. Synthesis of leucinyl-leucinyl-glycine vinyl sulfone tosic acid salt cis and
trans isomers (LLG-cVS, LLG-tVS)
The Boc protecting group was removed as described for the removal of Boc
from Boc-leucine-vinyl sulfone in chapter 2. Yield (52% trans isomer; 45% cis
isomer).
g. Synthesis of 4-hydroxy-3-nitrophenyl acetyl-leucinyl-leucinyl-glycine vinyl
sulfone cis and trans isomers (NP-LLG-cVS, NP-LLG-tVS)
The hapten 4-hydroxy-3-nitrophenyl acetic acid was added to LLG-VS cis
and trans isomers as described for the synthesis of NP-L3-VS (chapter 2). the cis
and trans products were purified by flash column chromatography using ethyl
acetate as the mobile phase.
NP-LLG-cVS 1H-NMR (300 MHz, DMSO-d 6 ) 6 8.29 (1H, d), 8.26 (1H, t), 7.96
(1H, d), 7.80 (1H, s), 7.44 (1H, d), 7.05 (1H, d), 6.53 (1H, dt), 6.18 (1H, dt), 4.13-
4.36 (4H, m), 3.47 (2H, s), 3.10 (3H, s), 1.48-1.62 (6H, m), 0.75-0.90 (12H, m).
FAB Mass Spectrum: [M+H] Calculated for C2 4 H36N4O8 S: 541.6 Found: 541.3.
NP-LLG-tVS H-NMR (300 MHz, DMSO-d 6) 6 8.29 (1H, d), 8.22 (1H, t), 7.79 (1H,
s), 7.42 (1H, d), 7.05 (1H, d), 6.70 (1H, dt), 6.64 (1H, d), 4.28 (2H, m), 3.94 (1H,
t), 3.89 (1H, t), 3.46 (2H, d), 2.98 (3H, s), 1.48-1.62 (6H, m), 0.75-0.90 (12H, m).
FAB Mass Spectrum: [M+HJ Calculated for C24H36N408S: 541.6 Found: 541.3.
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5. Synthesis of Phenolic Vinyl Sulfones
The phenolic vinyl sulfones were synthesized using the same protocol as
described for the methyl vinyl sulfones except the phenolic version of the
corresponding methyl phosphonate sulfone was used. Figure 3.2 shows the
synthesis of a typical phenolic vinyl sulfone.
a. Synthesis of 3-Hydroxy-thiophenyl-methyl-diethylphosponate
((EtO)2P(O)CH2S-Ph-OH)
To a dried flask flushed with argon was added 4-hydroxy-thiophenol (90%
stock, 4.44g, 31.7 mmol) in 20ml of diethyl ether. Sodium hydride (1.27 g, 31.7
mmol) was then slowly added and the reaction stirred at room temperature for
30 min. A solid mass formed upon standing. Diethyl iodomethyl phosphonate
(8.11 g, 29.17 mmol) was then added as a solution in 15 ml of diethyl ether. The
reaction was then stirred at room temperature for three hours. The reaction was
quenched with 60 ml of 0.5 M citrate buffer (pH 4.0) and the resulting aqueous
phase was extracted with three 40 ml volumes of diethyl ether. The combined
organic layers were dried over MgSO4 and concentrated to an oil. The crude oil
was oxidized as described below without further purification.
b. Synthesis of 3-Hydroxy-thiophenyl-methyl-diethylphosponate sulfone
((EtO)2 P(O)CH2S(O) 2 -Ph-OH)
The crude oil of 3-Hydroxy-thiophenyl-methyl-diethylphosponate was
dissolved in 30 ml of 1,4-dioxane and chilled on ice. Peracetic acid (30 ml, 32 %
solution, 145 mmol) was then slowly added while stirring the reaction mixture.
The reaction was maintained on ice for 20 minutes and then warmed to room
temperature for 4 hours. Crushed platinum on carbon (2.8 g) was then added
and the reaction stirred overnight at room temperature. Potassium iodide was
used to insure that no peracetic acid remained. The platinum carbon solids were
then removed by filtration and the remaining solution diluted with 250 ml of
saturated sodium bicarbonate. The aqueous phase was extracted with 3X100 ml
portions of ethyl acetate. The combined organic layers were then dried over
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Figure 3.2. Synthesis of the phenolic peptide vinyl sulfone.
(A) PyBOP, DIEA, CH3 NHOCH 3, CH2C12; (B) LAH, Et 20; (C) NaH, Et20; (D)
CH 3 C(O)OOH, 1,2-dioxane; (E) NaH, THF; (F) TsOH, Et2 O; (G) PyBOP,
DIEA, CH2 C12 .
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MgSO4 and dried to a crude solid by rotary evaporation. The pure product was
ob lined by re-crystallization from hexane/ethyl acetate (1:2). Yield (7.1 g, 23.4
mmol, 80%).
4-hydroxy-thiophenyl-methyl diethylphosponate sulfone 1H-NMR (300 MHz,
CDC13) 89.25 (1H, s), 7.80 (2H, d), 6.75 (2H, d), 4.22 (4H, p), 3.81 (21H, d), 1.36
(6H, t).
c. Synthesis of Leucinyl-leucinyl-leucine-vinyl sulfone phenol tosic acid salt
(L3-VS-PhOH)
L3-VS was synthesized as described in chapter 2 materials and methods
section for the methyl vinyl sulfone counterpart (compound VIII) except that for
the conversion of Boc-leucinal to Boc-leucine vinyl sulfone 4-hydroxy-
thiophenyl-methyl diethylphosponate sulfone was used instead of methyl-
thiomethyl diethylphosponate sulfone. The yields obtained in a typical reaction
were similar to those reported for the methyl derivative.
L3 -VS-PhOH 1H-NMR (300 MHz, CD 3OD) 6 7.68 (2H, d), 6.95 (2H, d), 6.78
(1H, dd), 6.45 (1H, d), 4.61 (1H, m), 4.42 (1H, t), 3.85 (1H, t), 1.40-1.78 (9H, m),
0.82-1.02 (18H, m).
FAB Mass Spectrum: [M+H] calculated for C25H41N3 0sS: 496.6 Found: 496.3
d. Synthesis of 4-hydroxy-5-iodo-3-Nitrophenyl acetyl-leucinyl-leucinyl-
leucine vinyl sulfone phenol (NIP-L3-VS-PhOH)
NIP-L3-VS-PhOH (IV) wa3 synthesized by addition of 4-hydroxy-5-iodo-3-
nitrophenyl acetic acid to L3-VS-PhOH as described for the synthesis of NIP-L3-
VS in chapter 2. Similar yields were obtained.
NIP-L 3-VS-PhOH H-NMR (300 MHz, DMSO-D6 ) 68.30 (1H, d), 8.06 (2H, d),
8.00 (1H, s), 7.89 (1H, s), 7.61 (2H, d), 6.94 (2H, d), 6.60 (1H, dd), 6.50 (1H, d),
4.52 (1H, m), 4.22 (2H, m), 1.28-1.65 (9H, m), 0.73-0.98 (18H, m).
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FAB Mass Spectrum: [M+H] Calculated for C33H45N409SI:801.7 Found: 801.4
e. Synthesis of Boc-leucinyl-leucinyl-leucinyl-leucine vinyl sulfone phenol
¶Boc-L4-VS-PlOH)
Boc-L4-VS-PhOH was synthesized from L3-VS-PhOH (m) by the addition
of Boc-leucine as described for the synthesis of Boc-YL3-VS described above
except that Boc-leucine was used instead of Boc-tyrosine and L3-VS-PhOH was
used instead of L3-VS. Similar yields were obtained.
Boc-L4 -VS-PhOH 1H-NMR (300 MHz, Acetone-d6) 9.52 (1H, s), 7.72 (lh, d),
7.68 (2H, d), 7.39 (1H, d), 7.28 (1H, d), 6.98 (2H, d), 6.83 (1H, dd), 6.70 (1H, d),
4.71 (H, m), 4.44 (1H, m), 4.15 (1H, m), 3.77 (1H, m), 1.30-1.89 (11H, m), 1.45
(9H, s), 0.74-0.97 (24H, m).
f. Synthesis of leucinyl-leucinyl-leucinyl-leucine vinyl sulfone phenol tosic
acid salt (L4-VS)
The Boc group was removed from Boc-L4-VS-PhOH by treatment with
trifluoroacetic acid as described above for the synthesis of YL3-VS. Yield (98%).
L4 -VS-PhOH H-NMR (300 MHz, CD 3 0D) a 7.72 (21-, d), 6.90 (2H, d), 6.75 (1H,
dd), 6.65 (1H, d), 4.60 (1H, m), 4.44 (1H, t), 4.30 (N, q), 3.85 (1H, m), 1.38-1.74
(12H, m), 0.80-1.00 (18H, m).
FAB Mass Spectrum: [M+H] Calculated for C3 1H52 N4 06 S: 609.8 Found: 609.3
6. Cells and Cell Culture
The mouse lyphoblastoid cell line EL-4 was maintained in Dubecco's
Modified Eagle's Medium supplemented with 10% fetal calf serum. The human
cell HOM-2 was maintained as described in chapter 2 Materials and Methods
section.
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7. Antibodies
The polyclonal rabbit anti-proteasome antibody was a kind gift of Dr. Migel
Cruez and Dr. John Monaco (University of Cincinnati, Cincinnati, OH). The
serum was prepared using purified 20S proteasomes as the immunogen.
8. Fluorogenic Substrate Hydrolysis Assay
Hydrolysis of the fluorogenic substrates: Suc-LLVY-MCA (chymotrypsin-
like substrate), Boc-LRR-MCA (trypsin-like substrate), and Cbz-LLE-0NA
(PGPH substrate) was measured. In a typical assay 5 !xg of protein generated
from the 5H 100,000 g centrifugation spin of lysates from the mouse
lymphoblastoma cell line EL-4 (see below for preparation) was diluted to a final
volume of 97p1. Inhibitors (1 p1l of DMSO stocks) were added to final
concentrations of 0, 1, 5, 10, 50, and 100 IM. Samples were pre-incubated for 45
min. at room temperature. Substrates were then added to a final concentration of
100 AtM (by addition of 2 l1 of a 5 mM DMSO stock). The hydrolysis reaction was
allowed to proceed for 45 min. at 37'C. The reaction was quenched by addition
of 1 ml of 1% SDS. Fluorescence was measured by excitation of samples at 380
nM (for MCA substrates) or 336 (for RINA substrates) and measurement of
emission at 415 nM. IC50 values were calculated from plots of Vi/Vo vs.
inhibitor concentration (where Vi is the fluorescence observed after inhibition
and Vo is the amount of fluorescence observed for samples in which DMSO alone
was added).
9. Partial Purification of Proteasomes from EL-4 Cells by Differential
Centrifugation
Proteasomes were enriched by centrifugation of lysates generated from the
mouse lymphoblastoma cells line EL-4 (for a description of preparation of lysates
see the material and methods in chapter 2). Post nuclear supernatants were
centrifuged at 100,000 g for 1 hour to remove microsomes and other cellular
organelles. The supematant from this centrifugation is called cytosoland was
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centrifuged a second time at 100,000 g for 5 hours to pellet the proteasome. This
pellet was re-suspended in homogenization buffer (50 mM Tris pH 7.4, 1 mM
DTT, 5 mM MgC12, 2 mM ATP, 20% glycerol). The 5H 100,000 g pellet is
considered to be highly enriched for the proteasome and is referred to
throughout this thesis as the 5H pellet. Protein concentration was determined
using the BCA assay (Pharmacia, Uppsala Sweden) according to the
manufacturer's instructions.
10. Labeling of Proteasomes with Peptide Vinyl Sulfones
Stock solutions of 125I -labeled inhibitors were quantitated on a gamma
counter so that equivalent amounts of radioactivity were used for all labeling
experiments. It should be noted, however, that all inhibitors may not have been
modified to the same extent during the iodination step described in chapter 2 and
therefore, it is difficult to determine the amount of unlabeled inhibitor present
in a given labeling stock. Since any unlabeled inhibitor may serve to compete for
the proteasome active site and thus, decrease labeling, these reagents can not be
used directly as quantitative measures of inhibitory activity. In all labeling
experiments, the labeled inhibitors were added to a final concentration of 1.8 X
104 Bq/ml. All samples were labeled for 2 hours at 37C unless otherwise noted.
Samples were quenched by dilution of 4X SDS sample buffer to 1X (for 1D SDS-
PAGE) or by dissolving urea to a final concentration of 9.5 M (for 2D SDS-
PAGE).
11. Competition Experiments
Partially purified proteasome preparations (20 glg total protein in 100 .1l
homogenization buffer; see above) were incubated 0, 1, 5 and 10 laM of GL3-VS or
YL3-VS for 45 min at room temperature. 1251I-YL3-VS (1.8 x 104 Bq/rl) was then
added and the samples incubated for 2 hours at 37'C. The labeling reaction was
quenched by the addition of 4x SDS-sample buffer to a final concentration of lx.
Samples were then separated on a 12.5 % SDS-PAGE gel.
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12. Gel Electrophoresis
One-dimensional SDS-PAGE, two dimensional, non-equilibrium SDS-
PAGE, and fluorography were performed as described in chapter 2.
13. Immunoprecipitation
All immunoprecipitations were performed as described in chapter 2.
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C. Results
-1. Synthesis of Peptide Vinyl Sulfones
A series of tri and tetra-peptide methyl vinyl sulfones were synthesized
based on the core sequence LLL, previously described as a potent inhibitor of the
proteasome (chapter 2). The structures of several typical methyl vinyl sulfones
are shown in figure 3.3. In addition to the methyl vinyl sulfones, we also
synthesized a related derivative in which the methyl group adjacent to the
sulfone moiety was replaced with a phenolic group (these vinyl sulfones will be
referred to as phenolic vinyl sulfones while the methyl vinyl sulfones will be
simply called vinyl sulfones). The structure of the phenolic vinyl sulfone
equivalent of the previously described vinyl sulfone Z-L3VS (Z-L3-VSphOH)
and NIP-L3-VS (NIP-L3-VS-PhOH) are shown in figure 3.3. This modification
allows for the examination of the effect of steric bulk in the position likely to
occupy a P-1 binding site (C-terminal to the site of hydrolysis). The P notation
used to identify specific residue positions in a substrate or inhibitor relative to
the site of hydrolysis is shown in figure 3.4. In addition, the phenolic group
allowed for attachment of 125I at the C-terminal end of the peptides and the
presence of an iodinatable N-terminal cap was no longer required for labeling
experiments.
The tri-peptide vinyl sulfone containing the L3 core and possessing a free
amino terminus (figure 3.5) was extended by addition of a fourth amino acid at
the P4 position. To examine the effects of the P4 amino acid on binding we
synthesized the sequences GLLL, YLLL, YAAF and LLLL as the corresponding
peptide vinyl sulfones. To examine whether the binding of the P4 amino acid
was sensitive to chiral geometry, the D-isomer of tyrosine was also added at P4.
We introduced the amino acid Benzoyl-phenylalanine (Bpa) in the P4 position
(Bpa-L3-VS) to examine whether a bulky un-natural sidechain group could be
accommodated by a secondary binding site. The Bpa group also offered the
possibility for its use as a cross-liking reagent to examine interactions between P4
and the proteasome. The structures of the tetra-peptides vinyl sulfones are
shown in figure 3.6.
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Figure 3.3. Structures of the methyl and phenolic N-terminally modified vinyl
sulfones.
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Phenolic Vinyl Sulfones
NIP-L3-VS-PhOH
Z-L3-VS-PhOH
Figure 3.4. The P-notation used to identify amino acid positions relative to the
site of hydrolysis.
The structures of a potential substrate as well as a tetra peptide inhibitor are
shown.
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Figure 3.6. Structures of the free-amino tetra-peptide vinyl sulfones.
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Finally, several other peptide vinyl sulfones were synthesized consisting of
the sequences LLG and AAF. Interestingly, the lack of a sidechain at the P1
position in the LLG peptide resulted in the generation of a mixture of cis and
trans geometric isomers of the vinyl sulfone group which could be separated by
chromatography (figure 3.7). These isomers showed drastic differences in
reactivity and will be discussed later in this chapter.
2. P4 amino acid influences inhibition of fluorogenic substrate hydrolysis
We examined the effects of the tetra-peptide vinyl sulfones on the ability of
the proteasome to hydrolyze fluorogenic substrates. Hydrolysis of the
proteasome substrates; Cbz-LLE-3NA (a substrate for the post-glutamyl
peptidase activity), Boc-LRR-MCA (a substrate for the trypsin-like activity ),
and Suc-LLVY-MCA (a substrate for the chymotrypsin -like activity) was
measured. As reported in chapter 2, the compounds Z-L3-VS and NIP-L3-VS
potently inhibited multiple proteasome activities. However, the omission of the
N-terminal carboxylbenzyl or nitro-iodo phenol yielded the free-amino
compound which was much less inhibitory. Hydrolysis of the chymotrypsin-like
substrate was dramatically reduced, with only 50% inhibition of activity at 100
giM (figure 3.8). Similar results were obtained for the LLE and LRR substrates.
However, this loss in activity seen for the free-amino terminus was overcome by
addition of a fourth amino acid. The free amino terminus-containing tetra-
peptides YLLL and BpaLLL and LLLL displayed inhibition kinetics similar to or
better than those observed for the amino-capped tri-peptide NLVS (Figure 3.9).
Of the three proteolytic activities examined using fluorogenic substrates, the
trypsin-like activity was most dramatically affected by the addition of an
aromatic, aliphatic, or bulky P4 amino acid. This activity was blocked by all the
tetra-peptide vinyl sulfones better than that observed for any of the tri-peptides
examined, including NLVS.
The related compound in which the P4 tyrosine was replaced with the D-
isomer ((D)YL3-VS) was less active than the L-isomer equivalent but showed
increased reactivity compared to free amino LLL-VS (figure 3.10). Interestingly,
the inhibitory capacity of YL3-VS against the trypsin-like activity of the
proteasome was most affected by the change from D to L isomer (20-fold
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Figure 3.7. Structures of the cis and trans isomers of NP-LLG-VS.
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Figure 3.8. The free-amino tri peptide L3-VS is a poor inhibitor of trypsin-like,
chymotrypsin-like and PGPH activities of the proteasome when compared to
NIP-L3VS and Z-L3-VS.
(A) Partially purified proteasome preparations from EL-4 cells (see Material and
Methods for preparation) were incubated with increasing concentrations of L3-
VS, NIP-L3-VS, and Z-L3-VS from 0-100 pM. Hydrolysis of the three fluorogenic
proteasome substrates; Suc-LLVY-MCA, Z-LLE-tNA, and Boc-LRR-MCA was
then measured. Plots are of Vi/Vo versus inhibitor concentration where Vi is the
inhibition observed at a given inhibitor concentration (i) and Vo is the
fluorescence observed for no addition of inhibitor (indicated as % residual
activity).
(B) IC50 obtained from extrapolation of concentration where % residual activity
equals 50% on the plots in (A). Values were obtained for all three fluorogenic
substrates as indicated.
cn ) e
3s, z
.. Zfi
ln
U I o ' f
o 
A0
AC; C0u
o o o J-
OSDI
Oa~~~~~ fr~~~~
P
I
w
o o O
A
1. 
0u
Z
aJ
N
O I , o
o 0 0
0 0 14
V" OSI
A o0
n o .
U
U
1
.4
"i
QI
°0 Ii NO0 0 0
USi1
2
V~
W
1.340o
'a -;
,, ._
E .
0a4%
z
.,
'-Ia
*" 5
S-j
I
01
la'
a 
LI
e
w
Figure 3.9. Addition of an aromatic, aliphatic, or bulky P4 amino acid to the free
amino tri-peptide L3-VS results in potent inhibition of the trypsin-like,
chymotrypsin-like and PGPH activities of the proteasome.
Inhibition of hydrolysis of fluorogenic peptide substrates by partially purified
proteasome preparations was measured and plotted as described in figure 3.8A.
ICso values (generated by extrapolation of the concentration of inhibitor at which
the % residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the tetra-peptide vinyl
sulfones: YL3-VS, BpaL3-VS, and L4-VS-PhOH compared to NIP-L3 -VS and the
corresponding free-amino derivative L3-VS.
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Figure 3.10. A D-amino acid at the P4 position results in a modest reduction of
inhibitory potency of substrate hydrolysis by the proteasome.
Inhibition of hydrolysis of fluorogenic peptide substrates by partially purified
proteasome preparations was measured and plotted as in figure 3.8A. IC50
values (generated by extrapolation of the concentration of inhibitor at which the
% residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the tetra-peptide YL3-VS
containing the D and L isomers of tyrosine in the P4 position compared to the
free amino tri-peptide L3-VS. Note the relatively modest reduction in activity of
the tetra-peptide containing the D-isomer.
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reduction compared to an 8-fold reduction for the chymotrypsin-like activity and
a 2.5-fold reduction for the PGPH activity). Thus, while the binding interaction
of the P4 amino acid seems to display some chiral discrimination, it does not
exclude binding of a D-isomer at this position.
The tetra-peptide GLLL, unlike the other tetra-peptides studied, has no
sidechain at the P4 position. This compound showed dramatically reduced
activity against hydrolysis of the Suc-LLVY-MCA and Boc-LRR-MCA substrates
when compared to YL3-VS (figure 3.11). Interestingly, the activity of GL3-VS
against the Z-LLE-3NA was nearly identical to the inhibition observed for YL3-
VS. These data indicate that the active sites for all three proteolytic activities
prefer a P4 amino acid, but the requirements for the P4 amino acid sidechain may
be different for different active sites.
A similar increase in inhibitory activity was observed when tyrosine was
placed in the P4 position by addition to the tri-peptide AAF-VS, indicating that
P4 binding is not dependent on the sequences at P1-3 but rather is a general
phenomenon which leads to increased potency of inhibitors (figure 3.12). Again
the greatest enhancement of activity was observed for the trypsin-like activity.
3. Labeling of proteasomes with tetra-peptide vinyl sulfones
The labeling pattern of proteasomes with the tri-peptide 12I-NIP-L3-VS has
been described (chapter 2). This compound covalently labels multiple 1-subunits
including the IFN-y inducible LMP-2 and LMP-7 subunits. Analysis of labeling
of proteasomes with 125I-NIP-L3-VS by SDS-PAGE results in three subunits
which overlap due to their nearly identical molecular weights but which are
easily resolved by 2 dimensional IEF-SDS-PAGE. One-dimensional SDS-PAGE
analysis of partially purified mixtures of 20S and 26S proteasomes, labeled with
12 5I-NIP-L3VS, 2sI-YL3 VS, 125I-YAAF-VS, and L4-VS- 125 I-PhOH indicate
difference in the relative intensities of individual polypeptides labeled (figure
3.13). 125I- NIP-L3-VS labels with greatest intensity a band of approximately 23
KDa in all three proteasome samples. This band was shown to be composed of
the 1-subunits LMP-7, X, and LMP-2 (in mouse the LMP-2 is resolved from
LMP-7 and X and can be seen as a slightly faster migrating polypeptide). Two
much less intensely labeled polypeptides are observed at around 28 and 30 KDa
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Figure 3.11. Glycine in the P4 position increases potency of the free-amino tri-
peptide L3-VS against the PGPH activity but not the trypsin-like or
chymotrypsin-like activities of the proteasome.
Inhibition of hydrolysis of fluorogenic peptide substrates by partially purified
proteasome preparations was measured and plotted as in figure 3.8A. ICso
values (generated by extrapolation of the concentration of inhibitor at which the
% residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the tetra-peptide GL3-VS
compared to the tetra-peptide YL3-VS and the free amino tri-peptide L3-VS.
Note the loss of reactivity in the GL3-VS inhibitor against the LLVY and LRR but
not the LLE substrate hydrolysis when compared to YL3-VS.
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Figure 3.12. Addition of tyrosine to the free-amino tri-peptide AAF-VS increases
potency against the chymotrypsin-like and trypsin-like activities of the
proteasome.
Inhibition of hydrolysis of fluorogenic peptide substrates by partially purified
proteasome preparations was measured and plotted as in figure 3.8A. IC50
values (generated by extrapolation of the concentration of inhibitor at which the
% residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the tetra-peptide YAAF-
VS compared to the tetra-peptide AAF-VS. Note the increase in potency against
hydrolysis of the LLVY and LLR fluorogenic substrates by additioin of the P4
tyrosine.
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Figure 3.13. The tetra-peptide vinyl sulfones label proteasomal 1-subunits with
different relative intensities.
Partially purified proteasome preparations were labeled with the N-terminally
modified tri-peptide 125I-NIP-L3-VS as well as with the tetra-peptide vinyl
sulfones; 125I-YL3-VS, 12 5 1-YAAF-VS, and L4 -VS-125 I-PhOH as described in the
Material and Methods section. Samples were either separated directly by SDS-
PAGE (Direct Load) or were first immunoprecipitated with the rabbit anti-
proteasome antibody and then separated by SDS-PAGE (Immunoprecipitations).
The relative molecular weights of the proteasomal polypeptides labeled are
indicated.
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and can be seen only upon long exposure of autoradiograms (see arrows).
Interestingly, in samples labeled with 125I-YL3-VS the 30KDa polypeptide is
labeled with nearly identical intensity to the 23 kDa polypeptides and with much
greater intensity when compared tc the labeling observed with 125I-NLP-L3-VS.
125I-YAAF-VS, on the other hand, labels nearly exclusively the 23 kDa
polyvpeptides and labels the 30 KDa species only weakly. L4-VS-125I-PhOH,
unlike the other tetra-peptides labels with the greatest intensity the smallest
polypeptide (likely to be LMP-2 or the Y subunit).This difference in labeling
patterns observed for the tri-and tetra-peptides exists in both
immunoprecipitated proteasomes as well as in partially purified proteasome
preparations, indicating that the labeled polypeptides in question are in fact
proteasome subunits and are not due to cross reactivity of the tetra-peptides with
other proteolytic enzymes (figure 3.13).
4. GL3-VS competes for binding of the 21 kDa proteasomal -subunit
Based on the finding that GL3-VS is a poor inhibitor of the trypsin-like and
chymotrypsin-like activities of the proteasome but a fairly good inhibitor of the
PGPH activity (see figure 3.11), we decided to examine whether this difference
in activity could be correlated with subunit binding. Partially purified
preparations of proteasomes were incubated with increasing concentrations of
GL3-VS or YL3-VS and then labeled with 125I-YL 3-VS (figure 3.14). The
competition experiment indicates that while YL3-VS is able to compete for
binding to all polypeptides labeled with 25I-YL3-VS, GL3-VS blocks binding of
125I-YL3-VS to only the 21 kDa polypeptide (likely to be LMP-2 or Y). This result
combined with the data obtained for fluorogenic substrate hydrolysis, provides
evidence that the 21 kDa polypeptide is responsible for the PGPH activity of the
proteasome.
5. Modifications at the C-terminus of the peptide vinyl sulfones
Peptide vinyl sulfones containing a phenol moiety adjacent to the sulfone
group were compared to the reactivity of peptide vinyl sulfones containing a
methyl group. These compounds allow for the examination of binding
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Figure 3.14. The tetra-peptide vinyl sulfone GL3-VS binds predominantly the 22
kDa proteasomal -subunit.
Partially purified preparations of proteasomes were incubated for 45 min. with
either YL3-VS or GL3-VS or DMSO as a control (-) and then labeled with 1251-YL3-
VS. Samples were separated on a 12.5% SDS-PAGE gel. YL3-VS competes for all
polypeptides labeled with 1251I-YL3-VS while GL3-VS competes only for the 22
kDa polypeptide.
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interactions at the C-terminal side of a predicted site of hydrolysis (likely to
mimic the P-1 position). Interestingly, replacement of the methyl group in the
compound NIP-L3-VS with the phenol (NIP-L3-VS-PhOH) resulted in very little
change in the potency of the compound against hydrolysis of the LLVY, LRR,
and LLE substrates (figure 3.15A). However, when the same comparison was
made for the methyl and phenolic vinyl sulfones for the sequence Z-L3-VS, a
large loss in activity against the PGPH activity was observed when the methyl
vinyl sulfone was replaced with the phenolic vinyl sulfone (figure 3.15B). These
data suggests that the active sites in the proteasome responsible for the different
hydrolytic activities are likely to have different substrate binding interactions
which may include different preferences for the P-1 position.
The iodinated forms of several compounds containing the phenolic vinyl
sulfone where then be used to examine the effects of the structural variation of
the C-terminal vinyl sulfone on subunit modification. Partially purified
proteasome preparations were labeled with the methyl vinyl sulfone containing
NLVS, as well as with NLVS-PhOH, Z-L3-VS-PhOH, and L4-VS-PhOH, all of
which contained the phenolic vinyl sulfone. Proteasome immuno-precipitations
were separated by SDS-PAGE and are shown in figure 3.16. The labeling
patterns obtained for these inhibitors indicated that binding was non-equivalent.
The greatest difference in intensity of labeling was observed for the smallest
polypeptide (-22 kDa). It therefore seems likely that this proteasome subunit has
the greatest binding discrimination for regions of a substrate that are C-terminal
to the site of hydrolysis.
Synthesis of the tri-peptide NP-LLG-VS allowed for the isolation of the cis
and trans isomers of the C-terminal vinyl sulfone. Interestingly, the ability of
these two compounds to inhibit hydrolysis of fluorogenic substrates by the
proteasome was quite different. The cis isomer had little or no inhibitory
capacity against any of the substrates, while the trans isomer was merely less
active when compared to tri-peptides containing three leucines (figure 3.17).
Even more surprising was the labeling pattern observed when these compounds
were equipped with a 125I moiety. The trans isomer, while a weaker inhibitor
than the LLL equivalent, was still able to covalently tag the proteasomal 0-
subunits. The cis isomer, on the other hand failed to label any polypeptides in
the 20-30 KDa size range expected for the proteasome, but efficiently labeled
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Figure 3.15. The phenolic vinyl sulfones inhibit the trysin-like, chymotrypsin-
like, and PGPH activities of the proteasome with similar potency as the methyl
vinyl sulfones.
(A) Inhibition of hydrolysis of fluorogenic peptide substrates by partially
purified proteasome preparations was measured and plotted as in figure 3.8A.
IC50 values (generated by extrapolation of the concentration of inhibitor at which
the % residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the phenolic vinyl
sulfones NLVS-PhOH compared to the methyl vinyl sulfone equivalent NLVS.
The two compounds have nearly identical inhibitory potencies.
(B) IC50 values were obtained for Z-L3-VS and Z-L3-VS-PhOH as described for A.
Note the loss of activity against hydrolysis of the LLE substrate observed for the
phenolic vinyl sulfone compared to the methyl vinyl sulfone.
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Figure 3.16. The phenolic vinyl sulfones modify 22 kDa proteasomal p-subunit
more effectively than the methyl vinyl sulfones.
Purified preparations of mouse proteasomes were labeled with NLVS-PhOH
NLVS, L3 -PhOH, and L4-PhOH and immunoprecipitated using the rabbit anti-
proteasome antibody as described in the materials and methods section. The
labeled polypeptides were separated by on a 12.5 % SDS-PAGE gel. Note the
increased intensity of the 22 kDa polypeptide observed in samples labeled with
phenolic vinyl sulfones compared to samples labeled with the methyl vinyl
sulfone (NLVS).
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Figure 3.17. A cis double bond abolishes the inhibitory potency of the peptide
vinyl sulfones.
Inhibition of hydrolysis of fluorogenic peptide substrates by partially purified
proteasome preparations was measured and plotted as in figure 3.8A. IC50
values (generated by extrapolation of the concentration of inhibitor at which the
% residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the cis (cVS) and trans
(tVS) isomers of NP-LLG-VS. Note the loss of activity by replacement of the
trans double bond with the cis double bond.
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Figure 3.18. The trans but not the cis isomer of NP-LLG-VS covalently modifies
proteasomal -subunits.
Partially purified proteasome preparations were labeled with the N-terminally
modified tri-peptide 125I-NP-LLG-cVS and 125I-NP-LLG-tVS as described in the
Material and Methods section. Samples were either directly separated by SDS-
PAGE (Direct Load) or were first immunoprecipitated with the rabbit anti-
proteasome antibody and then separated by SDS-PAGE (Immunoprecipitations).
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several other species of higher molecular weight (figure 3.18). The identity of
these additional polypeptides was not established. Thus, unlike replacement of a
methyl with a phenol which resulted in only minor changes in activity, the sharp
kink induced in the C-terminus by the cis double bond excludes binding to
proteasomal -subunits almost completely.
6. Inhibitor binding to 5-subunits is sequence specific
To investigate the effects of amino acid sequences on the binding of
inhibitors to specific subunits, we examined the ability of several tri-peptides to
inhibit fluorogenic substrate hydrolysis and to label specific f-subunits of the
proteasome when converted to 125I-labeled form. Results from analysis of
inhibition of the three proteasome substrates by the tri-peptide vinyl sulfones;
NP-LLG-VS (trans isomer), NP-AAF-VS, and NIP-L3-VS indicated that
inhibition by these three compounds is non-equivalent (figure 3.19). Both NP-
LLG-VS and NP-AAF-VS have little or no effect on the PGPH activity (IC50 = 100
gM or higher), while both are still able to inhibit the chymotrypsin activity,
although NP-AAF-VS is at least 20 times more potent than NP-LLG-VS. NP-
AAF-VS also has almost no activity against the trypsin-like activity, while NP-
LLG is only 10-fold reduced compared to NLVS.
Labeling of semi-purified proteasomes with LLG(trans isomer), AAF, and
LLL revealed differences in the relative intensity of polypeptides labeled. NIP-
L3-VS labeled predominantly the -subunits X and LMP-7 each with similar
intensity. Labeling of LMP-2, MECL-1(29 KDa PI 7.7) and Z (30 KDa PI 7.6) was
observed, however with much less intensity (figure 3.20). NIP-AAF-VS showed
labeling of predominantly LMP-7, with substantial reduction in the labeling of
X. The next most abundant signal was observed for the subunit Z. Little if any
labeling was observed for LMP-2 and MECL-1. NIP-LLG labeling resulted in a
reduction in the amount of LMP-7 labeled with respect to X and a complete loss
of labeling of LMP-2. The ratio of label intensity of Z to MECL-1 was similar to
those observed for NIP-L3-VS, but these subunits were modified to a greater
extent when compared to LMP-7 and X.
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Figure 3.19. Inhibition of proteasome by several N-terminally modified tri-
peptide vinyl sulfones containing different amino acid sequences.
Inhibition of hydrolysis of fluorogenic peptide substrates by partially purified
proteasome preparations was measured and plotted as in figure 3.8A. IC50
values (generated by extrapolation of the concentration of inhibitor at which the
% residual activity was found to be 50%) were obtained for inhibition of the
chymotrypsin-like, trypsin-like, and PGPH activities by the N-terminally
modified tri-peptides, NLVS, NP-AAF-VS, and NP-LLG.
150
1920'
0.38 070
Suc-LLVY-MCA
>100
* NLVS
O NP-AAF-VS
* NP-LLG-tVS
Boc-LRR-MCA
>>100 >100
7.0
Z-LLE-3NA
100
uU
0
100
:t 50
U
0
100'
50
A
=L
0
u
ros
0
.
I
-i w
I
_ _ 
I
Figure 3.20. Inhibitor binding to proteasomal 5-subunits is sequence specific.
Lysates generated from the human B-lymphoblastoid line HOM-2 were labeled
with 125I-NIP-L3 -VS, 2 5I-NIP-AAF-VS, and 125I-NIP-LLG-VS and labeled
polypeptides separated by NEPHGE using an 11% SDS-PAGE gel for the second
dimension. The identities of the individual subunits are indicated. Note the
change in relative intensity of spots labeled with LLG or AAF containing vinyl
sulfones compared to the L3 vinyl sulfone (NIP-L3-VS).
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D. Discussion
The use of modified tri-peptides which contain an active site-directed
inhibitory functional group at the C-terminus has proven to be an extremely
valuable method for studying proteasome-substrate binding interactions. The
synthesis of a series of tetra-peptide vinyl sulfones has uncovered the importance
of the P4 amino acid position for binding and inhibition. Modifications at the C-
terminal portion of the vinyl sulfone have also indicated some important
differences in the way in which subunits bind substrates. In addition, the study
of inhibitor binding by direct labeling experiments provide a link between
substrate binding and inhibition of hydrolysis. Labeling of proteasomes with
peptide vinyl sulfones containing different amino acid sequences has also
provided evidence that binding and subsequent covalent modification is
different for individual 3-subunits. These data may help explain how the
proteasome is able to control the multitude of proteolytic events which are
crucial for cell survival.
The ability of a free-amino tetra-peptide vinyl sulfones to potently inhibit
proteasomal proteolysis, while a slightly truncated free-amino tri-peptide
remains a poor inhibitor, is quite remarkable. The tri-peptides capped with a
bulky nitro phenol (NIP-L3-VS) or benzyl (Z-L3-VS) moiety are potent inhibitors,
but removal of the cap results in severely diminished binding and inhibition.
This loss of activity may be due in part to the exposure of a free amino group,
which is likely to mimic a short peptide, the product of a hydrolysis reaction.
However, this is not likely to be the only explanation for why the addition of a
fourth amino acid increases potency, since the addition of the t-butyl blocking
group (Boc-L3-VS) results in a rather weak inhibitor (data not shown). Also, the
placement of glycine at the P4 position results in a rather poor inhibitor,
indicating that it is specific sidechain interactions which are likely to lead to
increased binding.
The P4 binding site is unlikely to be as specific as that found for the P1
amino acid. Our data indicate that several different bulky residues including an
amino acid containing a benzophenone sidechain are accepted in this position.
In addition, unlike t.e P1 position in which use of a D-isomer results in complete
loss of binding (See Chapter 2), placement of a D-isomer at P4 results in an active
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inhibitor, albeit with reduced binding affinity. Thus, a binding site within the
cavity of e proteasome is likely to exist which serves to stabilize longer peptide
substrates and which does not possess a great deal of side-chain specificity. This
would be expected for a protease such as the proteasome, responsible for the
degradation of virtually all cytosolic proteins.
Our results also indicate that the structural requirements for binding of the
P4 amino acid are different for different active sites. The trypsin-like and
chymotrypsin-like activities of the proteasome seem to require a bulky, aromatic
or hydrophobic group in the P4 position, while the PGPH activity is equally
inhibited by glycine and tyrosine in the P4 position. Competition experiments
using GL3-VS indicate that it binds with highest affinity to the 21 kDa
polypeptide (likely to be LMP-2 or Y) and indicated that it may be possible to
correlate activity against substrate hydrolysis with subunit binding.
A rather surprising finding was the difference in labeling observed between
a capped tri-peptide such as NIP-L3-VS and a free-amino tetra-peptide such as
YL3-VS. Inhibition of substrate hydrolysis by the two compounds indicates that
both have remarkably similar inhibition profiles for all three substrates tested.
However, labeling experiments indicate that the two in fact bind with different
relative affinities to different 5-subunits of the proteasome. This difference in
labeling may be explained by a scenario in which a protein substrate is
processively degraded by the proteasome. In this case, a protein substrate binds
to an active site which is designed to accommodate a large protein, perhaps near
the opening of the inner cavity. The substrate is now cleaved and is able to
proceed to a second active site designed to accommodate the small peptide
fragments generated by the first active site. Thus, a slightly longer inhibitor may
more accurately mimic a protein substrate while a tri-peptide mimics the
products already acted upon by the proteasome. The difference in labeling may
if fact reflect how the proteasome deals with these different substrates.
Labeling of proteasomes using a variety if tetra-peptide vinyl sulfones
indicated that the increase in potency acquired by addition of the P4 amino acid
is not likely to be the result of a single specific inhibitor-p-subunit interaction. In
the case of YL3-VS, the most pronounced difference in labeling compared to the
tri-peptide NIP-L3-VS was the abundance of the 30 kDa polypeptide. This
increased modification of the 30 kDa species was not observed for YAAF-VS or
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for L4-VS. The binding site for a P4 amino acid may therefore contribute to
binding at multiple active sites. The sequence of the peptide may dictate which
active site binding is influenced the most by the presence of the P4 amino acid.
The differences between the labeling patterns and inhibition profiles
against fluorogenic substrate hydrolysis observed for the tri- and tetra peptide
inhibitors, as well as for the methyl and phenolic versions of NIP-L3-VS, also
indicate that pB-subunits, at last to some extent must overlap in their hydrolysis
activity. If each P-subunit were responsible for a single type of proteolytic
activity (i.e. chymotrypsin-like, trypsin-like, or PGPH) a change in subunit
labeling affinity would be directly reflected in the ability of a compound to
inhibit hydrolysis of a specific substrate and this is not observed.
The functional group placed adjacent to the sulfone group at the C-terminal
end of the inhibitor is likely to mimic the P-1 position of a protein substrate when
bound in the active site. Our data support the fact that not all the active sites
have the same degree of specificity, or lack there of, for the P-1 position.
Hydrolysis of the Z-LLE-3NA substrate is inhibited quite effectively by the
compound Z-L3-VS but not by the equivalent compound containing a phenolic
vinyl sulfone. Interestingly, the same difference is not observed when comparing
the activity of the methyl and phenolic version of NIP-L3 -VS (figure 3.15).
While some active sites may not depend on interactions with the region of a
substrate C-terminal to the site of hydrolysis, the inability of the cis double bond
containing vinyl sulfone to bind to any subunits of the proteasome indicates that
a dramatic kink in the peptide structure precludes binding.
Finally, labeling of proteasomes with inhibitors containing different amino
acid sequences demonstrates that individual subunits have sequence specificity.
It is not surprising that by changing the amino acid sequence of a tri-peptide
inhibitor it is possible to change the relative inhibitory capacity of that
compound. However, by comparing the changes in binding affinity of a
compound for individual subunits relative to one another it is possible to
examine how these inhibitors interact with individual subunits of the
proteasome. Of interest is the ability of a NIP-AAF-VS to bind specifically to
LMP-7 with greater affinity than to X. This is in direct contrast to NIP-L3-VS,
which binds both equally, and NIP-LLG-VS which bind preferentially to X. This
result is surprising in light of the findings that replacement of X with LMP-7
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results in the production of peptides with a hydrophobic C-terminal residues
suitable for binding to class I molecules (Driscoll et al., 1993; Gaczynska et al.,
1993; Gaczynska et al., 1994) and considering the fact leucine is a better C-
terminal anchor residue for class I binding.
Fluorogenic substrates are often used to evaluate the ability of a compound
to inhibit the proteolytic activity of an enzyme such as the proteasome. These
tools, while useful, often fail to shed light on the underlying mechanisms by
which a compound can cause inhibition. The data reported here serve to further
support the usefulness of radiolabeled affinity reagents such as the vinyl sulfones
to study substrate binding.
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IV. THE HUMAN CYTOMEGALOVIRUS US2 AND USll GENE
PRODUCTS DISLOCATE MHC CLASS I HEAVY CHAINS
FROM THE ENDOPLASMIC RETICULUM TO THE
CYTOSOL FOR DEGRADATION BY THE PROTEASOME
Adapted from:
Emmanuel J. H. J. Wiertz, Thomas R. Jones, Lei Sun, Matthew Bogyo,
Hans J. Geuze, and Hidde L. Ploegh. (1996). Cell 84, 769-779.
Emmanuel J. H. J. Wiertz, Domenico Tortorella, Matthew Bogyo, Joyce Yu,
Walter Mothes, Thomas R. Jones, Tom A. Rapoport, and Hidde L. Ploegh.
(1996). Nature 384, 432-438.
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A. Introduction
The virus life cycle begins with infection of a host and hijacking of its
cellular machinery to produce proteins necessary for the virus to survive and
propagate. The host organism must therefore be able to recognize and kill
infected cells if it is to eradicate the virus. This is accomplished by presentation
of peptide epitopes derived from viral proteins, primarily on MHC class I
molecules. These peptide -MHC complexes are displayed at the cell surface and
are recognized by circulating cytotoxic T-lymphocytes, which then proceed to
kill the infected cell . In order to escape this destruction by the immune response
of the host, the virus must devise clever strategies to interfere with the process of
antigen presentation. Over the course of tens of millions of years of evolution,
nature has selected viruses equipped with a myriad of evasion strategies which
include the synthesis of proteins that block the function of TAP to the ones that
catalyze the complete destruction of MHC class I molecules.
The Herpes simplex viruses HSV 1 and HSV 2 are closely related and part
of a family of viruses termed persistent viruses. Both undergo a period of latency
after initial infection, during which time the virus produces only a select few
proteins required for maintenance of the latent state. Over time these latent
viruses become activated and begin to produce a large number of progeny
viruses. It is at this time in the viral life cycle that it is most vulnerable to
detection by the host's immune cells. HSV has apparently circumvented this
dilemma by synthesizing a small cytosolic protein, ICP47 which inhibits the
ATP-dependent peptide transporter, TAP (York et al., 1994; Hill et al., 1995; Friih
et al., 1995). Thus, by plugging the hole by which peptides enter the ER and
bind to newly synthesized MHC class I molecules, viral epitopes fail to be
presented at the cell surface and the virus remains invisible to the host's immune
system.
Similar to HSV, infection by both the human (HCMV) and murine (MCMV)
cytomegalovirus results in a lifelong infection of the host (Reusser et al., 1991;
Quinnan et al., 1982). In the case of MCMV, the virus eludes detection by the
host immune response by multiple mechanisms; the details of some of these
strategies remain unknown. Viral infection by MCMV results in the retention of
the majority of class I molecules in ER and the few which escape to the cell
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surface are accompanied by a viral glycoprotein termed gp34 (Kleijnen et al.,
1997). The exact function of gp 34 is unknown but it has been suggested to lead
to a reduction in the affinity of class I-peptide complexes for the T-cell receptor of
CD 8+ cytotoxic T-cells (Kleijnen et al., 1997). The identity of the gene product
responsible for the retention of class I molecules is currently nearing
identification through the use of deletion studies of the viral genome. It appears
that multiple genes may contribute to ER retention (Thale et al., 1995).
HCMV infection, on the other hand results in the complete and rapid
destruction of MHC class I molecules (Beersma et al., 1993; Warren et al., 1994).
Systematic deletion of regions of the HCMV genome has uncovered two genes,
US2 and US11 (for Unique Short region) responsible for the phenotype of loss of
class I expression on the cell surface (Jones et al., 1995). These genes, when
transfected into class I + cell lines result in rapid destruction of class I heavy
chains. The mechanism by which US2 and US11 accomplish this destruction
involves the dislocation of newly synthesized Class I heavy chains from the ER to
the cytosol, at which point the single N-linked glycan is removed by a peptide
N-glycanase activity, followed by destruction by the proteasome. This process
of reverse translocation of a polypeptide from the ER to the cytosol is mediated
by Sec6lp protein complex, in what appears to be a reversal of the process by
which proteins are inserted into the ER.
Thus the study of a viral evasion strategy has uncovered a novel route by
which ER resident proteins may be destroyed in the cytosol by the proteasome.
This method of protein destruction is not likely to be unique to cells infected
with HCMV but rather a general process which a cell uses to remove unwanted
proteins from the ER.
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B. Materials and Methods
1. Cells and Cell Culture
U373-MG astrocytoma cells, US11 and US 2 transfectants prepared from
this cell line have been described (Jones et al., 1994; Kim et al., 1995). The cells
were cultured in Dulbecco's modified Eagle's medium supplemented with 5%
fetal calf serum and Puromycin (Sigma, St. Louis, MO) at a final concentration of
0.375 gg/ml.
2. Antibodies
The following antibodies were used: mono-clonal antibody W6/32 (Parham
et al., 1979), specific for assembled class I molecules; rabbit anti-heavy chain
serum (Beersma et al., 1993), which recognizes unfolded class I heavy chains;
anti-proteasome (Organon teknika, Oss, The Netherlands) which recognizes an
a subunit as part of the mature 720-kDa proteasome complex; The mono-clonal
antibody 661g10 which recognizes the human transferrin receptor (Beersma et al.,
1993); anti-Sec-61 described previously (Gdrlich and Rapoport, 1993); Rabbit
anti-US2 serum (Jones and Sun, 1997); and polyclonal rabbit serum reactive with
US11 (Jones et al., 1991).
3. Inhibitors
The proteasome inhibitor lactacystin was obtained from E.J. Corey
(Harvard University) and used at a final concentration of 20 giM. Leucyl-leucyl-
norleucinal (LLnL; Boehringer Mannheim, Germany) was dissolved in ethanol
and used at a final concentration of 50 gM. Carboxylbenzyl-leucyl-leucyl-leucinal
(Z-L3-H or CbzLLL) was synthesized as described (Wiertz et al., 1996a),
dissolved in ethanol, and used at a final concentration of 50 pM. Caboxylbenzyl-
leucyl-leucyl-leucine vinyl sulfone (Z-L3-VS) was synthesized as described in
chapter 2, dissolved in DMSO, and used at a final concentration of 50 gM.
Tunicamycin and Brefeldin A were from Sigma (Sigma Chemical Co., St. Louis).
Treatment with endoglycosidase H (Endo H; New England Biolabs, Beverly) or
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N-glycanase (Boehringer Mannheim, Germany) were performed as suggested by
the manufacturers.
4. Pulse Chase Analysis
Cells were detached by trypsin treatment and incubated in methionine-free
Dulbecco' modified Eagle's medium with or without added inhibitors for 1 hour.
Two million cells (pulse time as indicated in figure legend; 250 gCi of 35S-
Methionine ((1200 Ci/mmol) NEN-Du Pont) or for short pulses (45-60 seconds) 5
x 106 cells and 500 gCi of label were used per sample. Incorporation was
terminated by addition of non-radioactive methionine to a final concentration of
1 mM. Immediately following the chase, samples were placed on ice and lysed
in 1 ml of ice-cold NP-40 lysis mix. Preparation of lysates and
immunoprecipitations were performed as described (Beersma et al., 1993).
5. Gel electrophoresis
SDS-PAGE, one-dimensional IEF, and fluorography were performed as
described (Ploegh, 1995).
6. Subcellular Fractionatin
Cells (lx 108) were incubated in methionine-free medium with LLnL (20
gM; US11+ cells) or Z-L3 -H (20gM; US2+ cells) for 1 hour. Cells were then
labeled with [35S] methionine (250 jgCi/ml) in a volume of 2 ml for 15 min. The
cells were washed in homogenization buffer (0.25 M sucrose, 10 mM
triethanolamine, 10 mM acetic acid, 1 mM EDTA [pH 7.4] and the protease
inhibitors leupeptin [1 mM] iodoacetamide [50 gM], phenylmethylsulfonyl
fluoride [1 mM] and LLnL or Z-L3-H [20gM] and re suspended in 2 ml of
homogenization buffer. Cells were homogenized on ice using a dounce
homogenizer (30 or 50 strokes) with a tight fitting pestle (Thomas; Pestle type A).
The homogenate was spun at 1,000 g for 10 min. which yielded the 1,000 g pellet.
The supematant was subjected to 10,000 g centrifugation for 30 min., which
yielded the 10,000 g pellet. Finally, the 10,000 g supernatant was spun at 100,000
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g for 1 hr., which resulted in the 100,000 g pellet and the 100,000 g supernatant
(cytosol). Lysis mix was added to all pellets (but not the 100,000 g supernatant)
and immunoprecipitations, SDS-PAGE, and fluorography were performed as
described.
7. Re-immunoprecipitation of class I heavy chains or US2 from immuno
complexes containing proteasomes, US2, or Sec61l
US2+ cells were pulsed labeled as described above then chased for 0, 1, 2, 7,
20, and 60 minutes in the presence of Z-L3-H (20 gM) at 37°C. Cells were lysed
in digitonin lysis mix ( 1% Digitonin in 2.5 mM HEPES, pH 7.6, 10 mM CaC12).
First round immunoprecipitations were performed as described (Beersma et al.,
1993). Re-immunoprecipitations were performed by de-naturation of primary
precipitates by treatment with 1% SDS containing 5% -mercaptoethanol
followed by boiling. Samples were then diluted 10OX with NP-lysis mix described
above and precipitations were carried out using the antibody specified. Proteins
were then separated by SDS-PAGE.
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C. Results
1. Class I heavy chains are destroyed in US11+ and US2+ cells
The effects of expression of the HCMV gene, US11, were examined by
pulse-chase analysis in U373-MG cells transfected with the US11 gene. Cells
were pulse labeled with 35 S-methionine for 60 seconds followed by a chase of 1,2
5, and 10 min. Class I heavy chains were precipitated using a conformation-
specific antibody (W6/32) which recognizes only properly folded heavy chains
complexed with light chain ( 2M) as well as with a rabbit serum that only
recognizes free heavy chains (figure 4.1). Transferrin receptor was also
precipitated to monitor synthesis of a control protein. The amount of recovered
class I molecules increases from 0 to minute of chase, presumably because of
the time required for the methionine pools to equilibrate within the cells. Greater
than one half of the total recovered radioactivity disappears between the 1 and 2
minute chase points and complete destruction of heavy chains is observed by the
20 min time point in both W6/32 and anti-heavy chain precipitations. The
kinetics of degradation seen here are very similar to those observed for HCMV
infected cells (Wiertz et al., 1996b).
Due to the rapid time scale of this destruction process, degradation is likely
to take place immediately after the nascent polypeptide is synthesized and before
it can leave the ER for the Golgi apparatus. Transferrin receptor, on the other
hand, is synthesized, glycosylated normally and fails to be destroyed,
indicating that the observed break-down is specific for MHC class I molecules.
In addition, when the same pulse chase experiment is performed at the reduced
temperature of 26' C, there is little effect on the kinetics of the US 11 mediated
breakdown of class I molecules.
In the same U373 cells described above transfected with the HCMV gene
US2, class I heavy chains are much less stable than in non-transfected controls.
In a pulse chase experiment, all heavy class I heavy chains are destroyed by the
30 min. chase point. Similar to the findings for US11+ cells, the US2 mediated
destruction does not depend upon proper folding and assembly with 2m
(Wiertz et al., 1996b).
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Figure 4.1 The half-life of class I heavy chains in US11+ cells is less than 1
minute.
(A) Free class I heavy chains were immunoprecipitated with rabbit serum raised
against the lumenal domain of class I molecules (anti-heavy chain serum).
US11+ cells were pulse labeled with [35S] methionine for 60 s, and chased as
indicated, at 37C (lanes 1-7) or 26°C (lanes 8-14). The immunoprecipitations
were separated on a 12.5 % SDS-polyacrylamide gel and visualized by
fluorography.
(B) Class I heavy chain-02m complexes were immunoprecipitated with the
monoclonal antibody W6/32; otherwise as A.
(C) Transferrin receptor was immunoprecipitated with the monoclonal antibody
66Ig10; otherwise as A.
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2. A class I heavy chain break-down intermediate appears in US11+ and US2+
cells upon treatment with proteasome inhibitors.
In order to examine the mechanism by which US2 and US11 destroy newly
synthesized class I heavy chains, transfectants were treated with protease
inhibitors 30 minutes prior to pulse -chase analysis. Treatment of US11+ cells
with Brefeldin A, a natural product shown to block anterograde transport from
the ER to Golgi (Misumi et al., 1986) did not effect breakdown, indicating that
transport of class I molecules to a site downstream of the ER is not required for
efficient destruction (figure 4.2).
Treatment of US 11+ cells with The tri-peptide aldehyde leucyl-leucyl-
norleucinal, LLnL (an inhibitor of the cysteine protease calpain I which has also
been shown to inhibit the proteasome (Rock et al., 1994; Coux et al., 1996)
resulted in the appearance of a new polypeptide with a slightly lower apparent
molecular weight (40 kDa) than intact heavy chains (43kDa) in precipitations
performed with anti heavy chain serum. This intermediate could not be seen in
W6/32 precipitations and failed to appear when control (US11-) cells were
treated with LLnL (figure 4.2).
The effect of several other classes of protease inhibitors on class I
breakdown was examined next. In addition to LLnL, several more specific
proteasome inhibitors have been reported. The natural product lactacystin has
has exquisite specificity for the proteasome (Fenteany et al., 1995). Likewise, the
tri-peptide vinyl sulfone carboxylbenzy-leucinyl-leucinyl-leucine vinyl sulfone
(Z-L3VS) has very little cross-reactivity with non-proteasomal proteases
(Chapter 2). Finally, the tri-peptide aldehyde carboxylbenzyl-leucyl-leucyl-
leucinal (Z-L3-H or CbzLLL) is a potent inhibitor of the proteasome, although,
like LLnL, it is not proteasome-specific (see chapter 2). Pre-treatment of both
US11+ cells (figure 4.3A) and US2+ (figure 4.3 B)with these inhibitors resulted
in the appearance of the lower molecular weight breakdown intermediate in all
cases. These results provide strong evidence for the involvement of the
proteasome in US2 and US11 mediated class I heavy chain breakdown.
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Figure 4.2. LLnL, but not BFA, induces a class I breakdown intermediate in
US11+ cells.
Class I molecules were immunoprecipitated from US11+ cells using the
monoclonal antibody W6/32 (lanes 1-8), and rabbit heavy chain serum (lanes 9-
16). The cells were pretreated with the appropriate inhibitors for 60 minutes,
pulse labeled with [35S] methionine for 15 min. and chased for 20 min. The
proteins were separated on a 12.5 % acrylamide gel. The position of migration of
core-glycosylated class I heavy chain (43-44 kDa; HC) and the breakdown
intermediate (-40 kDa; HC with asterisk) are indicated.
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Figure 4.3. US11 and US2 mediated class I breakdown does not require N-linked
glycans and is inhibited by inhibitors of the proteasome.
(A) US11+ cells were pretreated with LLnL, Z-L3-H (CbzLLL), lactacystin,
tunicamycin, or both LLnL and tunicamycin for 1 hour. Cells were labeled for
15 minutes and chased for 45 minutes in the continued presence of the inhibitors.
the class I molecules were immunoprecipitated using the rabbit anti-heavy chain
serum.
(B) US2+ cells were pre-treated with lactacystin, Z-L3-H, Z-L3-VS, and
tunicamycin for 1 hour and then pulse labeled, chased, and immunoprecipitated
as described in A. The fully glycosylated heavy chain 43 kDa) is indicated as
HC + CHO and the de-glycosylated breakdown intermediate (40 kDa) is
indicated as HC - CHO.
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The identity of the lower molecular weight intermediate was further
examined by treatment of cells with the glycosylation inhibitor, tunicamycin.
The resultant non-glycosylated class I heavy chain co-migrated in SDS-Page gels
with the class I heavy chain breakdown intermediate (figure 4.3). Thus, the
heavy chain intermediate was likely to be the result of a deglycosylation reaction
prior to destruction by the proteasome. Such deglycosylation is not inhibited by
proteasome inhibitors.
3. N-linked glycans are removed from class I molecules in US11 and US2 cells
by a peptide N-glycanase activity.
Pulse chase experiments performed on US11+ cells in the presence of
proteasome inhibitors indicate that a precursor-product relationship exists
between intact heavy chain (43 KDa) and the breakdown intermediate (40 kDa).
Since SDS-PAGE fails to distinguish between a non-glycosylated (tunicamycin
treated sample) and a de-glycosylated (Endo H treated) class I heavy chain,
(since the difference in migration caused by the presence of a single GlcNAc
residue is too small to visualize), we could not exclude the possibility of the
existence of truncated sugar residues on the 40 kDa intermediate. Further,
involvement of an N-glycanase in conversion of intact heavy chain to the
intermediate would result in conversion of a the asparagine residue at the site of
glycan attachment to an aspartic acid upon hydrolysis (Tarentino and Plummer,
1994). This amino acid change would result in a change in the net charge of the
polypeptide which could then be resolved by isoelectric focusing (IEF).
A pulse chase was performed on US11+ cells treated with LLnL as well as
with tunicamycin. The class I heavy chain precipitates were subjected to SDS-
PAGE and IEF (figure 4.4a). Isoelectric focusing of class I heavy chains from
control cells results in the appearance of several bands due to the unique
isoelectric points of the three products of the HLA loci (HLA-A, -B, and -C) that
encode class I molecules. In US11+ cells treated with LLnL, the 40 kDa
breakdown intermediate appears in the IEF gel at a more acidic pH than the
intact glycosylated or non-glycosylated free heavy chains from tunicamycin
treated cells. Based on previous observations (Eichholtz et al., 1992) the
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Figure 4.4. N-linked glycans are removed from class I molecules in US11+ cells
by an N-glycanase type activity.
(A) The precursor-product relationship of the 43 kDa breakdown intermediate
was established in a 1 min. pulse chase experiment performed with US11+ cells
in the absence (minus) or presence of LLnL. The cells were pulse labeled for 60
seconds and chased for the rimes indicated. Class I heavy chains were
immunoprecipitated with rabbit anti-heavy chain serum and separated by SDS-
PAGE. Endo H digestion was performed for three samples (untreated cells, 1
min. chase; LLnL treated cells, 1 and 10 min. chase). Samples before and after
Endo H digestion are shown in lanes 15-21. The class I heavy chains obtained in
the presence of tunicamycin (TM; lane 17) are devoid of carbohydrates.
(B) Isoelectric focusing (IEF) gel loaded in exactly the same order as the SDS-
PAGE gel shown in (A). Note the shift in isoelectric point for the breakdown
intermediate.
(C) US11+ and control cells were labeled for 20 min. and chased for 0 or 20 min.
For US11+ cells, LLnL was included to the labeling and chase medium. Class I
heavy chains were digested with N-glycanase where indicated. Following
complete denaturation in SDS, heavy chains were re-immunoprecipitated with
rabbit anti-heavy chain serum, and analyzed by 1D IEF. In control cells,
digestion of class I heavy chains with N-glycanase shifts the banding pattern to a
more acidic position for both the 0 and 20 min. time points (brackets; Class I-
CHO). In US11+ cells, some of the core-glycosylated precursor is observed at
the 0 min. time point and is still susceptible to N-glycanase digestion. Note that
at the 20 min. time point, when only the breakdown intermediate is detectable,
(see figure 3.3a), digestion with N-glycanase does not effect the IEF banding
pattern. Moreover, the pattern observed in US11+ cells is indistinguishable from
that seen for the N-glycanase-digested Class I heavy chains from control cells.
The two panels shown are derived from the same electrophoretic separation, but
different exposures were required to compensate for levels of incorporation.
Cathode is at the top.
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difference in pI seen for the intermediate is consistent with a change in charge as
a result of conversion of a single Asn to Asp.
To confirm that the 40 KDa intermediate is the result of hydrolysis by
peptide N-glycanase (PNGase), immunoprecipitations from a pulse chase
reaction were digested in vitro with purified, recombinant PNGase and then
subjected to IEF (figure 4.4B). Treatment of class I heavy chain from control cells
with PNGase resulted in the appearance of several acidic polypeptides which co
-migrated with the acidic polypeptide observed in US11+ cells without in vitro
treatment with PNGase. Taken together, these results suggest that prior to
degradation by the proteasome, class I heavy chains are de-glycosylated by a
peptide N-glycanase activity which removes the single N-linked glycan by
hydrolysis of the amide linkage to asparagine.
4. The de-glycosylated class I heavy chain is found in the cytosol.
Since the proteasome and the peptide N-glycanase enzymes are thought to
be predominantly cytosolic, we next examined whether the heavy chain
intermediate could be found in the cytosol en route to destruction. Subcellular
fractionation was performed on lysates from pulse-chased control or US11+ cells
(figure 4.5I). The fraction obtained from the 1000 g spin is likely to represent
unbroken cells and larger cellular debris that may trap soluble proteins.
Therefore, the emphasis should be placed on the 10,000 and 100,000 g samples.
The intact, glycosylated heavy chain could be precipitated from all particulate
fractions (1000, 10,000, and 100,000 g) but not from the 100,000 g supernatant in
either control or US11+ cells. The de-glycosylated intermediate from LLnL
treated US11+ cells could also be precipitated from all three pellet fractions.
However, the majority of this polypeptide was found in the 100,000 g
supernatant. Further, to assure that the fractionation was successful, the lysate
fractions were used to precipitate several control membrane associated proteins.
In all cases, the membrane proteins were found exclusively in the pellet
fractions, including USll itself. The lack of detectable USll in the 100,000 g
supernatant fraction indicates that heavy chains must be escorted by US11 to the
cytosol and at this point no association remains between the two molecules.
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Figure 4.5. In US11+ cells treated with LLnL and US2+ cells treated with Z-L3-H,
most class I heavy chains are present in the cytosol.
(I) Subcellular fractionation on US11+ and control cells was performed as
described in the Experimental Procedures. Class I heavy chains were
immunoprecipitated from the subcellular fractions using the rabbit anti-heavy
chain serum (A). Note the recovery of the breakdown intermediate from the
100,000 g supernatant. The 12m molecules were immunoprecipitated using the
monoclonal antibody BBM.1 (B). The USll glycoprotein could be recovered from
US11+ cells but not from control cells (C). Note that US11 sediments largely with
the microsomal fractions and is absent from the 100,000 g supernatant, the
compartment that contains the heavy chain breakdown intermediate. Calnexin
(D) and transferrin receptor (TfR; E) were immunoprecipitated using the
monoclonal antibodies AF8 and 66Ig10, respectively.
(II) Subcellular fractionation of US2+ cells performed as described for (I) except
cells were treated with Z-L3-H instead of LLnL. Class I heavy chains were
immunoprecipitated using the rabbit anti-heavy chain serum. As found for
US11+ cells, the breakdown intermediate was found largely in the cytosolic
fractions (HC-CHO).
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A similar result is obtained from fractionation experiments performed on
US2+ cells (figure 4.511). The fully glycosylated class I heavy chains are found
predominantly in the pellet fractions from the 1000, 10,000, and 100,000 g
centrifugations, and the de-glycosylated heavy chains are found mainly in the
100,000 g supernatant. In contrast to US11, US2 exists as two forms that differ by
the presence of a single N-linked glycan (as identified by treatment with Endo
H). Both forms of US2 are detected in US2+ cells as well as in HCMV infected
cells (Wiertz et al., 1996). Direct association with class I heavy chains can be
demonstrated by co-immunoprecipitation of US2 using an antibody specific for
properly folded heavy chains (figure 4.6). Fractionation experiments also
indicate that the de-glycosylated form of US2 is found in the cytosol with the de-
glycosylated heavy chain. Cytosolic IJS2 which has lost its glycan is also
degraded by a process which is blocked by inhibitors of the proteasome (figure
3.6). These data, taken together, support a mechanism of dislocation of heavy
chains by US2 in which US2 itself undergoes the same destructive fate as the
heavy chains which it is escorting.
5. The de-glycosylated class I heavy chain directly associates with the
proteasome.
In order to further establish the involvement of the proteasome in the US11
and US2 mediated breakdown of class I heavy chains, we examined whether
breakdown intermediates could be detected in a physical complex with the
proteasome when incubated with inhibitors which blocked its proteolytic
activity. Precipitation of heavy chains from pulse chased control, US2+, and
US11+ cells followed by denaturaton of the primary precipiatations and re-
immunoprecipitation with the same anti heavy chain serum resulted in the
appearance of the characteristic 40 and 43 kDa bands for the glycosylated and de-
glycosylated heavy chains. Immunoprecipitation from the same samples first
using a proteasome specific antibody followed by denaturaton and re-
precipitation with anti heavy chain serum indicated that only the 40 kDa
polypeptide corresponding to the de-glycosylated class I heavy chain could be
detected in the second immunoprecipitation and only when US2 or US11 was
present (figure 4.7A).
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Figure 4.6. US2 molecules form complexes with properly folded class I heavy
chains, is deglycosylated and destroyed by the proteasome.
(A) US2+ cells were pre-treated with lactacystin, Z-L3-H, Z-L3-VS or
tunicamycin for 1 hour then pulse labeled for 15 min. and chased for 0 and 30
min. Properly folded class I molecules were immunoprecipitated using the
monoclonal antibody W6/32. Note the presence of the US2 glycoprotein (US2 +
CHO 24 kDa) in the W6/32 precipitates. The deglycosylated heavy chain is not
detected in the W6/32 precipitations.
(B) The same samples from (A) were precipitated with anti-US2 polyclonal
rabbit serum. US2 exists as a glycosylated (24 kDa, US2 + CHO) and as a non-
glycosylated formr (22 kDa; US2 - CHO). The non-glycosylated form is destroyed
in a manner sensitive to inhibitors of the proteasome.
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Figure 4.7. The deglycosylated class I heavy chain breakdown intermediate can
be found as a complex with the proteasome in US2+ and US11+ cells.
(A) US2+ and US11+ cells were pre-treated with Z-L3-H, pulse labeled and
chased as described in the Materials and Methods section. Digitonin lysates were
immunoprecipitated with rabbit anti-heavy chain serum and an anti-proteasome
antibody and the precipitates were completely dissociated and re-
immunoprecipitated with rabbit anti-heavy chain serum. The position of
migration of the heavy chains (HC) with or without N-linked glycan (+/- CHO)
are indicated. Note the presence of the de-glycosylated heavy chain in
proteasome precipitations from US2+ and US11+ transfectants only.
(B) A Pulse chase expelanment was performed on cells treated with Z-L3-H as
described in (A) except several chase points were taken as indicated. Digitoni 
lysates were immunoprecipitated with the antibodies indicated at the top of the
figure and the precipitates, following their complete dissociation in SDS, were
re-immunoprecipitated with rabbit anti-heavy chain serum. The position of
migration of US2 (US2) and heavy chain (HC) with and without N-linked glycan
(+/- CHO) are indicated.
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To further examine the interaction of the class I heavy chain breakdown
intermediate with the proteasome, a pulse chase was performed on US2+ cells
followed by immunoprecipitation, SDS denaturation, and re-
immunoprecipitation (figure 4.7B). The presence of the deglycosylated class I
heavy chain could be detected by pre treatment with the proteasome inhibitor Z-
L3-H. Again, only the de-glycosylated heavy chain could be re-precipitated
from primary proteasome IPs. The amount of deglycosylated heavy chains
recovered from proteasome precipitations was maximal between the 7 and 20
min chase point, consistent with the time scale for conversion of precursor
glycosylated heavy chains to deglycosylated product. taken together these results
prove a direct interaction of the proteasome with the deglycosylated heavy chain
prior to its destruction.
6. US2 and the class I heavy chain intermediate associate with Sec61lp.
We next examined whether it was possible to detect US2 and class I heavy
chains in the process of being reverse translocated from the ER into the cytosol.
Since the process of insertion in to the lumen of the ER is performed by the multi-
subunit translocation complex Sec6lp, we reasoned that perhaps the process of
reverse translocation is accomplished by same membrane pore that is responsible
for insertion of membrane bound glycoproteins. Due to the rapid kinetics of US2
and US11 catalyzed destruction of heavy chains, we examined whether we could
detect breakdown intermediates in a complex with Sec6lp in the process of
undergoing reverse translocation. A pulse chase was performed on Z-L3-H
treated US2+ cells followed by primary immunoprecipitation with an antibody
against the Sec61lp p subunit and then re-immunoprecipitation with antibodies
against either class I heavy chains or US2 (figure 4.8). Only the de-glycosylated
form of class I heavy chains could be isolated from precipitations of Sec61. This
data indicates that removal of the glycan from the intact heavy chain takes place
while the class I heavy chain is still tethered to the translocation complex.
Further, the heavy chain intermediate could not be isolated from Sec61
precipitations in the absence of the proteasome inhibitors, indicating that the
process of reverse translocation and degradation by the proteasome are likely to
be closely lcoupled. US2 could also be recovered from precipitations with the
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Figure 4.8. Class I molecules destined for degradation associate with Sec6lp.
Sec61 was immunoprecipitated from digitonin lysates of Z-L3-H-treated cells and
the precipitates were re-immunoprecipitated with either rabbit anti-heavy chain
serum (aHC) and or rabbit anti-US2 serum (aUS2). Sec61 depleted lysates were
also immunoprecipitated with a-IC or aUS2. These samples are designated as
direct immunoprecipitates. The positions of migration of heavy chains (HC) and
US2 molecules (US2) with or without N-linked glycan (+/- CHO) are indicated.
Exposure time of the autoradiogram for the re-precipitation experiments was 14
days; for direct precipitations, exposure was 2 days.
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Sec613 antibody. Similar to the results obtained for class I heavy chains, the de-
glycosylated form of US 2 was the predominant species found associated with
Sec6lp.
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D. Discussion
The process by which HCMV is able to elude the host immune response by
down regulation of class I expression at the cell surface is yet another example of
a clever viral evasion strategy. This down regulation of class I heavy chains is an
extremely rapid process catalyzed by the viral gene products US2 and US11,
involving the Sec61lp translocation complex and the proteolytic activity of the
proteasome. The process appears to be a reversal of the translocation process
used to insert the newly synthesized heavy chain into the ER. Upon exposure to
the cytosol, the fully glycosylated class I heavy chain is acted upon by a N-
glycanase, rapidly removing its sugars while still associated with the Sec61
membrane channel. This deglycosylated heavy chain is then destroyed by the
proteolytic action of the proteasome (figure 4.9).
Although transfection of cells with either US2 or US11 both result in the
loss of class I expression, details of the mechanism of this down-regulation
show that the two may accomplish their goal through different mechanisms.
Fractionation experiments performed on US11+ cells showed that although the
majority of the deglycosylated heavy chain was found in the cytosolic 100,000 g
fraction, no US11 was found co-localized in that fraction. Thus, US11 may exert
its effects distal to class I heavy chains and it may in fact be through other
accessory proteins that it is able to induce dislocation of class I molecules. A
possible scenario exists in which US11 interferes with proteins that have a
chaperone-like function and are required for proper membrane translocation. In
this case slowing or stopping of the translocation process may result in reversal
of the insertion process.
US2, on the other hand, directly associates with the newly synthesized
class I molecule and the de-glycosylated form, like the deglycosylated class I
heavy chain, is found in the cytosol. Direct association of the deglycosylated US2
molecule with the Sec6lp complex indicates that, in association with the class I
heavy chains it is designed to destroy, it is dislocated through the Sec61 pore
and is then deglycosylated by an N-glycanase and destroyed by the proteasome
(figure 4.9). The fact that two separate gene products exist in the HCMV genome
which are responsible for producing the same end result indicates the
importance of the class I mediated cytotoxic T-cell response in viral
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Figure 4.9. Model for Sec61-dependent dislocation.
(A) A nascent class I heavy chain inserts into the ER in a signal sequence-
dependent fashion. US2 interacts with the class I heavy chain before the lateral
escape from the Sec61 complex into the membrane. The lumenal, glycosylated
domains of both class I heavy chains and US2 are subject to dislocation. A
reaction that culminates in the action of N-glycanase and proteasomal
proteolysis.
(B) An ER resident, properly folded class I heavy chain can be recruited by US2
to re-enter the Sec61 complex. US2 itself re-enters the Sec61 complex and both
polyieptides are dislocated
(C) In normal cells, any misfolded or incompletely assembled protein could be
recruited by the action of an ER-resident chaperone to re-engage the Sec61
complex for dislocation and cytosolic destruction. Whereas in (A) and (B),
proteolysis may become rate-limiting owing to the high rate of dislocation, in (C)
dislocation is the rate-limiting step.
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clearance by the host. Further, the fact that US2 and US11 exert their effects by
separate mechanisms suggest that there is a reason for duplication of tasks in this
organism which may be explained by differential sensitivity of different hosts to
HCMV infection.
The process by which the newly synthesized class I heavy chains are
escorted by the viral gene products US2 or US11 into the cytosol through the
Sec61p complex is extremely rapid and therefore most of the polypeptides
undergoing this fate may yet have to be inserted into the lipid environment of
the ER membrane. However, US2 and US11 are also capable of causing the
destruction of properly folded class I molecules (Wiertz et al., 1996b). Since these
class I molecules have already left the translocation machinery and are likely to
have entered the membrane of the ER, it must also be possible for US2 and US11
to drag these molecules back into the Sec61 pore for reverse translocation (figure
4.9B). This process may be accomplished either directly or indirectly through
other chaperone proteins.
The process of reverse translocation of an ER-resident protein into the
cytosol for destruction by the proteasome is not likely to be unique for HCMV
mediated destruction of class I heavy chains. There is mounting evidence that
the process of retrograde transport from the ER into the cytosol is a general
phenomenon used by normal cells to purge the ER of misfolded and abnormal
proteins to be destroyed (figure 3.9C). In cells lacking the MHC class I light
chain 52M (known as Daudi cells), class I molecules are unable to assemble and
must be destroyed. This destruction is sensitive to inhibitors of the proteasome,
and a de-glycosylated form of the heavy chain can be detected (Hughes et al.,
1997). Likewise, when the T-cell receptor a. chain is expressed alone in TCR-
cells, the monomeric subunit is rapidly degraded. This breakdown process is
similar to the process described here, including the presence of a cytosolic de-
glycosylated intermediate which can be observed only in the presence of
proteasome inhibitors (Huppa and Ploegh, 1997). Interestingly, a similar
breakdown process is observed when the T-cell receptor 8 chain is expressed in
the absence of other TCR subunits, however, no cytosolic intermediate is
observed even thought the degradation can be inhibited by compounds such as
lactacystin (A. M. Weissman communicated at the Cold Spring Harbor
Symposium on the Biology of Proteolysis, 23-27 April, 1997). These findings
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suggest that the process by which a protein is translocated from the Sec61
complex may be directly and physically coupled to the proteasome. Finally,
there have been reports of integral membrane proteins which become
ubiquitinated and degraded by the proteasome (Jensen et al., 1995). Although
the process of reverse translocation is likely to be utilized in normal protein
turnover, there is evidence to suggest at least some ER resident proteins are
degraded within the ER in a proteasome-independent fashion (Mullins et al.,
1995; Brodsky and McCracken, 1997).
The steps by which US2 and US11 are able to accomplish the controlled
destruction of class I heavy chains were uncovered largely due to the ability to
modulate the activity of the proteasome using pharmacological agents in living
cells. The initial discovery that the commercially available compound, LLnL,
resulted in the presence of an intermediate in the breakdown process of class I
heavy chains was the first indication that the proteasome might be involved.
Further studies using more specific inhibitors such as lactacystin and the peptide
vinyl sulfone Z-L3-VS, as well as ability to detect the deglycosylated class I
heavy chain in a direct complex with the proteasome, proved that d. gradation
was in fact being performed by the proteasome. Although proteasome int ibitors
served to answer several important questions about the mode of action of hese
viral proteins, US2 and US11 transfectants may now also be uszd to answer
fundamental questions about the reactivity and potency of different cl :sses of
proteasome inhibitors in living cells. Tne appearance of the ,_' -Da
deglycosylated polypeptide from class I heavy chain immunoprecipltations can
be used as an indirect indication of proteasome inhibition. This system is likely
to be extremely useful for assessing the activity of pharmacological agents
against the proteasome, using a physiologically relevant target as a readout (see
Chapter 2)
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V. A NEW PROTEOLYTIC SYSTEM IN MAMMALIAN CELLS
THAT CAN COMPENSATE FOR THE LOSS OF
PROTEASOME FUNCTION
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A. Introduction
Cytosolic proteolysis is controlled predominantly by the proteasome. This
large, multi-catalytic protease complex is responsible for degradation of a wide
range substrates required for cell survival (Coux et al., 1996). Not surprisingly,
inhibition of proteasomes, either by genetic deletion or by inactivation by
pharmacological agents results in death of the organism (Drexler, 1997; Gordon
et al., 1993; Ghislain et al., 1993). We have found that prolonged exposure of cells
to the peptide vinyl sulfone inhibitors leads to the outgrowth of distinct
populations of cells whose survival is refractory to the action of these
compounds. These cells, termed adapted, provide information about additional
proteolytic systems that, in normal cells, may serve a complementary function
to the proteasome.
The proteasome has been implicated in the proteolytic destruction of a
large number of metabolically important proteins. The highly regulated timing
of progression of cell division is controlled at several stages by proteasomal
degradation of various cyclins and cyclin dependent kinase inhibitors (Glotzer et
al., 1991; King et al., 1994). These proteins are first tagged with a poly-ubiquitin
chain, known to be a signal for degradation by the 26S proteasome (Hershko and
Ciechanover, 1992). Selective inhibitors have been used to confirm the
proteasome's role in this degradation process. In addition, application of
compounds such as peptide aldehydes and lactacystin results in a G2 arrest in
the cell cycle (Drexler et al., 1997).
Proteasome subunit deletion mutants in yeast have shown the
indispensability of the proteasome for cell survival. Deletion of a single
catalytically active 5-subunit results in a lethal phenotype (Hilt et al., 1993;
Heinemeier et al., 1994; Hilt and Wolf, 1995; Orlowski, 1990). The lethality is
presumably due to the inability of proteasomes to form viable complexes with
the proper 7-fold symmetry, rather than elimination of proteolysis. However,
replacement of a wild type P-subunit gene with a catalytically inactive mutant f-
subunit results in viable yeast with impaired growth (Heinemeyer et al., 1993;
Heinemeyer et al., 1991; Hilt et al., 1993; Enenkel et al., 1994). These mutants
allow for the assembly of proteasome complexes which have impaired
proteolysis but nonetheless retain enough activity to allow the organism to
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survive. The extent to which proteasome mutants affect yeast cell growth
depends on the number and types of subunits inactivated by mutation (Hilt et
al., 1993; Hilt and Wolf, 1995). Mutations of this type have also helped to
establish the role of individual subunits in the generation of specific proteolytic
activities of the proteasome complex (Heinemeyer et al., 1993; Hilt et al., 1993;
Heinemeyer et al., 1991; Enenkel et al., 1994).
Inhibition of the proteasome by compounds such as the tri-peptide vinyl
sulfone, NIP-L3VS (NLVS), which are able to modify all catalytically active -
subunits (see chapter 2), results in cell death. This toxicity correlates with the
ability of a compound to inhibit the proteasome's multiple active sites and
therefore is likely to be the result of loss of proteasome function. We describe
here that when cells are maintained in the continuous presence of NLVS at the
lewest concentration that results in toxicity, a small population of cells (adapted
cells) are able to survive. These cells are not the result of a genetic mutation nor
are they caused by a multi-drug resistance mechanism which might have
prevented the inhibitor from reaching its target. Purification of proteasomes
from these adapted cells indicated that their ability to hydrolyze fluorogenic
substrates is greatly impaired. Likewise, proteasomes from adapted cells treated
with the radiolabeled form of NIP-L3VS fail to label, indicating that the active
sites have in fact been covalently inactivated.
The finding that adapted cells, unlike normal cells treated with proteasome
inhibitors, appeared to have normal levels of ubiquitin conjugated proteins and
are able to generate peptides for binding to MHC class I molecules prompted us
to look for other proteolytic systems which could compensate for the absence of
the active proteasome. Analysis of non-proteasomal proteolysis using the
fluorogenic substrate AAF-MCA, indicates that cleavage of this substrate is
enhanced in adapted cells. This AAF hydrolyzing activity was found to be a high
molecular weight protein complex which is distinct from the proteasome and
which behaves in gel filtration as a complex with an apparent molecular weight >
1,000 kDa. Blocking of this activity using a the tri-peptide chloromethyl ketone,
AAF-cmk results in a block of cell growth of adapted but not normal cells. Thus,
it appears that inhibition of proteasomal proteolysis results in activation of
additional proteases which promote survival by performing crucial functions
normally carried out by the proteasome.
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B. Materials and Methods
1. Cells and Cell Culture
The mouse lyphobiastoma cell line EL-4 was used for all experiments
reported in this chapter. Cells were maintained in Dulbecco's Modified Eagle's
medium supplemented with 10 % (v/v) fetal calf serum. Adapted EL-4 cells
were maintained in the presence of 50 gM of 5-iodo-4-hydroxy-nitrophenyl
acetyl-leucyl-leucyl-leucine vinyl sulfone (NLVS; see chapter 2 and 3). NLVS
was diluted from DMSO stocks such that the final concentration DMSO was less
than or equal to 1%.
2. Inhibitors
12 5I-NIP-L 3-VS, NIP-L 3-VS (NLVS), NP-AAF-VS, and NP-LLG-tVS were
synthesized as described in chapters 2 and 3. All inhibitors were added to lysates
and to cells by dilution of a DMSO stock solution such that the final
concentration of DMSO was 1% or less. The chloromethyl ketone AAF-cmk was
added to tissue culture media by dilution of a 5 mM water stock to a final
concentration of 5 gM. The synthesis of the tri-peptide chloromethyl ketone
AAF-cmk is shown below.
3. Synthesis of alanine-alanine-phenylalanine chloromethyl ketone (AAF-
cmk)
a. Synthesis of Boc-Ala-Phe-OMe
Boc-Alanine (1.3 g, 7.0 mmol), HOBt (1.1, 8.3 mmol) and
dicyclohexylcarbodiimide (DCC; 1.7 g, 8.3 mmol) were dissolved in 10 mls of
DMF. the reaction was stirred at room temperature for 30 min. Phenylalanine-
methyl ester hydrochloride salt (1.0 g, 4.6 mmol) was then added to the flask
followed immediately by diisopropylethyl amine (0.88 ml, 5.1 mmol) and the
reaction was stirred overnight at room temperature. The resulting reaction mix
was filtered to remove the dicyclohexylurea by-product and the DMF was
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removed by rotary evaporation. The crude oil was then diluted into 50 mls of
ethyl acetate and washed 3 times with equal volumes of 0.1 N HCi and 3X with
equal volumes of saturated sodium bicarbonate. The remaining organic phase
was dried over magnesium sulfate and dried to a solid. The product was re-
crystallized from ethyl acetate/hexane. Yield (1.25 g, 3.6 mmol, 77%).
Boc-ala-Phe-OMe- H NMR (500 MHz, CDC13): 6 7.10-7.35 (4H, m), 6.79 (1H, d),
5.10 (1H, t), 4.80 (1H, d), 4.20 (1H, q), 3.75 ,3H, s), 3.05-3.25 (2H, dd), 1.40 (9H,
m), 1.20 (3H, m).
b. Synthesis of Boc-Ala-Phe-OH
Boc-Ala-Phe-OMe (2.9 mmol, 1.0 g) was dissolved in 10 ml methanol.
Potassium carbonate (10 mls of a 20% solution) was added to the flask and the
reaction was stirred overnight. A white precipitate formed upon addition of the
aqueous carbonate solution but disappears overnight. The methanol was then
removed by rotary evaporation and the remaining water solution was diluted
wit 50 ml of citrate buffer pH 4.0 and acidified to pH 4 by addition of 3N HCI.
Upon neutralization the product precipitates as a white solid and is extracted
with 3 volumes of ethyl acetate. The organic phase is then dried over
magnesium sulfate and evaporated to dryness by rotary evaporation resulting in
pure Boc-Ala-Phe-OH (0.96 g, 2.87 mmol, 99%).
Boc-Ala-Phe-OH 1H-NMR (500 MHz, CDC13): same as for Boc-Ala-Phe-OMe
except loss of methyl ester signal at 6 3.75.
c. Synthesis of Boc-Ala-Phe-diazomethyl ketone (Boc-AF-CHN2)
Boc-Ala-Phe-OH ( 0.5g, 1.5 mmol) was converted to the mixed anhydride
by reaction with isobutyl-chloroformate (IBCF; 200 gl, 1.5 mmol) and N-methyl-
morpholine urea (NMM; 182 gL, 1.65 mmol) at -15°C (NaCl/ ice bath). The
activated Boc-Ala-Phe-OH was then added to etherial diazomethane freshly
distilled from diazald (3.55 g, 16.3 mmol) and potassium hydroxide (3.55 g, 61.4
mmol) as described by the manufacturer (Aldrich Chem. Co., Milwaukee, WI).
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The reaction is stirred for 30 min at O0C and then overnight at room temperature.
The reaction was quenched by the addition of water until the formation of N2 gas
ceased. The resulting solution was then diluted with ether and washed with
three volumes of water and three volumes of saturated sodium bicarbonate. The
organic phase was then dried over magnesium sulfate and concentrated to an oil
by rotary evaporation. The crude Boc-Ala-Phe-CHN2 was purified by flash
chromatography using a 1:1 ethyl acetate:hexane (v:v) as the mobile phase. Rf
(1:1 EtOAc:Hex): 0.35. Yield (285 mg, 0.8 mmol, 53%).
Boc-Ala-Phe-CHN2 1H-NMR (300 MHz, CDC13): 7.10-7.35 (4H, m), 6.62 (1H,
d), 4.8-535 (1H, d), 4.65 (1H, t), 4.10 (H, q), 3.05 (2H, d), 1.40 (9H, d), 1.25
(3H, d).
d. Synthesis of Ala-Phe-Chioromethyl Ketone (AF-cmk)
Boc-Ala-Phe-CHN2 (250 mg, 0.69 mmol) was dissolved in 1 ml of methanol.
HCI (1M solution in ether; 3.45 ml, 3.45 mmol) was then added dropwise. The
reaction was stirred until the formation of N2 gas ceased (20 min). The reaction
solution was then evaporated to dryness and the product was obtained in pure
form by trituration from ether. Yield (146 mg, 0.48 mmol, 69%).
Ala-Phe-cmk 1 H-NMR (300 MHz, CD 3OD): 7.21-7.38 (4H, m), 5.95 (1H, t),
4.22-4.50 (2H, dd), 3.90 (1H, q), 2.95-3.29 (2H, ddd), 1.48 (3H, d).
FAB Mass Spectrum: [M+H]Calculated for C13Hl7N202CI: 269.5 Found: 269.2
e. Synthesis of Boc-Ala-Ala-Phe-Chloromethyl Ketone (Boc-AAF-cmk)
Ala-Phe-cmk (50 mg, 0.16 mmol), Boc-alanine (34 mg, 0.18 mmol), and
PyBOP (99mg, 0.18 mmol) were dissolved in 1 ml of methylene
chloride/dimethyl formamide (1:1; v/v). Triethylamine (50 gl, 0.34 mmol) was
then added to the reaction mix. After 1 hour the reaction was quenched by
removal of solvent followed by addition of 5 volumes of ethyl acetate. The
resulting organic phase was washed three times with water then dried over
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magnesium sulfate. The crude solid was purified by flash chromatography using
1:1 ethyl acetate:hexane (v:v) as the mobile phase. Rf (1:1 EtOAc:Hex); 0.2. Yield
(26.2 mg, 0.06 mmol, 36%).
f. Synthesis of Ala-Ala-Phe-Chloromethyl Ketone (AAF-cmk)
The Boc group was removed from Boc-Ala-Ala-Phe-cmk (26.2 mg, 0.06
mmol) in ml of ethanol by the addition of 2 ml of a 1M solution of HC1 in ether.
The reaction was stirred for 2 hours at which time no starting Boc peptide could
be seen by TLC. The reaction mix was then evaporated to dryness and the pure
product was obtained by trituration from ether. Yield (22.2 mg, 0.059 mmol,
99%).
Ala-Ala-Phe-cmk H-NMR (300 MHz, CD3 0D): 6 7.21-7.30 (4H, m), 4.60 (1H,
dd), 4.25 (1H, q), 4.22-4.40 (2H, dd), 2.95-3.19 (2H, ddd), 1.45 (3H, d), 1.25
(3H, d).
Mass Spectrum: [M+H] Calculated for C16H22N30 3CI: 340.8 found: 340.1
4. Antibodies
The following antibodies were used: anti-C9 (kind gift of Dr. John Monaco,
University of Cincinnati) a polyclonal antiserum reactive against the C9 a-
subunit of the proteasome; Y3 a mono-clonal antibody which recognizes the
al/a2 domain of properly folded mouse class I heavy chains (Hammerling et al.,
1982). P8 a mono-clonal antibody which recognizes an epitope in the
cytoplasmic tail of H-2 Kb mouse MHC class I heavy chains (prepared in our
laboratory as described; (Smith et al., 1986)); and anti-ubiquitin (Kind gift from
Dr. Arthur L. Haas, Medical College of Wisconsin) a ployclonal antiserum
reactive with ubiquitin.
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5. Cell Growth Analysis
Cells (100,000 in 1 ml of media) were gro wn in the presence of inhibitor or
DMSO (1%) as a control in 24 well plates as described in the cell and cell culture
section above. Daily, the cells were re-suspended, 20 pil aliquots were removed
and mixed with trypan blue dye (0.1 %). Cells which did not take up the dye
were considered to be alive and counted. Growth curves were generated by
plotting number cells against time in days.
6. Limiting Dilution to Determine Frequency of Adaptation
EL-4 cells were plated in 96 well plates at increasing dilutions from 10,000
cells per well down to 39 cells per well by serial dilution by a factor of 4. Growth
was monitored for 1 month. Positive wells were scored by visual inspection.
The frequency of adaptation was determined by plotting the log of number of
negative wells versus the number of cells per well seeded. The number of cells
per well was extrapolated at which point 37 % of the wells were negative for cell
growth. Based on the Poisson Distribution (Taswell, 1981), this is the frequency
at which the number of adapted cells per well may be assumed to be 1.
7. Assembly of Proteasomes
Assembly of proteasome subunits was monitored by pulse-chase analysis
using a polyclonal antiserum against the C9 ao-subunit. This antiserum
precipitates both immature (i.e. complexes which still contain unprocessed D-
subunits) and mature 20S proteasome complexes. Cells (5 X 106) were treated
with 50 pM NLVS or DMSO (1% as a control) for 1 hour and then labeled with
[3-S5-methionine for 1 hour and chased with non-radioactive methionine for 24
hours. The same protocol was applied to adapted cells growing in the presence
of 50 pM NLVS. Cells were then lysed with NP-40 lysis mix and
immunoprecipitations were performed using the anti-C9 antiserum.
Precipitations were analyzed by two-dimensional non-equilibrium isoelectric
focusing SDS-PAGE, followed by fluorography as described in chapter 2.
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8. Affinity Labeling of Intact Cells with 125I-NIP-L3-VS
Cells (1.5 x 106) or lysates (50 lrg protein unless otherwise indicated) were
labeled with 125I-NIP-L 3-VS, diluted to a final concentration of 1.8 x 104 Bq/ml in
tissue culture media (cells) or reaction buffer (lysates; 50 mM Tris pH 7.4, 2 mM
DT, 5 mM MgCl2, 2 mM ATP). Samples were incubated at 37C for 2 hours
followed by addition of 1X (cells) or 4X (lysates) SDS sample buffer. Proteins
were separated by SDS-PAGE as described.
9. Preparation of Lysates from Control EL-4, NLVS Treated or Adapted Cells
Cells were lysed using a bead smashing technique. Briefly, cells were
washed 3X with cold PBS and then pelleted. A volume of glass beads (<106
microns, acid washed; Sigma Chem. Co., St. Louis, MO) equivalent to the
volume of the pellet were added followed by a similar volume of
homogenization buffer (50 mM Tris pH 7.4, 1 mM DTT, 5 mM MgC12, 2 mM
ATP, 250 mM sucrose). Cells were vortexed at high speed for 1 min. The beads
and broken cell debris was then removed by centrifugation at 10,000 g for 5 min.
The resultant homogenate was then centrifuged at 10,000 g for 20 min to remove
unbroken cells and nuclei. Protein concentration was determined using the BCA
protocol described by the manufacturer (Pierce Chem. Co., Rockford, IL).
10. Fluorogenic Peptide Substrate Assay
Proteolytic activity was measured using fluorescently tagged peptide
substrates. The substrates used were: Suc-LLVY-MCA and Z-LLG-MCA for
analysis of the chymotrypsin-like activity of the proteasome; Boc-LRR-MCA for
analysis of the trypsin-like activity of the proteasome; Z-LLE-INA for analysis of
the PGPH activity of the proteasome; and AAF-MCA for analysis of non-
proteasomal proteolysis. In a typical assay, partially purified proteasomes from
5h pellets (described above; 5 ug total protein), or total lysates (10 gg) were
diluted to a final volume of 100 jl in reaction buffer (50 mM Tris pH 7.4, 5 mM
MgCI2, 1 mM DTT). Inhibitors were added to samples as a DMSO stock as
described above. Fluorogenic substrates were added by dilution of a 5 mM
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DMSO stock to a final concentration of 100 itM. Samples were incubated at 37C
for 45 min. and the reaction quenched by addition of Iml of 1% SDS.
Fluorescence was then measured for each sample as described in chapter 3.
11. FACS Analysis of Cell Cycle
Cells (1 x106) were permeablized by treatment with ethanol (70%)
overnight at 4'C then treated with RNAse A (100 units/ml) and the DNA stained
with propidlum iodide (50 jig/ml) for 1 hour at room temperature. Cells were
then washed once in PBS and re-suspended in lml of PBS. Samples were
analyzed using a fluorocytometer (Becton-Dickenson, FACScan).
12. Class I Assembly
To monitor class I assembly, a pulse chase experiment was performed on
EL-4 cells, EL-4 cells treated with 50 gM NLVS, and EL-4 adapted cells. NLVS
treated cells were pretreated with 50 gM NLVS for 16 hours prior to performing
the pulse-chase. Cells were pulse labeled with [35S]-methionine for 10 min and
then chased for 0, 30 and 90 minutes by addition of media containing non-labeled
methionine as described in chapters 2 and 4. Cells from each chase point were
placed on ice and split into three equal portions. Each portion of cells was lysed
by the addition of I ml of ice-cold lysis buffer (50 mM Tris pH 7.4, 0.5 % NP-40,
5 mM MgC12). The class I binding peptide Ova8 (SIINFEKL) was added to one
portion of lysate from each chase point to a final concentration of 10 RM.
Samples with and without peptide added were incubated at 37 'C for 20 min and
returned to ice. One portion of lysate from each chase point was never exposed
to peptide and remained on ice for the duration of the experiment. Class I
molecules were isolated using the Y3 monoclonal antibody as described in
chapters 2 and 4. Proteins were separated on a 12.5 % SDS-PAGE gel and a
analyzed by fluorography as described above.
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13. Gel Filtration of Sh Pellets
Lysates vwere prepared from control EL-4 and EL-4 adapted cells (1 X 108
cells) and fractionated by differential centrifugation as described above. The 5
hour 100,000 g pellets wrere re-suspended in 0.5 ml of homogenization buffer (50
mhM tris pH 7.0, 20 % glycerol) and injected onto a superose 6 column (1.5 cm x
30 cm) at room temperature. The sample was eluted with a flow rate of 0.2 ml
per min. Fractions of 0.5 ml were collected and placed immediately on ice.
Aliquots of each fraction (20 gl) were used to measure hydrolysis of the Suc-
LLVY-MCA and AAF-MCA using the protocol outlined above and as described
in chapter 3. Mean fluorescence was plotted against fraction number.
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C. Results
1. EL-4 cells can adapt to prolonged exposure of NLVS
The mouse T-lymphoblastoid ckIi line, EL-4 was treated with 0, 1, 10 and
50 gM NLVS. Control cells (no addition) and cells grown in the presence of 1 gM
NLVS showed normal growth curves (figure 5.1A). However, growth of EL-4
cells was impaired upon addition of 10 or 50 gtM of the proteasome inhibitor, and
the majority of cells died within 3 days. Cells maintained at 10M NLVS began
to grow at a slow rate after nearly two weeks, while cells maintained in 50gM
failed to overcome the inhibitor's toxicity. When the population of cells that
survived in 10 gM NLVS were washed and re-exposed to increasing
concentrations of NLVS ranging from 0-50 gM, growth proceeded normally, even
in the presence of 50 gM NLVS (figure 5.1B). These cells will be referred to
throughout this chapter as adapted and are continuously maintained in the
presence of 50 gM of NLVS.
2. Adaptation is not the result of mutation
The frequency with which EL-4 cells became adapted to NLVS treatment
was examined to determine if this phenomenon was the result of a mutation
resulting in proteasomes that are refractory to inhibition by NLVS. Limiting
dilution experiments indicated that 1 in approximately 1000 EL-4 cells was able
to adapt and grow in the presence of NLVS (data not shown). This frequency of
adaptation effectively rules out the possibility of a genetic mutation whose
frequency is likely to be in the range of 1 in 1,000,000. In addition, when NLVS
is washed away from adapted cells, over time, they regain sensitivity to
inhibition by NLVS, again inconsistent with a permanent genetic mutation (see
figure 5.7).
3. The proteasome is synthesized and assembled normally in adapted cells
A pulse chase experiment was performed on normal, NLVS treated, and
adapted cells to monitor the synthesis and assembly of proteasome complexes.
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Figure 5.1. EL-4 cells adapt and grow in the presence of otherwise toxic levels of
NLVS.
(A) EL-4 cells (1 x 105) were maintained in the presence of 0, 1, 5, 10 and 50 pM
NLVS for three weeks. Cells were sampled daily and number of live cells, as
judged by trypan blue exclusion, were counted. Cell number is plotted against
time. Populations of adapted cells are indicted with a box.
(B) The adapted cells from A (box) were washed and re-plated in fresh medium
containing 0, 1, 5, 10 and 50 gM NLVS.
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Cells were pulsed for 1 hour followed by a chase of 24 hours and precipitation
with antiserum that recognizes the C9 a subunit and can immunoprecipitate the
entire proteasome complex via this interaction. Samples were analyzed by two-
dimensional NEPHGE/SDS-PAGE to resolve the multiple proteasomal subunits
in the 20-30 kDa size range (figure 5.2). The relative amount of proteasome
subunits were comparable in normal, NLVS treated, and adapted cells. The
only notable difference was the absence of the LMP-7 subunit in
immunoprecipitates from adapted cells. This loss of LMP-7 is not likely to
substantially affect proteasomal proteolysis, due to the fact that it normally
replaces the pre-existing X subunit upon IFN-y treatment and cells deficient in
LMP-7 and LMP-2 grow normally (Arnold et al., 1992; Driscoll et al., 1993
Gaczynska et al., 1993).
4. Toxicity of NLVS correlates with modification of proteasomal P-subunits
We examined whether the toxic effects observed from treatment of cells
with NLVS was the result of proteasomal inhibition using several related
analogs. The tri-peptide vinyl sulfones NP-LLG-VS (cis and trans) and NP-AAF-
VS are described in chapter 3 and are structurally similar to NLVS. These
compounds are less potent, however, and show reduced reactivity with some
of the 5-subunits modified by NLVS (see chapter 3). To examine the ability of
these tri-peptide vinyl sulfones to modify mouse proteasomes cells were pre-
treated for 16 hours with 50 gM of each of the four inhibitors, lysed and the
lysates labeled with 12I-NIP-L3-VS (chapter 2) (figure 5.3A). The characteristic
band at 23 kDa representing the LMP-2, LMP-7 and X proteasome subunits was
visible for untreated control cells and for cells treated with NP-LLG-VS or NP-
AAF-VS, but not for cells pre-treated with NVS. The inability of the LLG and
AAF vinyl sulfones to block labeling by 125I-NIP-L3-VS indicated that there are
subunits which are modified by NLVS but not by the related AAF and LLG
derivatives under the conditions used.
We next examined whether competition for NLVS labeling correlated with
toxicity of the LLG and AAF vinyl sulfones. Figure 5.3B shows the growth
curves for EL-4 cells treated with 0, 10, arid 50 gM of NLVS (NIP-LLL-VS), NP-
LLG-VS, and NP-AAF-VS. As expected, NLVS was toxic to growth at 10 and
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Figure 5.2. Synthesis and assembly of proteasome subunits is normal in adapted
cells.
Adapted and control EL4 cells were pulse labeled for 1 hour, chased for 24
hours and proteasomes immunoprecipitated using an anti-C9 polyclonal
antiserum as described in the materials and methods section. Samples were
separated by two-dimensional NEPHGE and subunits visualized by
fluorography. Note that the relative intensities of spots is the same for control
and adapted cells except for LMP-7 (indicated with a circle). The anode (-) and
cathode (+) are indicated.
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Figure 5.3. Acute toxicity of the peptide vinyl sulfones is sequence-specific.
(A) EL-4 cells (1 x106 ) were treated for 16 hours with DMSO (-), NLVS (LLL),
NP-LLG-tVS (Trans LLG), NP-LLG-cVS (Cis LLG), or NP-AAF-VS (AAF) and
then labeled with 125I -NIP-L3-VS for 2 hours at 37°C. Proteasome subunits were
then resolved using a 12.5 % SDS-PAGE gel and visualized by autoradiography.
Note the loss of labeling of proteasome subunits only when cells were treated
with NLVS.
(B) EL-4 cells (1 x 105) were maintained in the presence of 0, 10 and 50 M of
NLVS, NP-LLG-tVS, or NP-AAF-VS as indicated. The number of live cells (as
judged by trypan blue exclusion) were counted and plotted against time in
culture. Note that only NLVS treatment results in acute toxicity.
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50 pM. Neither of the related AAF or LLG derivatives were toxic to growth at
either concentration. This direct correlation between toxicity and proteasome
modification suggests that the toxicity observed for NLVS is due to its ability to
block the active sites of the proteasome. Thus, compounds that fail to bind
strongly to all the active f-subunits may leave some of the activity of the
proteasome intact, allowing the cells to survive.
5. Labeling of proteasomal 5-subunits by 12SI-NIP-L3-VS is blocked in adapted
cells
We next examined whether the -subunits of the proteasome were
modified and thus inhibited in adapted cells. Figure 5.4 shows labeling of mouse
liver proteasomes, normal EL-4 and EL-4 adapted cells with 125I-NIP-L 3-VS.
Labeling of 1, 10, 100, and 500 gg of mouse liver protein resulted in the
characteristic 23 kDa band (composed of LMP-2, LMP-7, and X) as well as the 29
and 30 kDa bands (MECL-1 and Z). At lower concentrations of protein, only the
single major 23 kDa band was observed. The same 23 kDa band was observed in
the labeling of normal EL-4 cells but was completely absent from labeling of
adapted cells. To rule out the possibility of a change in permeability of adapted
cells which could prevent the inhibitor from entering the cytosol and modifying
the proteasome, lysates obtained from normal and adapted cells were labeled
with 125I-NIP-L3-VS. Again we observed labeling of proteasomal P-subunits in
normal but not in adapted cells, nor in cells treated with 50 gM NLVS, indicating
that the active sites of the proteasome are modified in adapted cells (Figure 5.5).
6. Proteasomal hydrolysis of fluorogenic substrates is impaired in adapted
cells
The ability of proteasomes to hydrolyze a short fluorogenic peptide
substrate is often used as a way to assess their proteolytic activity. The
substrates, Suc-LLVY-MCA and Z-GGL-MCA are used to monitor the
chymotrypsin-like activity; Cbz-LLE-ONA is used to monitor the post-glutamyl
peptidase activity (PGPH activity); and Boc-LRR-MCA is used to monitor the
trypsin-like activity (see chapter 2). The hydrolysis of each of these substrates
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Figure 5.4. Labeling of proteasomal 5-subunits is blocked in adapted cells.
Control (EL-4) and adapted EL-4 (EL-4ad) cells were incubated with 125I-NIP-L3-
VS for 2 hours at 37C. Cells were then lysed in SDS-containing buffer and
proteins separated by SDS-PAGE on a 12.5 % gel. Labeled polypeptides were
visualized by autoradiography. Increasing amounts of protein from mouse liver
tissue lysates (tg protein) were also labeled as described above and were
included to show the labeling pattern of proteasomal -subunits at different loads
of protein.
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Figure 5.5. Labeling of proteasomal 3-subunits is blocked in adapted cell lysates.
Control EL-4 cells, EL-4 cells treated with 50 pM NLVS for 2 hours, and adapted
EL-4 cells were lysed. The resulting lysates were labeled with 125I-NIP-L3 -VS and
the labeled proteasomal B-subunits visualized by SDS-PAGE followed by
autoradiography (12.5% gel). Note the loss of labeling of both NLVS treated and
adapted cell lysates.
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was measured for lysates from normal EL4 cells, for EL-4 cells treated with
50pM NLVS and for adapted cells. As expected, the amount of hydrolysis of all
three substrates was substantially reduced upon treatment of cells with NLVS.
Adapted cell lysates showed a similar reduction in hydrolysis of all three
substrates. In both NLVS treated and adapted cells, the chymotrypsin-like
activity was diminished most strongly, followed by the PGPH and the trypsin-
like activity (figure 5.6).
We next examined whether the decrease in hydrolysis of fluorogenic
substrates correlated with active site modification by the vinyl sulfone moiety.
Normal EL-4 cells were treated for increasing times with 50gM NLVS. Cells
were lysed and hydrolysis of the chymotrypsin-like substrates Z-GGL-MCA and
Suc-LLVY-MCA were measured. The same lysates were subjected to labeling
with 125I-NIP-L3-VS to determine the extent of active site modification. The
same experiment was performed on adapted cells growing in the presence of 50
gM NLVS, except that the samples were taken at different times after removal of
the inhibitor (figure 5.7). These results indicate that loss of labeling with 12I-
NIP-L3-VS, as the result of prior active site modification, directly correlates with
loss of hydrolytic activity as measured using fluorogenic substrates.
To rule out the possibility that a adapted cells were up-regulating a
cytosolic factor which could inactivate NLVS before it had the opportunity to
inhibit the proteasome, we assayed the hydrolytic activity of proteasomes
isolated by a differential centrifugation protocol (see Materials and Methods).
Centrifugation of lysates from adapted cells for 5 hours at 100,000 g results in a
protein pellet which is highly enriched for the 20S and 26S proteasome.
Hydrolysis of the LLVY and GGL proteasome substrates was inhibited to a
similar extent in the cytosolic extracts, 5 hour spin supernatant, and 5 hour pellet
from adapted cells (figure 5.8). Again, the labeling of these fractions correlated
with hydrolysis data, with a near complete loss of labeling of proteasome in all
samples generated from fractionation of adapted cells. Thus, the proteolytic
activity of proteasomes isolated from adapted cells is greatly impaired.
The high speed spin pellet described above was fractionated by gel
filtration on a superose 6 column to further resolve proteins by size. When the 5
hour pellet obtained from normal EL-4 cells was fractionated, hydrolysis of the
Suc-LLVY-MCA substrate revealed the presence of two predominant peak
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Figure 5.6. Hydrolysis of fluorogenic substrates is reduced in cells treated with
proteasomal inhibitors as well as in adapted cells.
Lysates were prepared from control EL-4 cells (EL-4), from EL-4 cells treated for
16 hours with 50 lM NLVS (EL-4 + 50 pM NLVS), and from adapted cells (EL-4
Ad) as described in the materials and methods section. Hydrolysis of the
fluorogenic substrates; Suc-LLVY, Z-GGL-MCA, Boc-LRR-MCA, and Z-LLE-
PNA was then measured for each lysate. The fluorescence values obtained for
the control EL-4 cells were set at 100%. All other values are expressed as a
percentage of control hydrolysis.
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Figure 5.7. Proteasomal activity is rapidly restored upon removal of NLVS from
adapted cells.
EL-4 cells were treated with 50 M NLVS for 0-3 hours as indicated. Lysates
were prepared and hydrolysis of the fluorogenic substrates Suc-LLVY (LLVY-
MCA) and Z-GGL-MCA (GGL-MCA) was measured (top panel). The same
lysates were labeled with 125I-NIP-L3-VS, separated by SDS-PAGE and
visualized by auto-radiography (bottom panel ). EL-4 adapted cells grown in the
continuous presence of 50 gM NLVS were washed to remove NLVS and grown
in the absence of NLVS for 3 weeks. Samples were taken at various times after
washing and the same procedure was performed as described above . Note the
correlation between labeling and hydrolysis of fluorogenic substrates.
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Figure 5.8. Labeling of proteasomal -subunits with 125I-NIP-L3-VS in adapted
cells is blocked in cytosol fractions as well as in pellet fractions highly enriched
for the proteasome.
Control and adapted EL-4 cells were fractionated by differential centrifugation
and labeled with 12 5I-NIP-L3-VS. Hydrolysis of Suc-LLVY-MCA and Z-GGL-
MCA were measured as described in the materials and methods section. The
cytosol fraction represents the lysate after removal of nuclei and microsomes and
prior to the 5 hour 100,000 g centrifugation. Increasing amounts of protein were
labeled as indicated (total protein).
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activities, representing the 20S and the 26S proteasomes. When the same
experiment was performed using the 5 hour pellet from adapted cells, 20S and
26S proteasome peaks were almost completely absent, again indicating that
proteasomal activity in adapted cells is greatly diminished (figure 5.9).
7. Adapted cells are able to generate peptides for binding to MHC class I
molecules
The proteasome has been shown to play an integral role in the generation
of peptides for binding to MHC class I molecules and display to cytotoxic T-cells
(see chapter I). Inhibition of proteasome function results in a loss of class I
binding peptides (Harding et al., 1995; Rock et al., 1994). These peptides are
required for class I molecules to fold properly and exit the ER en route to the cell
surface. Thus, the ability of a MHC class I molecules to fold can be used as a
method for examining a cell's ability to generate peptides and can also be used as
an indirect measure of proteasome function. Class I maturation and assembly
can be monitored using an antibody (P8) which recognizes an epitope of the
cytoplasmic tail of the class I heavy chain. The light chain, 2m, is recovered
by this antibody only if it is associated with the heavy chain.
Normal EL-4 cells, EL-4 cells treated with 50gM NLVS, and adapted cells
were pulsed labeled and chased for 0, 30, and 90 minutes. The lysates obtained
for each of the chase points were then incubates at 4°C to stabilize empty class I
molecules or exposed to 370C in the presence and absence of a class I binding
peptide. Any class I-t2m complex which does not contain peptide dissociates at
370C. In normal cells, class I molecules were found associated with 02m and
were processed by addition of the single N-linked glycan. This processing is
seen as a shift in the apparent molecular weight of the heavy chain and is
complete within 90 min. of chase (figure 5.10). As expected, treatment of cells
with 50gM NLVS for 16 hours resulted in class I heavy chains which showed a
greatly reduced amount of associated P2m. Further, the small amount of heavy
chain-12m complexes obtained were completely lost upon incubation at 37°C in
the absence of peptide. However, the amount of heavy chain-32m complexes
recovered could be restored to the level of untreated cells by the addition of
peptide to the lysate. Thus, the reason for loss of stable assembly of these
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Figure 5.9. Partially purified proteasomes isolated from adapted cells have
severely diminished proteolytic activity.
Lysates obtained from control and adapted EL-4 cells were fractionated by
differential centrifugation as described. Pellets from the 100,000 g centrifugation
were passed over a Superose 6 column and Suc-LLVY-MCA hydrolysis was
measured for each fraction. Note the presence of a peak of activity for the 26S
and 20S proteasomes in control cells which is substantially reduced for adapted
cells.
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Figure 5.10. Assembly of MHC class I molecules is impaired in cells treated with
NLVS but not in adapted cells.
Control, NLVS treated (50 pM for 16 hours), and adapted EL-4 cells were pulse
labeled for 10 min. and chased for 0, 30, and 90 min. Properly conformed class I
molecules were immunoprecipitated using the Y3 antibody in the presence (+) or
absence (-) of class I binding peptide SIINFEKL. Lysates were also exposed to
37'C (37)to cause dissociation of class I molecules lacking bound peptide.
Polypeptides were separated by SDS-PAGE (12.5% gel) and labeled proteins
visualized by fluorography. The class I light chain (2m) is seen at the bottom of
each panel. Note the loss of recovery of class I molecules in the lysates exposed
to 37C and the slow maturation to the fully glycosylated form of the heavy chain
in NLVS treated cell lysates but not in adapted lysates.
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molecules was the absence of peptide. Treatment of normal cells with NLVS also
led to a slower rate of processing of newly synthesized heavy chains (compare
the 90 min. chase for treated and untreated cells). When the same experiment
was performed on adapted cells, assembly and maturation of class I molecules
was almost completely restored to the levels observed for control cells. Addition
of peptide to lysates from adapted cells resulted in only a minor increase in the
amount of properly folded class I molecules isolated. The time scale for
maturation of class I molecules in adapted cells was quite similar to that
observed for normal EL-4 cells. Thus, in adapted cells, although proteasome
function is impaired, peptides are generated for binding to class I molecules.
8. Poly-ubiquinated proteins accumulate in cells treated with NLVS but not in
adapted cells
One of the main functions of the 26S proteasome is the destruction of
proteins which have been tagged with ubiquitin. If cells are treated with
proteasome inhibitors, these ubiquitin-tagged proteins begin to accumulate. We
therefore investigated whether such an accumulation occurred in adapted cells.
EL-4 cells, EL-4 cells treated with 10gM NLVS for 24 hrs, and adapted cells were
lysed and post-nuclear supernatants were analyzed by Western blotting using a
polyclonal antiserum reactive with ubiquitin (figure 5.11). Poly-ubiquinated
proteins are heterogeneous in size and therefore are seen mostly as high
molecular weight aggregates near the top of the gel. As expected, a 24 hour
treatment with NLVS resulted in the accumulation of ubiquitin-conjugated
proteins in control cells. Only a slight increase in the amount of ubiquitin
conjugated proteins was observed in adapted cells. This observation suggests
that proteolytic activities other than the proteasome must be responsible, at least
in part, for the degradation of proteins modified by attachment of poly-ubiquitin
chains.
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Figure 5.11. Polyubiquinated proteins accumulate in NLVS treated but not in
adapted EL-4 cells.
Lysates were prepared from control, NLVS treated (25 gM for 24 hours), and
adapted EL-4 cells. Lysates (1, 10 and 100 gg) were separated by SDS-PAGE
(10% gel) and polyubiquinated proteins visualized by immunoblotting. Note the
accumulation of a high molecular weight smear in NLVS treated lysates only.
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9. Adapted cells overcome the G2 cell cycle arrest induced by proteasomal
inhibition
When normal cells are treated for prolonged periods of time with inhibitors
of the proteasome, growth arrest occurs. Since adapted cells are able to grow
normally in the presence of concentrations of NLVS which would otherwise
result in growth arrest, we examined DNA content of adapted cells. The
fluorescent DNA stain propidium iodide can be used to measure the total DNA
content of cells by cytofluorimetry. Since cells in S and G2 phases of the cell cycle
will have more DNA than cells in the Gi and M phases, this marker is often used
as an indirect measure of G1/G2 ratio of asynchronously growing cells. Upon
addition of 50 ugM of NLVS, cells accumulate in the G2 phase due to the block in
proteasomal proteolysis (figure 5.12, center panels). In adapted cells however,
cells overcome this block and the DNA content of cells in the G2 phase of the cell
cycle is restored to that observed for normal EL-4 cells (figure 5.12, right panels).
Adapted cells therefore are able to progress normally through the cell cycle,
even in the absence of functional proteasomes.
10. A non-proteasomal activity is up-regulated in adapted cells
In the process of examining the proteolytic activity found in lysates from
adapted cells using different fluorogenic substrates we found that hydrolysis of
the substrate AAF-MCA was increased. This tri-peptide free amine is a poor
substrate for the proteasome, but is efficiently hydrolyzed when the amino
terminus is capped with a succinyl moiety. Figure 2.13 shows hydrolysis of the
proteasome substrate Suc-LLVY-MCA and the non-proteasome substrate AAF-
MCA by lysates from normal as well as several independently isolated lines of
adapted cells. In all adapted cell lines examined, a reduction in LLVY hydrolysis
and an increase in AAF hydrolysis was observed.
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Figure 5.12. The G2 cell cycle arrest caused by NLVS treatment of EL-4 cells is
overcome in adapted cells.
(A) Control, NLVS treated (25 gM for 16 hours), and adapted EL-4 cells were
permeablized and DNA was stained with propidium iodide. The content of
DNA was quantitated using fluorocytometry. Cell number was plotted versus
total fluorescence (FL3-H). Cells with 2X the fluorescence observed for a peak of
G1 cells were considered to be in the G2 phase of cell cycle. The G1 and G2
populations of cells are indicated.
(B) Plot of the % of total cells injected into the fluorocytometer in A which are in
the G1 and G2 phase of the cell cycle for control, NLVS treated, and adapted EL-
4 cells. Note the increase in the % of cells in G2 for NLVS treated compared to
control and adapted cells.
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Figure 5.13. Multiple independent cell lines which are adapted to growth in the
presence of NLVS have an increase in AAF-MCA hydrolysis activity.
Lysates were prepared from multiple independently adapted cell lines (EL-4 adl,
ad6, ad7, ad8) and hydrolysis of fluorogenic substrates was measured as
described in the materials and methods section. Hydrolysis of the proteasome
substrate Suc-LLVY-MCA was reduced and hydrolysis of the non-proteasomal
substrate AAF-MCA was increased in all adapted cell lines tested.
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11. AAF-MCA hydrolytic activity fractionates as a high molecular weight
complex distinct from the proteasome
We next began purifying the proteolytic activity responsible for AAF-MCA
hydrolysis. High molecular weight proteins were isolated by centrifugation of
lystates from control and adapted EL-4 cells as described in the materials and
methods section. These fractions were then subjected to gel filtration on the same
superose 6 column described above for the fractionation of proteasomes.
Fractions were assayed for AAF-MCA hydrolysis activity. Figure 5.14 shows the
gel filtration profiles obtained for control and adapted 5 hour pellets assayed
with AAF-MCA. The same fractions were analyzed using the proteasome
substrate Suc-LLVY-MCA to indicate the elution position of proteasomes. As
described above, a peak of 26S proteasome activity (fraction 17) and a peak of
20S proteasome activity (fraction 20) was observed for normal EL-4 cells. This
activity was severely diminished in adapted cells. Unlike normal EL-4 cells,
adapted cells showed a peak of AAF-MCA activity in fractions 14 and 15. This
activity was lacking in normal EL-4 lysates and is distinct from the proteasome
peaks observed with the LLVY substrate. Thus the AAF-hydrolyzing activity
represents, at least in part, a protein or protein complex with larger apparent
molecular weight than the proteasome.
12. AAF-MCA hydrolysis activity is required for adapted cell survival
To address whether the AAF hydrolyzing activity was responsible for
survival of adapted cells, it was necessary to block this proteolytic activity.
Peptide chloromethyl ketones have been reported as covalent inhibitors of
several classes of proteolytic enzymes (Kettner and Shaw, 1981; Rauber et al.,
1988; Savory et al., 1993). We synthesized the AAF tri-peptide containing a
chloromethyl ketone at the C-terminus (AAF-cmk) and tested its ability to inhibit
the AAF hydrolysis observed in adapted cells. Figure 5.15 shows hydrolysis of
AAF-MCA by lysates generated from adapted cells pre-treated or not with 5 AiM
AAF-cmk for 16 hours. AAF-cmk was also added directly to lysates generated
from both normal EL-4 and adapted EL-4 cells to determine the dose-dependence
of inhibition. The AAF-hydrolyzing activity observed in normal EL-4 cells was
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Figure 5.14. The increased AAF-MCA hydrolysis activity found in adapted cells
is a high molecular weight protein or protein complex distinct from the
proteasome.
(A) Lysates obtained from control and adapted EL-4 cells were fractionated by
differential centrifugation as described. Pellets from the 100,000 g centrifugation
were passed over a Superose 6 column and Suc-LLVY-MCA hydrolysis activity
was measured for each fraction. Note the presence of a peak of activity for the
26S (fraction 18) and 20S (fraction 21) proteasomes in control cells which is
substantially reduced for adapted cells.
(B) Hydrolysis of AAF-MCA by fractions described above. Note the absence of
AAF-MCA hydrolysis by proteasomal fractions (fractions 18-23) in both control
and adapted EL-4 cell lysates. Hydrolysis of AAF-MCA is highest in adapted
cells in fractions of higher molecular weight than that of the proteasome
(Fractions 12-17). Note the absence of the AAF-MCA activity in control cells.
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Figure 5.15. The AAF-MCA hydrolysis activity is inhibited by treatment with the
tri-peptide chloromethyl ketone AAF-cmk.
Control EL-4 (EL-4) and adapted EL-4 cells grown in 25giM NLVS were treated
with AAF-cmk (5 gM) or DMSO as a control (-) for 16 hours at 37C (label at
bottom of graph). Cells were then washed, lysed and AAF-cmk (0, 1 or 10 gM;
see legend) added to the lysates. Hydrolysis of AAF-MCA was then measured as
described in the Materials and Methods section. Fluorescence was normalized so
that AAF-MCA hydrolysis by EL-4 lysates not treated with AAF-cmk was 100%.
AAF-cmk inhibits AAF-MCA hydrolysis when added to lysates and when added
to intact cells.
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inhibited in a dose-dependent manner by the addition of AAF-cmk to the lysate.
The high AAF hydrolyzing activity found in adapted cells could also be inhibited
by addition of 1 and 10 pM AAF-cmk to the lysates. Pre-treatment of adapted
cells with 5 gM AAF-cmk resulted in a near complete block in AAF-MCA
hydrolysis. These data indicate that AAF-cmk is a potent cell-permeable
inhibitor of the AAF-hydrolyzing activity observed in adapted cells.
The effects of AAF-cmk on cell growth were monitored for several days.
When normal EL-4 cells were incubated with 5gM AAF-cmk, a concentration
shown to block the AAF hydrolytic activity, little effect on growth was observed.
The same concentration of AAF-cmk, when added to adapted cells growing in
50 gM NLVS, resulted in a nearly complete block in growth (figure 5.16). To rule
out the possibility of a non-specific toxicity effect resulting from the addition of a
second protease inhibitor to adapted cells, we added the tetra peptide vinyl
sulfone YL3-VS (described in chapter 3) to adapted cells growing in 50 gM NLVS.
YL3-VS is toxic to normal cell growth at concentrations of 10 AM or higher, but
showed no toxic effects on adapted cell growth at concentrations as high as 50
pM (data not shown). Taken together, these results suggest that the non-
proteasomal proteolytic activity measured by AAF-MCA hydrolysis and which is
increased in adapted cells, is necessary for growth and survival in the absence of
an active proteasome.
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Figure 5.16. Inhibition of the AAF-MCA hydrolysis activity is toxic to adapted
growth of cells adapted to NLVS.
(A) Control EL-4 cells were maintained for several days in the presence of 50 pM
NIP-L3-VS or 5 pM AAF-cmk. Cells were counted daily and cell number plotted
against time in culture. Note the toxicity of NLVS but not AAF-cmk to normal
cell growth.
(B) Adapted EL-4 cells (maintained in 50 gM NLVS) were washed and treated
with either 50 gM NLVS or 50 glM NLVS and 5 jgM AAF-cmk. Growth was
measured and recorded as in A. Note the complete loss of cell growth upon
treatment with AAF-cmk
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D. Discussion
The proteasome's role in a wide range of important metabolic functions
makes it indispensable for the survival of an organism, as revealed by
mutational analysis in yeast. Treatment of cells with inhibitors which can block
proteasome function indeed leads to cell death. However, we have found that
populations of cells exist which are able to compensate for loss of proteolysis by
the proteasome. The frequency with which this phenomenon occurs makes an
explanation involving a genetic mutation unlikely. Biochemical analysis of
proteasomes isolated from adapted cells indicates that proteasome function is
severely impaired. It appears that adaptation results from the up-regulation of
additional proteolytic activities whose functions must resemble those of the
proteasome. This activity, when blocked using a somewhat non-specific
protease inhibitor, abolishes growth of adapted cells while having little or no
effect on the growth of normal cells.
The mechanism by which a cell becomes adapted to growth in the presence
of inhibitor concentrations which would otherwise be toxic is not yet fully
understood. We favor a scenario in which a small sub-population of cells within
a normal cell culture have elevated levels of additional proteases or the ability to
up-regulate such proteases. Under normal growth conditions, these cells do not
have an advantage for survival over other cells, but under selective pressure of
proteasome inhibitors, these cells are able to outgrow other cells that lack
adequate levels of such proteases.
Once adapted, these cells are able to overcome the proteolytic blockade
which results from proteasomal ihibition. Levels of ubiquitin-conjugated
proteins begin to return to normal and the block in cell cycle leading to a G2
arrest is abolished. Thus, the enzyme or enzymes that are responsible for
adaptation are likely to recognize and degrade proteins tagged with ubiquitin.
The presence of an increased AAF-MCA hydrolyzing activity in adapted
cells is likely to be important for the adaptation phenomenon. The fact that
hydrolysis of a single substrate increases in adapted cells in no way indicates that
adaptation is the result of increased activity of a single proteolytic enzyme. The
free amino terminus of the AAF-MCA substrate makes it likely to be a target for
a number of N-terminal peptidases. Likewise, the ability of the tri-peptide
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chloromethyl ketone to block adapted cell growth may not result from the
inhibition of a single protease.
Future work must focus on the molecular characterization of the enzyme or
enzymes responsible for adaptation. Initial studies are well underway to purify
factors with AAF hydrolyzing activity. Recently, a high molecular weight
protease complex, larger than the proteasome, was found in the archaebacteria
Thermoplasma (Tamura et al., 1996). Interestingly, this protease complex, named
tricorn protease, has preference for the AAF-MCA substrate containing a free
amino terminus, an observation that prompted our use of a similar substrate as
the corresponding inhibitor. Like the activity observed in adapted cells, it is
sensitive to inhibitors which contain a chloromethyl ketone functional group.
While these findings do not provide a direct link between the Tricorn protease
and the activity observed in adapted cells, the high molecular weight protease
activity which is activated in adapted cells may represent a mammalian homolog
of the bacterial tricorn protease.
We have also found that the phenomenon of adaptation is not limited to the
EL-4 cell line. We have succeeded in adaptation of the RBL-5 derived lymphoma
cell line RMA. These cells may serve as tools to further examine the role of the
proteasome as well as other proteases in such metabolically important functions
as cell cycle regulation and antigen presentation.
Finally, the ease with which the peptide vinyl sulfones are synthesized and
derivatized has made the discovery and characterization of the adaptation
phenomenon possible. Peptide aldehydes, due to their increased cross-
reactivity and non-specific toxicity are less likely to be useful for such studies. In
addition, the reversibility of inhibition observed with peptide aldehydes may
make removal by multi-drug resistance transporters a possible mechanism of
adaptation. Lactacystin, on the other hand, although highly specific for the
proteasome, is difficult to synthesize and thus the cost of obtaining sufficient
quantities for such a study is prohibitive, at least at present.
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VI. FUTURE DIRECTIONS
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Although inhibitors of the proteasome have become widely used to dissect
the role of the proteasome in many cellular processes, there still remains much
which can be done with these types of pharmacological agents. The work
presented in this thesis establishes the utility of the peptide vinyl sulfones as
active site-directed probes for the study of proteasome function. The structure-
function studies presented here allow for the correlation between enzymatic
inhibition and inhibitor binding. Further, the in vivo application of the peptide
vinyl sulfones has helped to uncover a novel mechanism by which a virus
escapes host immunity. Finally, the prolonged treatment of cells with the
peptide vinyl sulfones lead to the discovery of additional proteolytic systems that
may exist in normal cells and allow for survival in the absence of the proteasomal
activity. The exact physiological role of these newly discovered activities
remains to be established.
Compounds such as the peptide vinyl sulfones, which contain a peptide
backbone similar to a protein substrate, can be equipped with an appropriate tag
for biosynthetic labeling, and can covalently modify proteasomal active site
nucleophiles, offer the possibility of designing inhibitors which target specific
proteasomal subunits. The groundwork of such a study is described in chapter
3. Further C-terminally modified peptides may be synthesized with a variety of
different amino acid sequences using modem combinatorial methods.
Subsequent labeling of proteasome subunits with mixtures of compounds could
identify inhibitors which show selective binding properties. Subunit-specific
compounds could then be used to correlate subunit binding with inactivation of
individual peptidase activities of the proteasome. Furthermore, such subunit-
specific reagents would allow for the generation of pharmacological "knock-
outs", in which the role of individual proteasomal peptidase activities in various
metabolic processes such as antigen presentation could be explored.
While there can be no denying the importance of the proteasome in the
generation of antigenic peptides for presentation via MHC class I molecules,
many of the details of the proteasome's role in this process remain a mystery. A
wide range of inhibitors with differing specificity for proteasome active sites may
be extremely valuable in deciphering the details of antigen processir ; required
for an infected cell to be recognized by a cytotoxic T-lymphocyte. Work on the
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generation of such reagents is already underway and may someday be the focus
of a thesis such as this one.
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